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Abstract 
 The substrate scope and selectivity of toluene dioxygenase overexpressed in 
E.coli JM109 (pDTG601A) was investigated with series of ortho-halobenzoates and 
para-substituted arenes.  Palladium-catalyzed carbonylation methodology was developed 
to convert halogenated cis-dihydrodiol metabolites to the corresponding carboxylates and 
a comparison of the overall efficiency between the enzymatic and chemical methods of 
access was made.  Some of the metabolites produced by toluene dioxygenase were 
employed in a synthetic approach toward tetrodotoxin.  Enzymatic dihydroxylation of 
benzoic acid with R. eutropha B9 provided the corresponding ipso-diol that was used in 
the first total synthesis of pleiogenone A, a bioactive natural product.  Experimental and 
spectral data are provided for all new compounds. 
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1.0 Introduction 
 
 In reviewing the accomplishments in the field of organic synthesis since its 
inception with the synthesis of urea by Wöhler in 1828,
1
 some have described the field as 
a “mature” science.2  The implication being that organic synthesis is in a state of 
declining production and that truly revolutionary advances are not likely to be made.  
Although this idea can readily be refuted when one considers the innovative synthetic 
approaches which have recently been applied to the production of valuable compounds 
by Baran
3
 and many others, it was most eloquently addressed by Seebach some 25 years 
ago.
2
  Seebach argues that organic synthesis has not become a “mature” science, but has 
become increasingly integrated with other disciplines, and indeed with all of the natural 
sciences.
2
  Following Seebach’s article, Hudlicky published a discourse on design 
problems in synthesis.
4
  This article served as an introduction to a topical issue of Chem. 
Rev. edited by Wender that presented 24 articles by experts in various disciplines 
representing the state of the art in synthesis in 1996.
5
  The field of organic synthesis 
cannot be considered a “mature science” because of the continued contributions from 
other fields, and because of the questions in the field that have yet to be answered. 
 An example of a discipline which has continually made significant contributions 
to organic synthesis is the field of biocatalysis.
6
  Through the identification of enzymes 
and the isolation of metabolites, the field of biocatalysis has made the practical synthesis 
of many important compounds possible.
6
  The advances in the field of biocatalysis have 
also provided the means of meeting the metrics for efficiency in organic synthesis.  This 
is true of traditional metrics such as step economy,
7
 atom economy
8
 and redox economy,
9
 
and is particularly true when metrics which take into account environmental factors such 
 2 
 
as effective mass yield (mass of product / mass of all non-benign materials used)
10
 or E-
factor (mass of total waste / mass of product)
11
 are applied.  Enzymatic transformations 
are typically performed in aqueous media and byproducts are often entirely 
biodegradable, therefore biocatalysis significantly increases the efficiency of a synthesis 
when metrics such as effective mass yield are applied.  These advantages have led many 
synthetic chemists to adopt the use of enzymatic transformations.   
A particularly fruitful example has been the use of dioxygenase enzymes such as 
toluene dioxygenase (TDO)
12
 and benzoate dioxygenase (BZDO)
13
 to produce cis-
cyclohexadienediol metabolites, such as 2
14
 and 4
15
 respectively, which have been widely 
used in enantioselective synthesis (Figure 1). 
 
 
 
Figure 1: Dihydroxylation of substituted aromatics by toluene dioxygenase (TDO) and 
benzoate dioxygenase (BZDO) and the application of metabolites in synthesis.
12-15
 
 
 This thesis will describe new developments in the utility of these metabolites.  
First, the study of the substrate scope and selectivity of the enzymatic dihydroxylation 
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performed by TDO will be undertaken.  This study will apply a small library of ortho-
halobenzoates (5) as substrates for the enzyme (Figure 2).   
 
 
Figure 2: The study of the enzymatic dihydroxylation of ortho-halobenzoates.
 
 
Second, para-disubstituted aromatics (8) will be investigated as substrates for 
toluene dioxygenase, with the goal of identifying a suitable starting material for a 
potential synthesis of tetrodotoxin (10) (Figure 3).   
 
 
Figure 3: Investigation of p-disubstituted aromatics as substrates for toluene dioxygenase 
(TDO). 
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Third, carbonylation methodology will be explored to provide a more practical 
route to (13) which has been identified as a useful starting material in the synthesis of 
oseltamivir,
16
 as well as other compounds (Figure 4).   
 
 
 
Figure 4: Carbonylation of halogenated metabolites to their corresponding carboxylates. 
 
 Finally, the enzymatic metabolite of benzoic acid, ipso-diol (4), will be used in an 
approach to the synthesis of a recently identified
17
 alkylcyclohexenone natural product, 
pleiogenone A (14) (Figure 5).   
 
 
Figure 5: Chemoenzymatic synthesis of pleiogenone A (14). 
 
The following section will provide historical background for each of the endeavours 
described above. 
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2.0 Historical 
 The following historical chapter is divided into four sections covering: 1) History 
of Biocatalysis, 2) Arene dioxygenases, 3) Carbonylation chemistry and 4) 
Alkylcyclohexenone natural products.  The role of arene dioxygenase enzymes in the 
degradation of environmental contaminants by soil bacteria, as well as the importance of 
the metabolites produced in organic synthesis will be discussed.  A brief discussion of the 
history and importance of carbonylation chemistry will be provided.  The isolation, 
synthesis and biological significance of alkylcyclohexenone natural products will also be 
discussed. 
 
2.1.1 History and evolution of biocatalysis 
  The most ubiquitous example of the use of enzymatic transformations throughout 
history is their application in the production of fermented beverages.  This process can be 
dated back as far as 7000 BCE, when rice, honey, and fruits were combined to make 
fermented beverages in China.
18
  It is clear that the role of biological entities in the 
production of these beverages was recognized even at this time.  The fermentation 
process in China has been shown to have evolved over time to include the addition of 
Aspergillus, Rhizopus and/or Monascus fungi (among others) to promote amylolysis.
18
  
The production of fermented beverages also has a long history in other countries, 
including ancient Egypt, where it has been shown that Saccharomyces cerevisiae was 
added to beverages to promote fermentation as early as 3150 BCE.
19
  In addition to using 
biological entities in the production of fermented beverages, it has also been shown that 
natural extracts were added to prevent the growth of bacteria responsible for their 
 6 
 
spoilage.
20
  Indeed, the earliest wine vessel ever discovered (5400-5000 BCE, Northern 
Iran) was shown to contain an extract from the Pistacia atlantica tree which prevents the 
growth of Actinobacter responsible for the conversion of ethanol to acetic acid.
20
  
Whether or not the exact nature of the biological entities being employed was understood, 
it is clear that humans have had a long history of utilizing the power of enzymatic 
transformations to their benefit. 
 Despite thousands of years of experience, it was not known whether fermentation 
was a biological or purely chemical process.  In 1833, Payen and Persoz made a 
tremendous step in the understanding of enzymatic catalysis.
21
   Payen and Persoz 
isolated a white precipitate from barley malt extract, which was shown to catalyze the 
conversion of starch to maltose, making this the first in vitro enzymatic transformation.
21
  
Payne and Persoz named the white precipitate diastase, thereby establishing the 
convention of naming enzymes with the suffix “-ase”.21  In the study of the fermentation 
process, it was still not known whether yeast was a living organism or a purely chemical 
entity.  van Leeuwenhoek observed yeast cells as early as 1680, but did not regard them 
as living organisms.
22
  In the late 1830s, Caginard de Latour, Kutzing and Schwann all 
independently determined that yeast was indeed a living organism, having observed yeast 
cells reproducing through budding.
23
  Schwann would go on to refer to yeast as “sugar-
fungus” and Kuntzig proposed that yeast was an organized body and not an individual 
compound.
23
  With yeast identified as a living organism, the understanding of enzymatic 
transformations was taken a step further by Traube in 1858.
23
  Traube proposed that all 
fermentation processes occuring in living organisms were caused by discrete chemical 
entities called “ferments” that were produced in the cell.  Furthermore, Traube considered 
 7 
 
that these “ferments” were closely related to proteins and that their function was to 
transfer oxygen and hydrogen molecules to facilitate intramolecular oxidation and 
reduction.
23
  Traube’s ideas about fermentation and the biological entities that cause this 
process, began to approach the modern understanding of enzymatic transformations. 
 The final proof that fermentation is indeed a biological process was provided by 
Pasteur in 1857.  Pasteur meticulously demonstrated that the products of alcoholic 
fermentation were more numerous and complex than just ethanol and carbon dioxide, 
indicating that a portion of the fermentable material was being integrated into the yeast.  
Furthermore, Pasteur demonstrated that alcohol production occurs simultaneously with 
yeast multiplication, and that the yeast must be alive for fermentation to occur.
24,25
  In 
addition to these seminal contributions, Pasteur was also the first to observe the 
stereospecificity of enzymatic transformations.  He reported a “mode of fermentation” of 
tartaric acid, which occurred very readily with one enantiomer of tartaric acid and not at 
all with the opposite enantiomer.
24
  Pasteur had settled the debate about the biological 
nature of fermentation, and provided tremendous insight on the “ferments” which had 
been proposed by Traube.
23
  Just twenty years after Pasteur’s seminal report, Kuhne 
renamed these “ferments” enzymes, as it was recognized that an intact organism was not 
required for enzyme activity to occur.
26
  
 With the increased understanding of the biological nature of fermentation, 
chemists began to recognize the potential to harness these biotransformations, leading to 
the birth of the field of biocatalysis.  The true inception of the field of biocatalysis 
occurred in 1886, when  Brown used Actinobacter cells to perform a series of 
biotransformations including the conversion of ethanol to acetic acid and the conversion 
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of mannitol to fructose.
27
  Brown recognized the value of this work to the field of 
chemistry, as the following quote demonstrates: 
“I think the experiments just described will be of interest to biologists as well as 
chemists, as they help to show that the vital functions of certain organized ferments are 
most intimately connected with the molecular constitution of bodies on which they act.”27   
The field of biocatalysis was expanded from the use of whole cells to the use of 
enzyme extracts in 1903, when Dakin utilized crude pig liver esterase to perform the 
kinetic resolution of ethyl mandelate.
28
  This seminal report led to the widespread 
application of lipases as catalysts for acylation, ester hydrolysis, and as a means for 
desymmetrization and resolution.
6,29
  The first report of the use of yeast to perform the 
reduction of a carbonyl was made in 1911 by Lintner and von Liebig.
30
  This finding 
represents one example of the advances in biocatalysis directly benefitting synthetic 
chemists. 
In 1894, Emil Fischer provided a significant advance in the understanding of 
enzymatic reactions by proposing the “lock and key” model for the interaction of an 
enzyme and its corresponding substrate.
31
  This model describes the specific interactions 
between an enzyme and a substrate, and effectively explains the stereospecificity that was 
observed by Pasteur in his study of fermentation 40 years earlier.  Fischer’s “lock and 
key” model has evolved over time to include the concept of “induced fit”, which was 
introduced in 1958 by Koshland.
32
  The “induced fit” model describes the conformational 
changes that occur to an enzyme upon binding a substrate, caused primarily by non-
covalent interactions between the substrate and amino-acids in the active site.  These 
conformational changes serve to orient the substrate and the amino-acids in the active site 
 9 
 
so as to stabilize the transition state of the reaction in question.
32
  The induced fit model, 
proposed 100 years after Traube first hypothesized the existence of “ferments”, is 
represents just one of the tremendous gains that have been made over this period of time.   
The role of enzymes as biological catalysts that increase the rate of reactions by 
decreasing the activation energy, was well understood by the early 1900s.
33
  This allowed 
biochemists to envision many practical applications for enzymes.  As early as 1908, 
Rosenberg utilized nitrilase enzymes isolated from almonds in the synthesis of optically 
active cyanohydrins.
34
  In 1916 it was shown that enzymes could be immobilized on solid 
supports without a loss of activity.
35
   Enzymes began to be employed in new industrial 
applications including the introduction of pancreatic enzymes for the cleaning of laundry 
in 1908.
33
  This trend continued until the cultivation of the first industrial scale cultures of 
Bacillus licheniformus for the production of protease enzymes in 1960.
33
   
Today, the advent of technologies such as selective mutagenesis and directed 
evolution have allowed for the design of catalysts for specific transformations or to 
operate under a particular set of desired conditions.
36
  The continued use and 
improvement of these techniques allowed for the development of biocatalysts for organic 
synthesis beyond what can be isolated from natural sources. 
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Figure 6: Timeline of the major accomplishments in the field of biocatalysis. 
 
 With more enzymes isolated and characterized, a classification system was 
developed in order to organize enzymes based upon the type of transformation they 
catalyze.
37
  The nomenclature used for the classes of enzymes was derived from the 
terminology used by Payne and Persoz in 1833.
18
  The six primary classes of enzymes are 
outlined in Table 1.
37
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Table 1: Classes of enzymes and the types of transformations they catalyze.
37
 
Enzyme Class Examples of transformations catalyzed 
Oxidoreductase Reduction of carbonyls/alkenes; Oxidation of C-H, C=C, C-N, C-O 
bonds; Cofactor oxidation/reduction 
Transferase Transfer of functional groups (i.e. acyl, glycosyl, aryl, methyl, 
phosphoryl, nitro, amino, etc.) from donor to acceptor 
Hydrolase Hydrolysis of esters, amides, lactones, anhydrides, nitriles, etc.; 
Formation of esters, amides, lactones, etc. 
Lyase Cleavage of C-C, C-O, C-N, C-S, C-X and P-O bonds without energy 
input from adenosine triphosphate (ATP) 
Isomerase Intramolecular rearrangements (isomerization, epimerization, 
racemization), intramolecular oxidation/reduction 
Ligase Bond formation (C-C, C-O, C-N, C-S, etc.) with energy input from 
ATP 
 
In addition to the application of known enzymatic catalysts in novel ways, new 
enzymes are continuously being identified both from natural sources and from the design 
of these catalysts through synthetic biology.
36
  The continuing advancement in the field 
of biocatalysis will ensure that enzymatic catalysts remain important in the field of 
organic synthesis 
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2.2 Arene Dioxygenases 
 The following section will provide a brief discussion of the role of oxidoreductase 
enzymes in the oxidation of arenes.  The dioxygenase enzymes TDO and BZDO will 
discussed in detail. 
 
2.2.1 Oxidoreductase Enzymes in Arene Oxidation 
 Oxidoreductase enzymes are a broad class of catalysts that facilitate a wide 
variety of reactions.
37
  In the context of arene oxidation, oxygenases represent a 
particularly important subset of oxidoreductase enzymes.  Oxygenases are enzymes that 
transfer oxygen atom(s) from molecular oxygen to the given substrate.
38
  Oxygenases can 
be divided into two classes: monooxygenases, which transfer one atom of molecular 
oxygen to a substrate; and dioxygenases, which transfer both oxygen atoms of molecular 
oxygen.
38
  Dioxygenase enzymes typically make use of a metal-ion cofactor in order to 
facilitate the activation of molecular oxygen and to establish an oxidation-reduction 
cycle.
38
   
 The metabolism of aromatic substrates by microorganisms was first reported by 
Stormer, who in 1908 isolated Bacillus hexacarbovorum, which metabolized xylene and 
toluene.
39,40
  In 1914, Wagner identified multiple strains of Bacterium benzoli that 
metabolized xylene, toluene, benzene, naphthalene and phenol.
40,41
  The intermediate(s) 
produced in the metabolism of aromatics by dioxygenases were not known until the 
isolation of 1,2-dihydronaphthalene-1,2-diol (16) from the urine of naphthalene (15)-fed 
rats by Young in 1947 (Figure 7).
42
  Haccius isolated pyrocatechol (18) as the major 
product of the metabolism of benzene (17) by Nocardia coralline in 1957,
43
 providing 
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further understanding of this process. The mammalian dehydrogenation of 3,5-
cyclohexadiene-1,2-diol (19) to pyrocatechol (18)
44
 allowed for the connection of the 
observations made by Young and Haccius.  Based upon these observations, in 1961 Marr 
and Stone proposed trans-cyclohexa-3,5-diene-1,2-diol (20) as a likely intermediate in 
the bacterial oxidation of benzene (17) (Figure 7).
45
  In accordance with the proposal of 
trans-cyclohexa-3,5-diene-1,2-diol (20) as a likely intermediate, an epoxide intermediate 
was proposed as a precursor leading to the production of catechols (Figure 7).
46,47
     
 
 
Figure 7: Early studies on the metabolism of aromatics by dioxygenase enzymes.
42-46 
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In 1968, Gibson reported the oxidative metabolism of benzene by Pseudomonas 
putida.
48
  In this report, Gibson suggests the cis-addition of molecular oxygen to the 
substrate, as was proposed by Kobayashi in the degradation of anthranilic acid (22) to 
pyrocatechol (18) (Figure 8).
49
  Gibson also disproved the existence of the hypothesized 
epoxide and trans-dihydroxy intermediates by feeding Pseudomonas putida cultures with 
synthetic trans-3,5-cyclohexadiene-1,2-diol (20).  These experiments demonstrated the 
inability of the bacteria to metabolize this compound, proving that this compound could 
not be an intermediate in the production of pyrocatechol (18) from benzene (17).
48
  A 
second publication by Gibson in 1968 demonstrated the metabolism of halogenated 
aromatics by P. putida to the corresponding 3-halocatechols.
50
  In the course of this 
study, Gibson isolated (+)-cis-4-chloro-2,3-dihydroxy-1-methylcyclohexa-4,6-diene (25) 
and 4-chloro-2,3-dihydroxy-1-methylbenzene (26) as the products of the metabolism of 
p-chlorotoluene (24) (Figure 8).
50
  The isolation of (+)-cis-4-chloro-2,3-dihydroxy-1-
methylcyclohexa-4,6-diene (25) confirmed the proposed cis-addition of molecular 
oxygen to the aromatic substrate.  
18
O-labling studies demonstrated that both atoms of 
molecular oxygen are incorporated into the substrate. 
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Figure 8: Studies on the metabolism of aromatics by dioxygenase enzymes.
49,50
 
In order to conclusively prove the relative stereochemistry of the intermediates of 
type 25, toluene (27) was metabolized by P. putida to (+)-cis-2,3-dihydroxy-1-
methylcyclohexa-4,6-diene (28) (Scheme 1).
51
  This compound is only available in small 
quantities from fermentation cultures of wild-type P. putida as it is readily metabolized to 
3-methylcatechol.  In order to produce metabolite 28 in larger quantities, a mutant strain 
(P. putida 39/D) was developed by Gibson to permit the accumulation of metabolite 28 in 
fermentation cultures.
51 
 The mutant strain was used to produce 28 which was then 
acetylated, treated with maleic anhydride and hydrogenated to produce cycloadduct 29 
(Scheme 1).
51
   The value of the coupling constant between Ha and Hb (8.5 Hz, Scheme 1) 
provided the final proof of the cis relationship between the hydroxyl groups in 
metabolites of type 28. 
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Scheme 1: Derivatization of metabolite 28 for the determination of relative 
stereochemistry.
51
 
 
The absolute stereochemistry of 28 was confirmed through derivatization to a 
compound with known absolute stereochemistry, (R)-(−)-methyladipic acid (32) (Scheme 
2).
52
  This process involved the hydrogenation and mono-benzoylation of 28 to afford a 
mixture, which was separated and hydrolyzed to afford diastereomers 30 and 31.  The 
cis,cis relative stereochemistry of compound 31 was confirmed by NMR analysis, and 
this compound was subjected to oxidation to afford (R)-(−)-methyladipic acid (32).  By 
matching the optical rotation of (R)-(−)-methyladipic acid (32) produced from the 
degradation of metabolite 28 to the reported value in the literature, Gibson provided the 
final proof of the absolute stereochemistry.
52
 
 
 
Scheme 2: Derivatization of metabolite 28 for the determination of absolute 
stereochemistry.
52
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With the development of P. putida 39/D, it became possible to produce 
metabolites of type 28 in larger quantities.
51
  In small scale biotransformations (0.5 L), 
the use of this organism allowed for the production of ~300 mg of diol metabolite per 
litre of fermentation culture.
53
  In 1989, Gibson developed a recombinant E. coli strain 
(JM109 pDTG601A) expressing toluene dioxygenase.
54
  The use of the recombinant 
strain in larger biotransformations (10-15 L) further increased the quantity of metabolites 
which can be isolated, with yields of >15 g/L for certain substrates.
14(m)
  The availability 
of these compounds led to wide variety of chemical applications for metabolites of this 
type, as will be discussed in detail in subsequent sections.   
In 1971, a similar study was performed by Reiner, working with Alcaligenes 
eutropha (later renamed Ralstonia eutropha).
55
  Alcaligenes eutropha was shown to 
metabolize benzoic acid (12) to pyrocatechol (18) in an enzymatic process which 
proceeds through 1,2-dihydro-1,2-dihydroxybenzoic acid (4) (Scheme 3).  In order to 
permit the accumulation of ipso-diol (4) in fermentation cultures, a mutant strain was 
employed (Ralstonia eutropha B9), in which the conversion of this compound to 
pyrocatechol (18) was blocked.
55
  This mutant strain was developed and provided by 
Johnson.
55
  
18
O-labeling studies demonstrated that both atoms of molecular oxygen were 
incorporated into the substrate,
55
 as demonstrated by Gibson in the metabolism of 
aromatics by P. putida.
51
  Based upon qualitative experiments, Reiner proposed a cis 
relationship between the hydroxyl groups of ipso-diol (4), in agreement with Gibson’s 
results.
51
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Scheme 3: Metabolism of benzoic acid by R. eutropha (previously A. eutropha).
55
 
 
Early observations indicated a cis relationship between the hydroxyl groups of 
ipso-diol (4),
55
 and the absolute stereochemistry of this compound was conclusively 
proven in 1995.
56
  Widdowson proved the absolute stereochemistry of ipso-diol (4) 
(Scheme 3) by conversion to its corresponding (p-bromobenzoyl)methyl ester and x-ray 
diffraction analysis of this compound.
56
 
 Despite the seminal work by Gibson, Reiner and many others, the identity of the 
dioxygenase enzymes involved in these processes were not known when the 
Pseudomonas putida 39/D and Ralstonia eutropha B9 strains were developed.  It was 
later determined that the enzyme responsible for catalyzing the 2,3-dihydroxylation 
observed in P. putida 39/D is toluene dioxygenase (TDO)
12
 and benzoate dioxygenase 
(BZDO) catalyzes the 1,2-dihydroxylation observed in R. eutropha B9.
13
   
The nature of these enzymes, the mechanism by which they catalyze the 
dihydroxylation of aromatics, their structure, substrate scope and selectivity will be 
discussed in the following sections. 
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2.2.2 Toluene Dioxygenase (TDO) 
 The following section will provide a discussion on the structure, mechanism, 
substrate scope, selectivity and applications of toluene dioxygenase (TDO). 
 
2.2.2.1 Structure and Mechanism of Catalysis 
 Toluene dioxygenase (TDO) catalyzes the 2,3-dihydroxylation of aromatic 
compounds (Figure 9).
12
  The selectivity depicted in Figure 9 will be discussed in detail 
in Section 2.2.2.2.
57
  The extensive research performed by Gibson and others has 
elucidated the nature and absolute stereochemistry of the metabolites produced by this 
enzyme. However, the mechanism by which the dihydroxylation occurs remains a subject 
of debate.  In order to discuss the mechanism of this transformation, it is necessary to 
understand the structure of the toluene dioxygenase system and its key catalytic subunits. 
 
 
Figure 9: Metabolism of substituted aromatics by TDO.
57,12
 
 
TDO belongs to a class of dioxygenase enzymes referred to as Rieske non-heme 
iron dioxygenases.
58
  This classification indicates that TDO contains a Rieske iron-sulfur 
cluster [2Fe-2S] as well as a mononuclear iron atom in the catalytic subunit.
59
  Although 
“toluene dioxygenase” is often used colloquially to refer to this enzyme, the TDO system 
in fact consists of three enzymes: the terminal dioxygenase (TDO-O), a Rieske ferredoxin 
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(TDO-F) and a reductase (TDO-R).  The terminal dioxygenase (TDO-O) is a hexamer of 
three β-subunits and three α-subunits, with each α-subunit containing a catalytic site 
(Figure 10).
59 
 
 
Figure 10: Structure of TDO-O hexamer (α-subunits = red, green, yellow; β-subunits = 
pink, light green, gray; Fe = magenta, S = orange).
59 
 
Electrons are transferred from nicotinamide adenine dinucleotide (NADH) to 
flavin adenine dinucleotide (FAD) in TDO-R where they are then passed on to TDO-F, 
which shuttles the electrons to the terminal dioxygenase, TDO-O.
59
  Within TDO-O, a 
Rieske iron-sulfur cluster receives the electrons from TDO-F and then passes them on to 
a mononuclear iron atom through a highly conserved aspartate residue (Figure 11).
58,59
  It 
is clear that the role of the loosely-bound mononuclear iron atom in TDO-O, coordinated 
by two histidine residues and one aspartate,  is important in the catalytic mechanism, as 
the loss of this atom results in a complete loss of activity.
59
  This follows from the fact 
that the mononuclear iron is known to be the site of oxygen and substrate binding,
58,59
 but 
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the exact role of the iron atom in the mechanism of the dihydroxylation however is still 
debated. 
 
 
Figure 11: Active site configuration of TDO.
58,59
 
 
 Multiple proposals have been made as to the mechanism of the enzymatic 
dihydroxylation.  These hypotheses include the formation of a dioxetane intermediate 
(35) with singlet oxygen (
1
O2),
60
 as well as the formation of intermediates 35 and 36 
through a [3+2] cycloaddition with an iron-peroxide species (Figure 12).
14(r)
  A 
covalently bound iron-peroxide intermediate of type 38 has also been proposed,
61
 as has 
the formation of iron-peroxide 39 leading to iron-peroxo species 40 (Figure 12).
62
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Figure 12: Mechanistic proposals for dioxygenase-mediated dihydroxylation.
14(r),60-62
 
  
 The mechanism involving the formation of dioxetane 37, first suggested by 
Gibson in 1970, would involve a 2 electron reduction of the dioxetane by the enzyme.
60
  
This mechanism is unlikely however, as the presence of iron-sulfur clusters indicates 
single electron transfer in the mechanism.
38
  Furthermore, this mechanism would require 
the activation of triplet oxygen to high-energy singlet oxygen.
38
   
The proposal involving the formation of intermediates 35 and 36, though 
consistent with single electron transfer in the catalytic mechanism, has yet to be 
supported by any experimental evidence.
14(p)
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The existence of the covalently bound iron-peroxide of type 38 was first proposed 
by Ramaswamy in 2000, based upon the study of naphthalene dioxygenase (NDO).
61
  
This mechanistic proposal is supported by the observation that both NDO and TDO can 
perform the monohydroxylation of certain substrates.
63
  It is also supported by the fact 
that oxygen activation in NDO can be decoupled from substrate hydroxylation, 
suggesting a stepwise rather than a concerted mechanism.
64
 
Upon further study of the catalytic mechanism of NDO, Ramaswamy proposed a 
mechanism involving the iron-peroxo species 40 in 2003.
62
   This mechanism was based 
on the observation of “side-on” binding of oxygen to iron in the crystal structure of NDO, 
leading to the formation of peroxide species 39.
62
  Based upon the crystal structures of 
NDO with substrate bound, with oxygen bound, with substrate and oxygen bound, and 
with product bound, the catalytic mechanism shown in Figure 13 was proposed.   
 
 
Figure 13: Mechanistic proposal for NDO-mediated dihydroxylation.
62
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There is no current consensus regarding the mechanism of dioxygenase enzymes 
such as TDO and NDO.
14(r)
   
 
2.2.2.2 Substrate scope and selectivity 
 With the development of the mutant strain P. putida 39/D,
51
 the investigation of 
the substrate scope of TDO and the isolation of any new metabolites produced was 
greatly expedited.  Isolation of metabolites was complicated, however, by the need to 
induce the up-regulation of TDO with an aromatic inducer.
51
  This would invariably 
result in a mixture of metabolites upon dihydroxylation of the inducer and the substrate of 
interest.  To resolve this issue, a recombinant E. coli strain (JM109 pDTG601A) was 
developed that did not require the use of an aromatic inducer.
54
 
 P. putida 39/D and E. coli (JM109 pDTG601A) have been used to study  the 
substrate scope of TDO,
14(o)
  and this topic has been comprehensively reviewed up to 
2004.
14(o)  
A small representative sample of the metabolites that have been isolated is 
shown in Figure 14.  TDO has been shown to accept a wide variety of monosubstituted 
aromatics, producing metabolites of type 41-45.  TDO also accepts ortho-, meta- and 
para-disubstituted aromatics (46-49) as well as trisubstituted aromatics (50).
14(o)
  
Biphenyls (51) and some heteroaromatics (52) have also been shown to be substrates for 
TDO.
14(o)
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Figure 14: Examples of metabolites produced by TDO.
14(o)
 
 
 Despite the relative promiscuity of TDO, the substrate scope has been shown to 
be limited by the size and polarity of the substrate.
65
  Bulky substrates such as t-butyl 
benzoate (53)
66
 and polar substrates such as the heterocyclic picoline 55
67
 have been 
shown not to be substrates for TDO (Figure 14). 
 
 
Figure 15: Limitations in the substrate scope of TDO.
66,67
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 The large substrate scope observed in the study of TDO has led to the continued 
investigation of the limits of the substrate scope and the isolation of unique metabolites.  
In the TDO-mediated dihydroxylation of arenes with multiple substituents (57, 60, 63), 
two isomeric metabolites can be produced, as shown in Figure 16.
57,68
 
 
 
Figure 16: Metabolites produced in dihydroxylation of multiply-substituted arenes.
57,68
 
 
 In order to develop a predictive model for the outcome of these 
biotransformations, Boyd investigated a series of para-disubstitued arenes (33) as 
substrates for TDO (Figure 17).
57
  In this study, the steric size of the arene substituents 
was varied and the enantiomeric excess of the metabolites produced (34 : 66) was 
analyzed (Figure 17).
57 
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Figure 17: Dihydroxylation of para-disubstituted arenes and ratio of metabolites.
57
 
 
From these data, Boyd determined that the sterically larger substituent dictated the 
facial selectivity of the enzymatic dihydroxylation.
57
  On the basis of this study, a model 
was proposed which could be used to predict the outcome of the dihydroxylation of 
multiply-substituted arenes (Figure 18a).
57
  This model was later visualized in the context 
of the TDO active site by Hudlicky (Figure 18b).
68(b)
 
 
a)           
b)  
Figure 18: Model for the dihydroxylation of multiply-substituted arenes.
57,68(b) 
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 This model was later examined in the context of ortho-disubstituted arenes by 
Hudlicky.
69
  By studying the dihydroxylation of ortho-halo methyl benzoates (67), it was 
shown that sterically larger substituents have a stronger directing effect on the 
dihydroxylation (Figure 18).
69
  In this way, Hudlicky confirmed the applicability of 
Boyd’s model57 to ortho-disubstituted arenes (Figure 19). 
 
 
Figure 19: Dihydroxylation of ortho-disubstituted arenes and ratio of metabolites.
69
 
 
 The validity of Boyd’s model57 was further supported in 2009 when TDO was co-
crystallized with toluene.
59
  The resulting crystal structure (Figure 20) demonstrated the 
alignment of the positions ortho- and meta- to the sterically largest substituent with 
modelled dioxygen.
59
  This visualization of the active site with bound substrate served to 
explain the selectivity of the dihydroxylation and the cis relationship of the hydroxyl 
groups in the metabolites produced.
59 
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Figure 20: Crystal structure of TDO active site with bound substrate (toluene) (Red ball 
= mononuclear Fe center).
59
 
 
2.2.2.3 Use of cis-cyclohexadienediols in organic synthesis 
 As discussed in the Introduction, biocatalysis has the potential to significantly 
increase the efficiency of a synthetic sequence.  In the synthetic application of cis-
cyclohexadienediols, this potential was first recognized by Imperial Chemical Industries 
(ICI, now AzkoNobel) in 1983.
70
  ICI applied the meso-diol (41) derived from the 
dihydroxylation of benzene by P. putida in the synthesis of polyphenylene (71) (Scheme 
4).
70 
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Scheme 4: Synthesis of polyphenylene (66) by Imperial Chemical Industries.
70
 
 
 The synthetic application of cis-cyclohexadienediol metabolites was first adopted 
in academia by Ley in 1987.
71
  Ley also used the meso-diol 41 to synthesize (±)-pinitol 
(72) in just six steps.
71
  Shortly after this seminal publication, Hudlicky applied cis-
cyclohexadienediols in synthesis for the first time in North America.
72
  Hudlicky utilized 
the metabolite of toluene (28) in a short formal synthesis of prostaglandin (PGE2α, 73).
72
  
In 1990, Hudlicky demonstrated the versatility of cis-cyclohexadienediols in 
enantioselective synthesis by applying the metabolite of bromobenzene (74) in the 
synthesis of both (+)- and (−)-pinitol (72).73 
 These early reports led many synthetic chemists to recognize the potential utility 
of cis-cyclohexadienediol metabolites.
14
  A small, representative sample of the syntheses 
which have originated in cis-cyclohexadienediol metabolites is given in Table 2.
71-85
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Table 2: Examples of chemoenzymatic syntheses using cis-cyclohexadienediols.
71-85
 
Starting 
material 
Product Author Year Reference 
 
 
 
 
41 
 
 
 
(±)-pinitol (72) 
 
 
Ley 
 
1987 
 
71 
 
 
 
28 
 
 
 
Prostaglandin (PGE2α, 73) 
(Formal Synthesis) 
 
Hudlicky 
 
1988 
 
72 
 
 
 
 
74 
 
 
 
(+)- and (−)-pinitol (72) 
 
 
Hudlicky 
 
1990 
 
73 
 
 
 
 
 
74 
 
 
 
(+)-pancratistatin (75) 
 
 
Hudlicky 
 
1995 
 
74 
 
 
 
74 
 
 
 
 
76 
 
 
Banwell 
 
1996 
 
75
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74 
 
 
 
oligoinositols (77) 
 
 
Hudlicky 
 
2002 
 
76 
 
 
 
 
 
78 
 
 
 
carba-β-L-glucopyranose (79) 
 
 
Boyd 
 
2005 
 
77
 
 
 
 
28 
 
 
 
(+)-hirsutic acid (80) 
 
Banwell 
 
2007 
 
78
 
 
 
 
 
 
81 
 
 
 
(+)-codeine (82) 
 
 
Hudlicky 
 
2007 
 
79
 
 
 
 
R = Br (74)
80,81
 
 
R = CO2Et (83)
82
 
 
 
 
 
Tamiflu (84) 
 
 
Fang, 
 
Banwell, 
 
Hudlicky 
 
2008 
 
2008 
 
2009 
 
80
 
 
81
 
 
82
 
 
 
 
85 
 
 
 
 
(+)-nangustine (86) 
 
 
Banwell 
 
2008 
 
83
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87 
 
 
 
Kibdelone A (88) 
 
Porco, 
Hudlicky 
2013 
84 
 
 
 
74 
 
 
 
 
Vindoline analogue (89) 
 
 
Banwell 
 
2016 
 
85
 
 
 
Despite the fact that more than 400 cis-cyclohexadienediol metabolites have been 
identified,
14(o)
 only a small fraction (< 10) of these have been applied in synthesis.
14(r)
  
The fact that so many metabolites have yet to be applied, combined with the versatility of 
these compounds, leaves tremendous potential for continued advancement in this field.  
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2.2.3 Benzoate dioxygenase (BZDO) 
 The following section will provide a discussion on the structure, mechanism, 
substrate scope, selectivity and applications of benzoate dioxygenase (BZDO). 
 
2.2.3.1 Structure and Catalytic Mechanism 
 Benzoate dioxygenase (BZDO) catalyzes the 1,2-dihydroxylation of benzoic acid 
and related derivatives (Figure 21).
13
  Like TDO, BZDO is a Rieske non-heme iron 
dioxygenase system which is made up of multiple protein components.
86
  The BZDO 
system consists of a reductase enzyme (BZDO-R) and a terminal oxygenase (BZDO-
O).
86
  Unlike TDO, the BZDO system lacks a distinct ferredoxin protein.
86
   
 
 
Figure 21: Metabolism of benzoic acid (3) by BZDO.
13
 
 
 Despite lacking a distinct ferredoxin protein, electron transport in BZDO occurs 
in a very similar manner as in TDO (discussed in Section 2.2.2.1).
58,87
  BZDO-R consists 
of three domains; an NADH binding domain, a flavin binding domain, and a ferredoxin 
domain (Figure 22).
87
  As in TDO, electrons are transferred from NADH to FAD within 
the reductase, where they are then passed on to the Rieske [2Fe-2S] centre in the 
ferredoxin domain, and finally on to the terminal oxygenase.
87
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Figure 22: Structure of BZDO-R (FAD domain = yellow, NADH domain = blue, 
ferredoxin domain = red).
87 
 
 Although no crystal structure is available for BZDO-O, this terminal oxygenase 
has been shown to be a hexamer of three β-subunits and three catalytic α-subunits.86(c)  
The structure of the catalytic site in the α-subunit can be drawn from analogy to other 
dioxygenase enzymes (Figure 11, Section 2.2.2.1), as this site has been shown to be 
highly conserved throughout this family.
58,59
   
 As in the case of TDO, the catalytic mechanism of BZDO remains the subject of 
debate.  Careful study of the mononuclear iron centre in the catalytic site through EPR 
spectroscopy provided evidence of a reactive intermediate of type 39 (Figure 12, Section 
2.2.2.1).
62
  This finding, as well as evidence of the side-on binding of oxygen to the 
mononuclear iron centre observed in other dioxygenase enzymes,
59,62
 have led to a 
proposed mechanism which is analogous to that shown in Figure 13 (Section 2.2.2.1).   
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2.2.3.2 Substrate scope and selectivity 
 Although the substrate scope of BZDO has been shown to be more limited than 
TDO, this enzyme system does accept a range of substituted benzoic acid 
derivatives.
14(o),15
  Metabolism of ortho-, meta- and para-substituted benzoic acid 
derivatives by BZDO has led to the isolation of metabolites of type 90-96 (Figure 
23).
14(o),15,88
  BZDO also accepts a limited range of tri-substituted benzoic acid derivatives 
to produce metabolites of type 97-99 (Figure 23).
14(o),15
 
 
 
Figure 23: Examples of metabolites produced by BZDO.
14(o),15,88
 
 
 In his study of the metabolism of substituted benzoic acid derivatives as substrates 
for BZDO, Knackmuss demonstrated that substitution at the meta position is most well 
tolerated.
89
  Para substitution was less well tolerated, with 4-methyl and 4-chlorobenzoic 
acid being metabolized only very slowly.
89
  Substitution at the ortho position was the 
least well tolerated, with only 2-fluorobenzoic acid being metabolized.
89
  The substrate 
 37 
 
scope of BZDO has also been shown to be limited by the steric size of the substituents, as 
2-,3- and 4-iodobenzoic acid (100) were shown not to be metabolized (Figure 24).
90
   
 
 
Figure 24: Attempted dihydroxylation of iodobenzoic acids with BZDO.
90
 
 
 Boyd’s model for the regioselectivity of dioxygenase-mediated dihydroxylation 
(Figure 18)
57
 has been shown not to apply to BZDO, as the dihydroxylation is directed by 
the carboxylate moiety in all cases.
14(o),15
  In the metabolism of meta-substituted benzoic 
acid derivatives, it was initially reported that 5-halo metabolites (104) were formed in 
preference to 3-halo metabolites (103) (Figure 25).
89(a)
  This finding was revised in later 
studies, as it was shown that 3-halo metabolites (103) were preferentially produced in the 
metabolism of 3-methyl and 3-halobenzoic acids (Figure 25).
89(c),91
 
 
 
Figure 25: Regioselectivity in the metabolism of meta-substituted benzoic acid 
derivatives.
89,91
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2.2.3.3 Use of ipso-cyclohexadienediols in organic synthesis 
 The first synthetic application of the metabolite of benzoic acid produced by 
BZDO was reported by Widdowson and Ribbons in 1995,
92
 24 years after this compound 
was first characterized.
55
  This report demonstrated the stereo- and regioselectivity by a 
series of cycloaddition reactions between derivatives of metabolite 4 and various 
cycloaddition partners (Scheme 5).
92
     
 
 
Scheme 5: First synthetic application of metabolite 4 by Widdowson and Ribbons.
92 
 
 In the same report, the absolute stereochemistry of metabolite 4 was demonstrated 
through the formation of its (p-bromobenzoyl)methyl ester (111) (Scheme 6).
92
  X-ray 
crystallographic analysis of ester 111 confirmed the absolute stereochemistry of 
metabolite 4 to be as shown in Scheme 6.
92
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Scheme 6: Derivatization of metabolite 4 for the determination of absolute 
stereochemistry.
92
 
 
 The reactivity of metabolite 4 was further studied by Myers
93
 and by 
Mihovilovic,
94
 who demonstrated the versatility of this metabolite and described its 
potential synthetic utility.  In 2004, the first total synthesis using metabolite 4 was 
reported by Parker at Johnson and Johnson.
95
  This synthesis utilized ipso-diol 4 in the 
production of analogues of an anti-convulsant agent, an example of which is shown in 
Table 3.
95
  The first natural product synthesis to use ipso-diol 4 was reported by Myers in 
2005, in the synthesis of tetracycline antibiotics.
96
  This synthesis represented a 
significant improvement in yield over previous approaches to tetracyclines,
15(a),96
 and 
likely played a significant role in the recognition of the utility of ipso-diol 4.  Following 
this 2005 report, ipso-diol 4 has been applied in the synthesis of many compounds of 
interest,
15
 relevant examples of which are shown in Table 3.
95-101
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Table 3: Examples of chemoenzymatic syntheses using ipso-diol 4.
95-101
 
Starting Material Product Author Year Reference 
 
 
 
4 
 
 
 
 
topiramate analogue (112) 
 
 
Parker 
 
2004 
 
95 
 
 
 
4 
 
 
 
 
(−)-6-deoxytetracycline (113) 
 
 
Myers 
 
2005 
 
96 
 
 
 
4 
 
 
 
 
(+)-grandifloracin (114) 
 
Lewis 
 
2011 
 
97
 
 
 
 
4 
 
 
 
 
“inosaminoacid” (115) 
 
 
Lewis 
 
2011 
 
98
 
 
 
 
4 
 
 
 
 
(−)-idesolide (116) 
 
Hudlicky 
 
2011 
 
99
 
 
 
 
4 
 
 
 
(+)-zeylenol (117) 
 
Lewis 
 
2012 
 
100
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4 
 
 
 
 
“iminosugar” (118) 
 
Hudlicky 
 
2014 
 
101
 
 
 As evident from Table 3, all of the reported total synthesis employing BZDO have 
used ipso-diol 4.  Reports by Banwell
88
 and Lewis
90
 demonstrated the versatility and 
potential utility of the metabolites of substituted benzoic acid derivatives (such as those 
shown in Figure 23). Despite these reports, none of these compounds have yet been 
applied in total synthesis.  The fact that so many metabolites have yet to be applied, 
combined with the versatility of these compounds, leaves tremendous potential for 
continued advancement in this field. 
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2.2.4 Synthetic Dioxygenase Analogues 
 As the dioxygenase-mediated cis-dihydroxylation of aromatics is one of the few 
natural transformations without a synthetic equivalent, efforts have been made to identify 
catalysts that mimic the functions of dioxygenases.
102,103
  In 1995, Motherwell used 
osmium tetraoxide under light irradiation to achieve the catalytic dihydroxylation of 
benzene (17) (Scheme 7).
102(a)
  The transformation was proposed to proceed through 
intermediate 119, and was used in the synthesis of cyclitol derivatives such as 120, and 
later in the synthesis of (±)-pinitol (72).
102
 
 
 
Scheme 7: Catalytic dihydroxylation of benzene (17) by Motherwell.
102
 
 
 More recently, Que reported an iron-based catalyst which performed the cis-
dihydroxylation of naphthalene with hydrogen peroxide in low yield (Scheme 8).
103
  This 
catalyst system was used to study the mechanism of oxygen incorporation from hydrogen 
peroxide to diol 122.
103
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Scheme 8: Catalytic dihydroxylation of naphthalene (15) by Que.
103
 
 
 Although research in this field has identified multiple potential catalyst 
systems,
102,103
 the enantioselective, or even racemic, dihydroxylation of aromatics with a 
synthetic dioxygenase mimic has yet to be achieved.  Research in this field remains 
active. 
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2.3 Carbonylation Chemistry 
 One of the topics discussed in this thesis will be the chemical generation of 
metabolites that are produced in low yield by fermentation.  In section 3.2, the synthesis 
of diols derived from benzoates in relatively low yield (< 1 g/L) will be presented.  The 
diols derived from halobenzenes are produced in high yields (10-20 g/L).  Conversion of 
these diols to those derived from benzoates is accomplished by palladium-catalyzed 
carbonylation.  The following section provides a brief review of this methodology. 
 
2.3.1 History 
 Carbonylation chemistry is a field with a long history dating to the discovery of 
the cobalt-catalyzed hydroformylation of olefins by Roelen in 1938 (Scheme 9).
104
  Its 
importance is exemplified by the fact that the hydroformylation process was used in the 
industrial production of 10.4 million metric tons of compounds of type 124 and 125 as 
recently as 2008.
105
  Because carbonylation chemistry is a tremendously varied and well-
studied field, the discussion here will focus on the palladium-catalyzed carbonylation of 
aryl and vinyl halides and pseudohalides. 
 
 
Scheme 9: Hydroformylation process discovered by Roelen (R, R’ = H, alkyl, aryl).104 
  
Over the past 50 years, palladium-catalyzed cross coupling reactions have become 
increasingly important tools in synthetic chemistry, as evidenced by the awarding of the 
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Nobel Prize to Heck, Negishi and Suzuki in 2010.
106
  Palladium-catalyzed carbonylation, 
an example of an important of cross-coupling methodology, was first reported by Heck in 
1974 (Scheme 10).
107
  These seminal reports described the reaction of aryl and vinyl 
halides with carbon monoxide to form acylpalladium intermediates, which are then 
converted to carbonyl compounds by reaction with a nucleophile (Scheme 10).
107
  Heck 
reported three variations of the carbonylation reaction: alkoxycarbonylation, 
aminocarbonylation, and reductive carbonylation that allowed access to three different 
potential products (127-129) (Scheme 10).
107
 
 
 
Scheme 10: First report of palladium-catalyzed carbonylation by Heck.
107 
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 These reports established the applicability of aryl and vinyl bromides and iodides 
to this methodology, and demonstrated the requirement for a tertiary amine base.  The 
standard catalyst system of a palladium (II) species with an excess of triphenylphosphine 
ligand, or a pre-formed palladium-triphenylphosphine catalyst was also established.
107
   
The relatively mild conditions of these transformations led to their wide-spread 
application
108
 and to studies aimed at expanding their potential utility.  The applicability 
of alkoxy- and aminocarbonylation was extended to aryl and vinyl chlorides,
109
 
triflates,
110
 tosylates,
111
 and mesylates.
112
  In order to overcome the energy barrier for 
oxidative insertion into some C-X bonds, ligand systems were designed to increase the 
electron density at palladium, examples of which are shown in Figure 26 (130-
132).
109,113,114
 
 
 
Figure 26: Alternate catalyst systems designed to increase electron density at 
palladium.
109,113,114 
 
 In an effort to eliminate the need for toxic, gaseous CO, it was shown that 
Mo(CO)6 could act as a surrogate.
115
 Stille demonstrated that Bu3SnH could be 
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effectively used as a hydride donor in reductive carbonylation as an alternate to hydrogen 
gas.
116
  Silanes such as Et3SiH were also shown to be effective hydride sources.
117
   
 More recently, the focus of carbonylation research has shifted to creating a more 
efficient and environmentally benign catalyst system,
106(e)
  leading to the development of 
re-usable, polymer supported catalysts, such as those shown in Figure 27 (133, 134).
118
  
These catalysts can readily be filtered from the reaction mixture and reused many times, 
and they eliminate the need for the addition of external phosphine ligands.
118
   
 
 
Figure 27: Re-usable, polymer supported carbonylation catalysts.
118 
 
 Other transition metals have been shown to catalyze the carbonylation of aryl and 
vinyl halides, including nickel
107(a),119
 and cobalt.
120
  Carbonylation reactions catalyzed by 
nickel require higher catalyst loading and higher temperatures,
107(a),119
 while catalysis 
with cobalt required simultaneous irradiation with light.
120
  For these reasons, palladium 
catalysis remains the preferred means for the carbonylation of aryl and vinyl halides in 
academic and industrial settings.
108
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2.3.2 Mechanism 
 In his seminal report of palladium-catalyzed alkoxycarbonylation, Heck proposed 
two potential mechanisms, as shown in Figure 28.
107(a)
  Although Heck considered both 
possible mechanisms, mechanism B was favoured, as it was known that organopalladium 
species can readily undergo CO insertion.
107(a) 
 
Figure 28: Mechanistic proposals made by Heck in 1972 (R = aryl/vinyl, L = 
ligand).
107(a) 
 
 The primary difference between the two proposed mechanisms lies in the mode of 
attack of the nucleophile on the palladium-bound CO (136) and the subsequent reductive 
elimination in A.
107(a)
  This is contrasted by the migratory insertion of CO in the organo-
palladium species (136) followed by nucleophilic attack to form the product in B.
107(a)
   
 It is now recognized that CO ligands reduce the electron density at palladium, 
making it likely that the palladium (II) pre-catalyst is reduced to the active palladium (0) 
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species by the binding of ligands or solvent as opposed to the binding of CO (135) 
(Figure 28).
106(e),109
  Oxidative insertion of palladium (0) to the carbon-halide bond of the 
substrate then occurs, forming an organo-palladium species of type 136 (Figure 
28).
106(e),107(a)
  The binding of CO follows oxidative insertion, and occurs rapidly for 
unhindered substrates, but can be rate limiting for hindered substrates.
121
  Migratory CO 
insertion into the carbon-palladium bond then proceeds rapidly and irreversibly, even at 
room temperature, which precludes the possibility of mechanism A, as originally 
proposed by Heck.
107(a),109(a)
  The steps following migratory insertion remain the subject 
of debate. 
Yamamoto proposed a mechanism shown in Figure 29, in which migratory 
insertion was followed by nucleophilic attack at palladium to form an intermediate of 
type 142.
122
  This contrasted with the direct nucleophilic attack of the acyl-palladium 
species proposed by Heck (mechanism B) (Figure 28).
107(a),109(a)
  For details on the 
research supporting this mechanism, see reference [122]. 
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Figure 29: Carbonylation mechanism proposed by Yamamoto.
122
 
 
Research by Hidai and Milstein however, supported the direct nucleophilic attack 
of the acyl-palladium species (138) as proposed by Heck.
109(a),123
  For details on this 
research supporting this proposed mechanism, see references [109(a),123]. 
 In the mechanism proposed by Yamamoto, product release occurs from complex 
142 by reductive elimination,
122
 and in the case of the direct nucleophilic attack, product 
release occurs as a result of base-assisted alcoholysis (or aminolysis) of the acyl-
palladium species (138).
109(a)
  Regardless of whether the direct nucleophilic attack 
mechanism is favoured, the overall mechanism for the palladium-catalysed carbonylation 
of aryl and vinyl (pseudo)halides can be generalized as shown in Figure 30.
106
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Figure 30: General mechanism for Pd-catalysed carbonylation of aryl/vinyl 
(pseudo)halides.
106
 
  
2.3.3 Use of carbonylation chemistry in organic synthesis 
 Palladium-catalyzed carbonylation has become an extremely valuable tool in 
synthetic chemistry, because of its utility for the installation of various carbonyl 
functionalities and its functional group tolerance.
106,108
  The use of this transformation in 
organic synthesis is ubiquitous, and the discussion here will serve only to highlight key 
examples of the application of alkoxycarbonylation, aminocarbonylation and reductive 
carbonylation.
106,108 
 
An excellent example of the versatility of palladium-catalyzed carbonylation is 
the synthesis of 8-carboxamidocyclazocine analogues (144-149) by Wentland (Scheme 
11).
124
  In this study, both alkoxy- and aminocarbonylation were applied in the late-stage 
introduction of ester and amide functionalities to 8-carboxamidocyclazocine analogues.
124
  
In this way, six different analogues (144-149) were synthesized from one common 
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intermediate (143) (Scheme 11).
124
  These compounds were shown to have an 
unexpectedly high affinity for opioid receptors, and have contributed significantly to the 
understanding of the structure-activity relationship of this family of compounds.
124
 
 
 
Scheme 11: Synthesis of 8-carboxamidocyclazocine analogues (143-149) by 
Wentland.
124 
 
 Reductive carbonylation was applied in a “scalable” synthesis of lactone 152, a 
key intermediate in the production of the potent insecticide (+)-nodulisporic acid (153) 
(Scheme 12).
125
  This carbonylation reaction was readily performed on ten-gram scale in 
very high yield (Scheme 12).
125
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Scheme 12: Synthesis of lactone 152 by Smith.
125 
 
 
Pseudohalides such as triflates are commonly employed as carbonylation 
substrates in organic synthesis because of their ready availability from 
alcohols.
106,108,124,125
  Halides are also commonly used, as was the case in the synthesis of 
the potent anti-viral compound (−)-virantmycin (155) by Kogen (Scheme 13).126  In this 
particular carbonylation reaction, water acted as the nucleophile resulting in the 
production of the carboxylic acid moiety of (−)-virantmycin (155) (Scheme 13).126 
 
 
Scheme 13: Synthesis of (−)-virantmycin (155) by Kogen.126 
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Although exceptionally brief, the above discussion serves to exemplify the 
versatility and the potential practical applicability of the palladium-catalyzed 
carbonylation of aryl and vinyl (pseudo)halides. 
 The following section will provide a discussion on alkylcyclohexenone natural 
products including their isolation, biological activity and their production by organic 
synthesis. 
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2.4 Alkylcyclohexenone natural products 
  One of the topics discussed in this thesis will be the chemoenzymatic synthesis of 
pleiogenone A (14) (Figure 31).  The following section will provide a brief review of the 
isolation, biological activity and synthesis of various compounds of this type. 
 
2.4.1 Isolation and biological activity 
 In the past 20 years, many hydroxylated cyclohexenone natural products have 
been isolated from various plant and fungal sources, representative examples of which are 
shown in Figure 31 (14, 156-165).
17,127,128,129,130,131,132
  Many of these compounds have 
interesting and potentially useful biological activity, leading to an interest in these 
compounds by medicinal and synthetic chemists. 
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Figure 31: Examples of hydroxylated cyclohexenone natural products.
17,127-132 
 
 The first of the compounds discussed here is xylosmin (156), which was isolated 
from Xylosma flexuosum in 1995 by Gibbons.
127(a)
  Gibbons also proved the structure and 
absolute stereochemistry of xylosmin.
127(a)
  In 2012, a series of closely related compounds 
were also identified, differing from xylosmin only in the extent and regioselectivity of 
their benzoylation.
127(b)
  These compounds have been shown to inhibit the replication of 
dengue virus,
127(b)
 as well as the growth of malaria parasites.
133
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 Zeylenone (157) was isolated from Uvaria grandiflora by Liao in 1997, who also 
determined its structure and relative stereochemistry.
128(a)
  Zeylenone (157) was shown to 
be a potent inhibitor of nucleoside transport in carcinoma cells,
128(a)
  and was later shown 
to induce apoptosis in a variety of cancer cell lines.
134
  Furthermore, zeylenone has 
recently been tested in animal studies as a potential local-delivery anti-tumour agent.
135
  
In 2001, the related compounds 3-O-debenzoylzeylenone and 2-O-benzoyl-3-O-
debenzoylzeylenone as well as zeylenone (157) were isolated from Uvaria purpurea, and 
these compounds were all shown to inhibit root growth in Lactuca sativa.
128(b)
   
 Compound 158 was isolated from Tapirira obtusa by Cordell in 2001, who also 
determined the structure and relative stereochemistry of this compound.
129
  Cordell 
proposed that 158 was a biogenetic precursor to dermatitis-causing n-alkylphenols known 
to be produced by plants in this family, but did not report any biological activity data.
129
  
Compounds 159 and 160 were isolated from Lannea edulis by Hostettmann in 2003.
130
  
Hostettmann also determined the structure of these compounds, as well as their absolute 
configuration, through the use of the Mosher ester method.
130,136
  Compounds 159 and 
160 did not demonstrate any anti-fungal or anti-bacterial activity.
130
  More recently, 
Roumy and Fabre isolated compound 161 from Tapirira guianensis, and determined its 
structure and relative configuration.
131
  Compound 161 was shown to have anti-
plasmodial and anti-bacterial properties, which supported the traditional use of Tapirira 
guianensis in the treatment of external infections.
131
   
   The pleiogenone family of compounds (14, 162, 163) was isolated in 2015 by 
Kingston.
17
  After determining the structure of these compounds by nuclear magnetic 
resonance (NMR) and mass spectrometry (MS) analysis, Kingston determined the 
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absolute configuration of pleiogenones A-C (14, 162, 163).
17
    The anti-proliferative 
properties of pleiogenones A-C (14, 162, 163) were tested against an ovarian cancer cell 
line, and all three compounds exhibited moderate activity (IC50 = 0.7-0.8 µM).
17 
 The pseudohygrophorones (164, 165) were isolated in 2016 by Arnold,
132
 from 
the fruiting bodies of the basidiomycete Hygrophorus abieticola.  The 
pseudohygrophorones A and B were the first hydroxylated cyclohexenone natural 
products to be isolated from fungal sources.  Arnold also determined the structure as well 
as the relative and absolute stereochemistry of these compounds.  Pseudohygrophorone A 
and B (164, 165) were shown to inhibit the growth of plant pathogenic fungi, with 
efficacy comparable to that of commercial pesticides.
132
 
 
2.4.2 Biosynthesis 
 Although none of the compounds discussed in the section have been specifically 
studied in the context of their biosynthesis, proposals have been made as to the 
biosynthetic pathway towards hydroxylated cyclohexene natural products.  The example 
of the biosynthesis of zeylenone (169) is given in Scheme 14.   
The biosynthesis of compounds of this type was first addressed by Ganem, who 
stated that the pathway likely occurs through the initial formation of epoxide 166, derived 
from benzyl benzoate (Scheme 14).
137,138
  Opening of this epoxide would lead to trans-
diol 167, a motif which has been identified in compounds isolated from plants of the 
Uvaria genus.
139
  A second epoxidation and benzoylation would afford intermediate 168, 
which could be converted to zeylenol (169) though epoxide opening.
100,137,138
  The 
oxidation of zeylenol (169) would afford zeylenone (157) (Scheme 14). 
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Scheme 14: Proposed biosynthetic pathway for zeylenol (169) and zeylenone 
(157).
100,138,139
 
 
 Because many hydroxylated cyclohexene natural products have been isolated in 
both enantiomeric forms, including zeylenol (169) and zeylenone (157) congeners,
100
 
proposals have been made to account for the biosynthesis of both enantiomers.  The first 
proposal stated that epoxide 166 can racemize through the formation of oxepin 170 
(Figure 32).
140
  The existence of the enantiomeric form of epoxide 166 would lead to the 
enantiomer of zeylenol (169) and zeylenone (157) through the biosynthetic scheme 
outlined in Scheme 14.  The second proposal stated that neighbouring-group assistance 
from the ester moiety of epoxide 166 can lead to the opening of the epoxide at C-2 (171), 
as opposed to C-3 opening shown in Scheme 14.
141
  This process would lead to the 
production of the enantiomer of trans-diol 167, and therefore to the eventual biosynthesis 
of the enantiomeric forms of hydroxylated cyclohexene natural products. 
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Figure 32: Proposed transformations in hydroxylated cyclohexene biosynthesis.
140,141
 
 
 These biosynthetic proposals can be used to account for the hydroxylation 
observed in many hydroxylated cyclohexene natural products including xylosmin (156), 
zeylenone (157) and pleiogenones A-C (14, 162, 163).  The biosynthetic origin of other 
moietites such as the alkenyl groups present in the pleiogenenones, the 
pseudohydrophorones and compounds 158-161, remains unknown. 
 
2.4.3 Syntheses 
 Of the compounds discussed in this section, synthetic approaches have been 
reported for xylosmin (156) and zeylenone (157).  Inspired by recent reports of the anti-
malarial and anti-viral properties of compounds of this type,
127(b),133
 the first approach 
towards the synthesis of xylosmin (156) was undertaken by Hudlicky in 2015.
142
  This 
synthetic approach was focused on the production of the hydroxylated cyclohexenone 
fragment of xylosmin (156), as the phenolic and saccharide moieties can be readily 
installed at a later stage.  The enzymatic metabolite, ipso-diol 4 was used as the starting 
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material, as it contains some of the desired functionality present in xylosmin (156).  In the 
first approach towards xylosmin, ipso-diol 4 was converted to lactone 172, through a 
process developed by Myers (Scheme 15).
93
  Lactone 172 was then opened with sodium 
methoxide to isolate an epoxide which was selectively opened with bismuth triflate and 
oxidized with 2-iodoxybenzoic acid (IBX) to afford enone 173.  Unfortunately, all 
attempts to invert the stereochemistry of the C-2 hydroxyl group, either through 
enolization/epimerization or Mitsunobu reaction, failed.  
 
 
Scheme 15: First approach towards xylosmin (156) by Hudlicky.
142 
 
The synthetic strategy was then altered to involve a key hydrogen-bond directed 
Donohoe dihydroxylation
143
 of ester 175 (prepared in two steps from ipso-diol 4), to 
ensure the correct C-2 stereochemistry.  Following dihydroxylation, the selective 
oxidation of the allylic alcohol in triol 176 was affected with 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (DDQ) (Scheme 16).  Attempts to hydrolyse the para-bromo benzoyl 
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ester moiety were not successful, however this report constitutes the first synthetic 
approach towards xylosmin (156). 
 
 
Scheme 16: Second synthetic approach towards xylosmin (156) by Hudlicky.
142 
 
 The first synthesis of zeylenone (157) was reported by Ogawa in 1999.
144
  This 
synthesis used silyl ether 179, previously prepared by Ogasawara,
145
 as the starting 
material (Scheme 17).  Methoxycarbonylation of 179 and the subsequent hydroxylation 
and reduction all occurred from the convex face of the molecule, affording diol 180.  
Bromo-ether formation was then effected with NBS, and was followed by a four-step 
sequence to produce benzoate 181.  Upjohn dihydroxylation
146
 was performed after the 
benzoylation step, a design which allowed for the benzoylation of only the required 
positions.  Upjohn dihydroxylation
146
 occurred exclusively on the convex face of the 
molecule, and was followed by regeneration of the cyclopentene olefin and silyl 
protection of the resulting triol to afford olefin 182.  The hetero Diels-Alder reaction of 
 63 
 
olefin 182 and subsequent silyl deprotection furnished zeylenol (169), which was then 
oxidized to zeylenone (157).   
 
 
Scheme 17: Synthesis of zeylenol (169) and zeylenone (157) by Ogawa.
144
 
 
 The second synthesis of zeylenone (157), published in 2004 by Liu and Xu,
147
 
reported the production of the enantiomer of the natural product, (+)-zeylenone (157), 
and was later expanded to the synthesis of the natural enantiomer (−)-zeylenone (157).148  
This approach employed a chiral pool strategy, with shikimic acid (183) as the starting 
material (Scheme 18).  In a sequence of five steps, shikimic acid (183) was converted to 
benzoate 184, the desired substrate for the key Upjohn dihydroxylation step.  The 
stereoselective Upjohn dihydroxylation occurred on the less hindered β-face of benzoate 
184, and was followed by acetonide protection of the resultant diol and selective 
deprotection to afford diol 185.  The diol moiety was then converted to the corresponding 
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alkene, producing olefin 186.  All attempts to oxidize olefin 186 at C-6 with the goal of 
introducing the enone functionality failed, causing the authors to alter the order of 
operations and prepare benzoate 187.  The C-6 oxidation of benzoate 187 was successful, 
and was followed by acetonide deprotection to afford (+)-zeylenone (157). 
 
 
Scheme 18: Synthesis of (+)-zeylenone (157) by Liu and Xu.
147
 
 
 In 2006, this synthetic strategy was adjusted in an enantiodivergent manner in 
order to produce the natural enantiomer, (−)-zeylenone (157) from the same starting 
material.
148
  The enantiodivergence was achieved by the application of the Mitsunobu 
reaction to ester 188, a known intermediate from the previous synthesis, to afford alcohol 
189 (Scheme 19).  This stereochemical inversion also altered the steric influence on the 
key Upjohn dihydroxylation, resulting in stereoselective dihydroxylation from the α-face 
(190).  In this way, the required stereochemistry was achieved in the synthesis of natural 
(−)-zeylenone (157). 
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Scheme 19: Enantiodivergent synthesis of (−)-zeylenone (157) by Liu and Xu.148 
 
 The most recent approach to zeylenone congeners was reported by Lewis in 
2012.
100
  This report describes the synthesis of zeylenol (169), as well as two natural 
zeylenol isomers, and the natural zeylenone congener 3-O-debenzoylzeylenone (195). As 
in Hudlicky’s approach towards xylosmin, the enzymatic metabolite ipso-diol 4 was used 
as a starting material (Scheme 20).  The key transformation in this synthesis is the 
cycloaddition of benzoate 191 (prepared in three steps from ipso-diol 4) with singlet 
oxygen, which occurred exclusively on the less hindered β-face of the molecule to afford 
endoperoxide 192.  Reduction of the endoperoxide moiety led to diol 193, which was 
selectively protected and the free alcohol oxidized to afford enone 194.  The acetonide 
and silyl protecting groups were then simultaneously deprotected with iodine in methanol 
to afford 3-O-debenzoylzeylenone (195), completing the synthesis in a total of eight steps 
and in an overall yield of 15%.
100
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Scheme 20: Synthesis of 3-O-debenzoylzeylenone (195) by Lewis.
100 
 
 The primary challenge in the syntheses discussed in this section is the 
introduction of the many hydroxyl moieties in the correct stereochemical configuration.  
Some of the strategies discussed here addressed this challenge in part by applying a chiral 
pool approach, while others used enzymatic dihydroxylation.  In order to introduce the 
additional hydroxyl moieties in a stereoselective manner, Hudlicky, Ogawa as well as Liu 
and Xu employed osmium-mediated dihydroxylation, while Lewis used a stereoselective 
cycloaddition with singlet oxygen.
142,144,145,148
  This concludes the historical overview of 
key areas that will be discussed in this thesis. 
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3. Results and Discussion 
 
3.1 Introduction 
 With the review of dioxygenase enzymes, carbonylation chemistry and 
hydroxylated cyclohexenone natural products complete, the key projects of this 
dissertation will be discussed.  These are, in order; 
1) Investigation of TDO selectivity and substrate scope 
2) Carbonylation of halo cis-cyclohexadiene diols to the corresponding carboxylates 
3) Approaches towards the synthesis of tetrodotoxin 
4) Synthesis of pleiogenone A 
 
3.2 Investigation of TDO selectivity and substrate scope 
 
3.2.1 Dihydroxylation of ortho-halo benzoates 
 
 In 2011, Hudlicky reported the formal synthesis of kibdelone C and its congeners, 
through the production of intermediate 199 (Scheme 21).
149
  This key intermediate was 
synthesized in just two steps from diol 198, as compared to Porco’s 14-step synthesis of 
this compound from glyceraldehyde.
150
  Although this reported process demonstrated a 
high degree of brevity, it was limited by the fact that diol 198 was produced as the minor 
isomer from the TDO-mediated enzymatic dihydroxylation of methyl 2-iodobenzoate 
(196).  This report led to a collaboration between Hudlicky and Porco in the synthesis of 
kibdelone A.  In the course of this collaboration, it was found the brominated analogue 
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203, made from diol 202, could be used as a starting material (Scheme 21).
151
  In 
agreement with Boyd’s model for the regioselectivity of TDO-mediated 
dihydroxylation,
57
 (Section 2.2.2.2) the dihydroxylation of methyl 2-bromobenzoate 
(200) led to the preferential production of the desired regioisomer 202, which 
significantly increased the yield of the overall process. 
 
 
Scheme 21: Use of metabolites 198 and 202 in the synthesis of kibdelone 
congeners.
149,151
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 In 2012, the TDO-mediated dihydroxylation of the full series of methyl 2-
halobenzoates was studied, as discussed in section 2.2.2.2 (Figure 19).
69
  The ratio of 
regioisomeric products was investigated, and the findings provided further support to 
Boyd’s model,57 with sterically larger halogen substituents demonstrating a greater 
directing effect on the dihydroxylation (Figure 19).
69
    
In order to expand this study, the steric size of the ester substituent was varied in 
addition to the halogen (Figure 33).  The goals of this study were to measure the effect of 
differential steric size on the ratio of regioisomeric products, and to provide greater 
predictive power to Boyd’s model57 in planning future synthetic sequences. 
 
 
Figure 33: TDO-mediated dihydroxylation of ortho-halobenzoates (5). 
 
 To investigate the regioselectivity of the dihydroxylation of ortho-halo benzoates, 
large-scale (10 L) fermentation cultures of E. coli JM109 (pDTG601A)
54
 were grown 
according to reported procedures.
14(m)
  The cultures were grown to maximum optical 
density, and fed with the aromatic substrate until consumption of the substrate was no 
longer observed (monitored as a function of O2 consumption).  The ratio of regioisomeric 
products was determined by 
1
H NMR analysis of the crude fermentation extract, and 
yields were determined after purification of the mixture.  As the regioisomers proved 
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difficult to separate, the purification of these compounds was performed with the use of 
preparative high-pressure liquid chromatography (HPLC).  The results of this study are 
reported in Tables 4-7. 
 
Table 4: Results of the TDO-mediated dihydroxylation of 2-iodobenzoates. 
 
 
 
 
R = Ratio of products
a
 Yield (g/L)
b
 
methyl (196) 4 (197) : 1 (198)
69
 0.33
69
 
ethyl (205) 1 (210) : 1 (211) 0.04 
n-propyl (206) 1 (212) : 2 (213) trace 
allyl (207) 1 (214) : 4 (215) 0.01 
propargyl (208) 1 (216) : 12 (217) 0.07 
t-butyl (209) - - 
a
 determined by H NMR analysis of crude fermentation extract;  
b
 yield of combined mixture 
 
 The initial results, obtained with 2-iodobenzoates (Table 4), provided support for 
Boyd’s model.57  As is evident from table 4, as the steric size of the ester substituent 
increased, its directing effect on the enzymatic dihydroxylation also increased.  
Furthermore, a general trend was observed that as the size of the ester substituent 
increased, the overall yield of the fermentation decreased.  This result was expected based 
on previous reports.
66
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Table 5: Results of the TDO-mediated dihydroxylation of 2-bromobenzoates. 
 
 
 
 
R = Ratio of products
a
 Yield (g/L)
b
 
methyl (200) 1 (201) : 3.5 (202)
69
 0.40
69 
ethyl (218) 1 (223) : 3 (224) 0.30 
n-propyl (219) 1 (225) : 4 (226) trace 
allyl (220) 1 (227) : 10 (228) 0.02 
propargyl (221) 1 (229) : 48 (230) 0.35 
t-butyl (222) - - 
a
 determined by H NMR analysis of crude fermentation extract;  
b
 yield of combined mixture 
 
 The results obtained with 2-bromobenzoates (Table 5) were similar to those 
observed with 2-iodobenzoates (Table 4), further supporting Boyd’s model.57  The yields 
for fermentations with 2-bromobenzoates were generally higher than those observed with 
2-iodobenzoates, as expected from previous reports.
66
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Table 6: Results of the TDO-mediated dihydroxylation of 2-chlorobenzoates. 
 
 
 
 
R = Ratio of products
a
 Yield (g/L)
b
 
methyl (231) 1 (237) : 4 (238)
69
 0.33
69
 
ethyl (232) 1 (239) : 3.5 (240) 0.04 
n-propyl (233) 1 (241) : 20 (242) trace 
allyl (234) 1 (243) : 7 (244) 0.02 
propargyl (235) 3 (245) : 97 (246) 0.30 
t-butyl (236) - - 
a
 determined by H NMR analysis of crude fermentation extract;  
b
 yield of combined mixture 
 
 The results obtained with 2-chlorobenzoates (Table 6) were similar to those 
previously obtained (Tables 4 and 5), with respect to the general trends in regioselectivity 
and in yield.  Despite the smaller steric size of the chlorine substituent relative to 
bromine, the lower yields observed with 2-chlorobenzoates relative to 2-bromobenzoates, 
were expected based upon previous results.
152
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Table 7: Results of the TDO-mediated dihydroxylation of 2-fluorobenzoates. 
 
 
 
 
R = Ratio of products
a
 Yield (g/L)
b
 
methyl (247) - (253) : 100 (254)
69
 0.33
69
 
ethyl (248) - (255) : 100 (256) 0.04 
n-propyl (249) - (257) : 100 (258) trace 
allyl (250) - (259) : 100 (260) 0.02 
propargyl (251) - (261) : 100 (262) 0.30 
t-butyl (252) - - 
a
 determined by H NMR analysis of crude fermentation extract;  
b
 yield of combined mixture 
 
 Consistent with previous findings,
69
 2-fluorobenzoates yielded only one 
regioisomer upon TDO-mediated dihydroxylation, irrespective of the size of the ester 
substituent (Table 7). Furthermore, significantly higher yields were obtained using 2-
fluorobenzoates relative to the use of the other halogenated substrates. 
 As the diene diol metabolites (210-217, 223-230, 239-246) were found to be 
somewhat labile, these compounds were characterized by 
1
H NMR, IR and optical 
rotation before being converted to their partially reduced derivatives (263-271) (Scheme 
22).  Fluorinated metabolites (254, 256, 260, 262) displayed significantly greater levels of 
stability and were characterized fully.  Reduced derivatives 263-271 had significantly 
increased stability, and were fully characterized.  Because of the hydrogenation of the 
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allyl and propargyl ester moieties, all allyl and propargyl substituted metabolites 
converged to reduced derivatives 267, 269 and 271 (Scheme 22).  Metabolites 212-214, 
216, 225-227, 229, 241-243, 245 were not produced in quantities significant enough to 
facilitate characterization. 
 
 
Scheme 22: Partial hydrogenation of diol metabolites to facilitate full characterization. 
 
 In order confirm the absolute stereochemistry in the new metabolites, all of the 
fluorinated derivatives were converted to the corresponding methyl ester 254 (Scheme 
23), the absolute stereochemistry of which has been previously published.
69
  In the case 
of the iodo, bromo, and chloro compounds, their reduced derivatives (263-271) were 
converted to their corresponding methyl esters (272, 273) (Scheme 23).  The partially 
reduced methyl ester metabolites (272, 273) were matched by 
1
H NMR, melting point, 
and optical rotation to their corresponding compounds previously prepared from 
metabolites 198-201, 237, 238.
69 
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Scheme 23: Derivatization of metabolites for the confirmation of absolute 
stereochemistry.
69
 
 
An interesting trend emerged when examining the isomeric ratios associated with 
the propargyl compounds. In the case of iodo, bromo, and chloro compounds, the 
propargyl ester substituent was shown to be a much stronger directing group than any 
other.  Attempts to quantify the directing effect of a substituent by considering traditional 
metrics for steric size led to some confusion.  A-values are a commonly used metric for 
steric size, representing the free energy difference of a mono-substituted cyclohexane 
ring in the more stable (equatorial) and less stable (axial) conformations.
153
  The A-values 
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of the halogens (Table 8)
153
 do not reflect the observed difference in regioselectivity.  For 
esters, the A-values should roughly correspond to the A-values of the alkyl group of the 
alkoxide as the carboxylates remain constant.  Thus, a comparison of methyl, ethyl, n-
propyl, allyl, and the propargyl group could be made on the basis of the difference 
between terminal substituents (H for methyl ester, CH3 for ethyl ester, ethyl for n-propyl 
ester, vinyl for allyl ester, and acetylene for propargyl ester). As with the halogen 
substituents, the A-values (Table 8) cannot be used to explain the directing effects of the 
ester substituents.  Thus, other factors need to be considered to justify the observed 
regioselectivity trends.  
 
Table 8: Metrics for the steric size of halogen and ester substituents.
153,154
 
 
   
X =  A-value
153
 Charton value (ν)154 R =  A-value153 Charton value (ν)154 
F 0.25-0.42 0.27 H 0 0 
Cl 0.53-0.64 0.55 Me 1.7 0.52 
Br 0.48-0.67 0.65 Et 1.8 0.56 
I 0.47-0.61 0.78 vinyl 1.5 1.51 
 alkynyl 0.4 - 
 
Another metric to consider would be the Taft/Charton
154
 steric parameter value 
(ν) for both halogens and ester alkyl groups. The Taft/Charton steric parameter is 
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calculated from the rates of acid-catalyzed hydrolysis of aliphatic esters.
154
  Unlike the A-
values, these follow a logical trend (Table 8), although the value for alkynyl is not 
available.  While there is no clear linear relationship to explain the reversal of directing 
trends between the “apparent size” of the halogen versus that of the ester, at least some of 
the trends may be rationalized by using the internally consistent ν values for halogens and 
for the alkyl groups. For the esters it is clear that propargyl groups, regardless of apparent 
size, override the directing effects of halogens, as evidenced from the ratios of the two 
regioisomers obtained in all cases.  Although it would be possible to speculate, at this 
time, and without additional information, the origin of the selectivity apparent for 
propargylic esters and the difference in observed yields for these substrates cannot be 
explained. 
 This study provides greater predictive power in determining the regioselectivity in 
the dihydroxylation of ortho-disubstituted arenes.  This study also determined the steric 
limitations on the substrate scope of TDO with respect to ortho-halobenzoates, as all tert-
butyl benzoates were shown not to be substrates for the enzyme.  This results of this 
study were published in 2014.
155
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3.2.2 Dihydroxylation of para-disubstituted arenes 
 As part of an ongoing program in the synthesis of tetrodotoxin (10), a marine 
toxin first isolated in 1950,
156
 a series of para-disubstitued arenes were investigated as 
substrates for TDO (Figure 34).  In any approach to tetrodotoxin (10), a significant 
challenge would be the installation of the syn-carbon chains highlighted in Figure 34.  An 
approach toward this compound was envisioned wherein the core structure could be 
accessed through the use of 1,4-disubstituted diene-diol metabolites (9).  An ideal 
substrate (8) would include both carbon chains prior to enzymatic dihydroxylation, and a 
primary goal of the investigation of para-disubstituted arenes as substrates for TDO was 
to identify such a substrate. 
 
 
Figure 34: Potential synthesis of tetrodotoxin (10) using 1,4-disubstituted metabolites. 
 
 As discussed in Section 2.2.2.2, para-disubstituted arenes have previously been 
investigated as substrates for TDO by Boyd (Figure 17).
57
  In the course of this study, 
Boyd quantified the ratio of enantiomeric metabolites produced, and found that the ratio 
was determined by the steric size of the substituents on the aromatic ring.
57
  In designing 
a starting material for a potential enantioselective synthesis of tetrodotoxin (10), the 
enantioselectivity of the enzymatic dihydroxylation must be an important consideration.  
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Therefore, the goals of the investigation of para-disubstituted arenes as substrates for 
TDO must consider providing greater predictive power to Boyd’s model,57 in order to aid 
in the design of an appropriate starting material.   
 In order to investigate para-disubstituted arenes as substrates for TDO, small-
scale (1 L) fermentation cultures of E. coli JM109 (pDTG601A)
54
 were grown and fed 
with substrates according to reported procedures.
14(m),69
  In order to determine if an 
aromatic compound was metabolized by TDO, the crude fermentation extract was 
analyzed by 
1
H NMR.  In cases where the metabolism of a given substrate was observed, 
large-scale (10 L) fermentations were performed,
14(m)
 in order to provide an accurate 
measure of the fermentation yield and to provide sufficient material for characterization. 
 With the goal of identifying metabolites with carbon substituents at para-
positions, compounds 278-283 (Figure 35) were tested as substrates for TDO.  In each 
case, no conversion to the corresponding diene-diol metabolites was observed, and the 
aromatic starting material was recovered from the fermentation media. 
 Because of the lack of success in the metabolism of p-disubstituted substrates 
(278-283), halogenated substrates 284-288 (Figure 35) were investigated.  These 
substrates may also be applied to the synthesis of tetrodotoxin, as the halogen substituent 
could be converted to the desired carbon substituent through coupling chemistry.  
Carboxylic acids 284-285 were shown not to be substrates for TDO, with the aromatic 
starting material being recovered from the fermentation media.  Attempts to increase the 
solubility of these compounds, either by conversion to their corresponding sodium salts 
or by dissolution in dimethyl sulfoxide (DMSO) before feeding, produced identical 
results.   Compounds 286 and 287 were shown not to be substrates for TDO, with the 
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starting material being recovered from the fermentation media.  Compound 288 was 
shown to be consumed in the fermentation broth, although no conversion to the 
corresponding diene-diol metabolite was observed.  Consumption of compound 288 by 
the fermentation culture presumably occurs through oxidation of the sulfur atoms, as has 
been reported.
157
 
 
 
Figure 35: para-Disubstituted arenes shown not to be substrates for TDO. 
 
 Some success was achieved when halogenated substrates 289-292 were 
investigated, as trace amounts of the corresponding diene-diol metabolites 293-296 were 
detected in the crude fermentation extracts (Figure 36).  Although the diene-diol 
metabolites 293-296 were detected by 
1
H NMR analysis of the crude fermentation 
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extract, these compounds were not produced in quantities significant enough to facilitate 
isolation and characterization. 
 
Figure 36: Metabolites produced in trace amounts from fermentation cultures. 
*Stereochemistry shown is based on analogy to related compounds. 
 
 In contrast, brominated arenes 297-300 were metabolized by TDO in reasonable 
yields from large-scale (10 L) fermentation cultures (Figure 37).  Enantiomeric ratios (er) 
were determined through the use of chiral HPLC.  Interestingly, the metabolism of both 
the alcohol and aldehyde compounds 297 and 298 afforded the same metabolite, triol 
301, in similar yields.  The difference in enantiomeric ratios, however, indicates that the 
in situ aldehyde reduction occurs at least in part after the enzymatic dihydroxylation.  
Furthermore, the greater selectivity observed with aldehyde substrate 298 indicates that 
the aldehyde functionality has a more significant directing effect on the enzymatic 
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dihydroxylation when compared to the benzyl alcohol moiety.  The use of the allyl 
substrate 299 led to a further increase in selectivity, with the allyl moiety directing the 
enzymatic dihydroxylation.  The greatest level of selectivity was observed with alkynyl 
substrate 300, with the alkyne substituent demonstrating the strongest directing effect of 
any substituent investigated in this study.  This observation was in accordance with the 
particularly strong directing effect of propargyl ester substituents that was observed in the 
metabolism of ortho-halobenzoates by TDO (Section 3.2.1). 
 
Figure 37: Metabolism of para-disubstituted arenes by TDO. 
 
 In order to confirm the absolute stereochemistry of diene-diol metabolites 301-
303, each compound was converted to a compound of known absolute stereochemistry 
(305-307) (Scheme 24).  These derivatized compounds were matched to their previously 
reported counterparts by 
1
H NMR and optical rotation.  Metabolite 301 was protected as 
its corresponding acetonide, and hydrogenated with Adam’s catalyst158 to afford 
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cyclohexane 304.  Tosylation of 304 led to decomposition, presumably through 
elimination of the tosylate functionality and acid-catalyzed hydrolysis of the acetonide 
protecting group.  Hydride reduction of the decomposition residue afforded the known 
diol 305.
159
  Allyl metabolite 302 was subjected to debromination under standard 
conditions to provide the known diol 306.
160
  Acetonide protection and hydrogenation of 
alkynyl metabolite 303 afforded the protected diol 307, which was previously reported by 
Gibson in 1977.
161
  This initial report however, did not provide any characterization data.  
Therefore, in order to match the derivatized compound, protected diol 307 was prepared 
from the known metabolite 308,
160,162
 and was matched to the sample prepared from 
metabolite 303. 
 
Scheme 24: Derivatization of metabolites 301-303 to confirm absolute stereochemistry. 
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 Although this study did identify three new para-disubstituted metabolites (301-
303), one of which was produced in a reasonably high enantiomeric ratio (303), none of 
these compounds have yet been applied in the synthesis of tetrodotoxin (10).  For more 
information on this topic, see Section 3.4.  This study did provide valuable information as 
to the limits of the substrate scope of TDO with respect to para-disubstituted arenes.  
This information will aid in planning of future synthetic sequences from other substrates.  
Furthermore, analysis of the enantiomeric ratios of metabolites 301-303 produced by 
TDO (Figure 38) provides information on the relative directing effect of the substituents 
on the aromatic precursors.  From this information, the relative directing effect of these 
substituents can be described as follows: alkyne > allyl > aldehyde > alcohol > bromine.  
This observation is in accordance with the particularly strong directing effects exhibited 
by propargyl ester substituents in the investigation of ortho-halobenzoates.
155
  The results 
of this study were published in 2013.
163
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3.3 Carbonylation of halo cis-cyclohexadiene diols to the corresponding carboxylates 
 
3.3.1 Development and substrate scope of carbonylation methodology 
 In 2010, Hudlicky published an efficient synthesis of the potent anti-viral 
compound oseltamivir (84), which used the enzymatic metabolite of ethyl benzoate, diol 
83, as a starting material (Scheme 25).
82
  The success of this work led to a collaboration 
with Professor Machara (Charles University, Prague) with the goal of applying 
Hudlicky’s methodology to produce analogs of oseltamivir (84).164  Subjecting these 
analogs to biological testing would provide information on the structure-activity 
relationship of these compounds, and potentially identify compounds that are more active 
than oseltamivir. 
 
 
Scheme 25: Synthesis of oseltamivir (84) from diol 83 by Hudlicky.
82 
 
 A major obstacle in the production of a library of oseltamivir analogs is the 
efficient production of metabolites of type 83 in large quantities.  As is evident from 
Table 9, the metabolites of benzoates are produced by TDO in relatively low titres,
66
 
particularly when compared to the titres obtained with halogenated aromatics.
152
  In order 
to pursue the production of oseltamivir analogs, as well as other syntheses that require 
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metabolites of type 83 (see section 3.4.2), a means of producing these compounds in 
greater yields was required. 
 
Table 9: Yields of the enzymatic dihydroxylation of halogenated aromatics and 
benzoates.
66,152
 
 
 
R =  Yield (g / L) Reference 
I (78) 10 
152 
Br (74) 20 
152 
Cl (85) 12 
152 
CO2Me (310) 1.5 
66 
CO2Et (83) 1.0 
66 
CO2n-Pr (311) 0.07 
66 
CO2i-Pr (312) 0.05 
66 
CO2t-Bu (313) - 
66 
CO2Bn (314) - 
152 
 
 Palladium-catalyzed carbonylation of halogenated metabolites such as diols 74 
and 78 was investigated as a means for the production of esters of type 83 (Scheme 26).  
Some precedent for this process was provided by Boyd, who prepared a number of 
compounds through the cross-coupling of metabolites of this type, in some cases with the 
diene functionality being partially saturated.
165
  Furthermore, Banwell had successfully 
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performed the sp
2
-sp
3
 coupling of the vinyl iodide moiety of metabolite 78 at elevated 
temperatures.
166
   
 For the preliminary investigation of the palladium-catalyzed carbonylation 
methodology, iodo-metabolite 78 was chosen as the starting material because of the 
increased reactivity of the vinyl iodide functionality relative to other halogens.
107,109
  The 
diol moiety of metabolite 78 was protected as its corresponding acetonide prior to being 
subjected to the carbonylation conditions. This protection step was performed because of 
the increased stability of acetonide-protected derivatives relative to their corresponding 
free diols.  Carbonylation conditions (Scheme 26) were adapted from initial reports by 
Heck,
107
 and from reports of similar reactions performed by Boyd.
165
  These conditions 
were chosen based upon their past success, and because of the relatively low cost of the 
palladium (II) source (Pd(OAc)2) relative to other commercial palladium catalysts. 
 
 
Scheme 26: Initial study of the palladium-catalyzed carbonylation of halogenated 
metabolites. 
 
 To our delight, the initial reactions were effective, with acetonide 315 being 
produced in good yields from the acetonide derived from metabolite 78 (Scheme 26).  A 
better substrate was metabolite 74, as it was produced in high titres from enzymatic 
dihydroxylation (Table 9).
152
  Unfortunately, carbonylation reactions performed with this 
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substrate afforded significantly lower yields (Scheme 26).  Thus, iodo-metabolite 78 was 
established as the standard substrate for this methodology. 
 Acetonide-protected metabolites of type 315 are well known to undergo 
stereoselective Diels-Alder type dimerization even at low temperatures.
167
  In order to 
monitor this unwanted side-reaction during the study of the carbonylation methodology, 
dimers 318-320 were prepared from their corresponding monomers by refluxing a 
solution of these compounds in xylene (Scheme 27). 
 
 
Scheme 27: Synthesis of dimers 318-320. 
 
 With the success of the initial study of the palladium-catalyzed carbonylation 
reaction (Scheme 26), the substrate scope was subsequently expanded (Table 10).  This 
was accomplished by performing the reaction in different alcoholic solvents, or in the 
case of compounds 323-326, performing the reaction in a solution of the desired alcohol 
and THF (1:9).  The reaction was shown to be quite versatile, as good yields were 
obtained for many substrates.  Performing the reaction in the presence of allyl alcohol, 
propargyl alcohol or t-butyl alcohol led to increased reaction times, and correspondingly 
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lower yields.  Despite initial concerns, little to no dimerization of either the acetonide 
starting materials or the ester products was observed in most cases. 
 
Table 10: Palladium-catalyzed carbonylation of acetonide 314 to corresponding esters. 
 
 
R = Yield 
Me (317) 68% 
Et (315) 73 % 
n-Pr (321) 68 % 
i-Pr (322) 76 % 
t-Bu (323) 10 % 
allyl (324) 27 % 
propargyl (325) 20 % 
benzyl (326) 70 % 
 
 Having established the applicability of this methodology to acetonide-protected 
metabolites of type 315, this study was expanded to include the carbonylation of free diol 
78 (Table 11).  Carbonylation reactions were similarly successful using free diol 78 as a 
substrate, as comparable yields to those obtained with acetonide 315 were observed in 
most cases.  As was previously observed, reactions performed in the presence of allyl 
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alcohol, propargyl alcohol or t-butanol resulted in longer reaction times and 
correspondingly lower yields. 
 
Table 11: Palladium-catalyzed carbonylation of diol 78 to corresponding esters. 
 
 
R = Yield 
Me (310) 68 % 
Et (83) 72 % 
n-Pr (311) 62 % 
i-Pr (312) 72 % 
t-Bu (313) 17 % 
allyl (327) 6 % 
propargyl (328) 36 % 
benzyl (314) 10 % 
 
 In an attempt to quantify the efficiency of the palladium-catalyzed carbonylation 
methodology, and compare the amounts of esters 83, 310-315, 327, 328 available through 
the two methods, quantities produced are shown in Table 12.  The first column shows the 
total amount of each ester available through direct enzymatic dihydroxylation, when one 
large-scale (10 L) fermentation is performed.  The second column shows the total amount 
of each ester available when one large-scale (10 L) fermentation is performed using 
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iodobenzene as the substrate, and the isolated metabolite 78 (100 g)
152
 is subjected to 
carbonylation conditions.  Although this metric does not take into account factors such as 
man-hours required to perform the carbonylation chemistry and the cost of the palladium 
catalyst, the benefits of the carbonylation chemistry are clear from Table 12.  For 
example, in the production of ester 83, the desired substrate for the synthesis of 
oseltamivir analogues, over five times more material is available through the 
carbonylation methodology compared to the direct dihydroxylation of ethyl benzoate.  
Performing large-scale biotransformations is considered to be the primary factor in 
determining the efficiency of these processes, due to the time and man hours involved.  
For this reason, it can be said that the carbonylation process is significantly more efficient 
as a means of producing ester 83. 
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Table 12: Comparison of yields through direct dihydroxylation and through 
carbonylation. 
 
 
 
 
 
R = Yield by direct fermentation (g)
66
 Yield by carbonylation (g)* 
Me (310) 15 49 
Et (83) 10 56 
n-Pr (311) 0.7 52 
i-Pr (312) 0.5 60 
t-Bu (313) - 15 
allyl (327) 6 6 
propargyl (328) 10 29 
benzyl (314) - 10 
*
 
a
Hypothetical yield for comparison. Biotransformation of iodobenzene affords up to 
100 g of the metabolite 78.  This yield was multiplied by the actual yield of the 
subsequent carbonylation step to reflect the relative amount available through this 
method. (Ex. (100 g (biotransformation yield) / 238.02 g/mol) x 0.72 (carbonylation 
yield) x 184.19 g/mol = 56 g) 
 
 In examining table 12, a second benefit of the palladium-catalyzed carbonylation 
methodology becomes evident,  namely the potential to access ester compounds such as 
313 and 314, which are unavailable through direct enzymatic dihydroxylation.
66,152
  
Previous studies have demonstrated that t-butyl benzoate and benzyl benzoate are not 
substrates for TDO, presumably due to the steric size of the ester substituents.
66,152
  By 
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applying the carbonylation methodology, ester metabolites with sterically large 
substituents, including but not limited to 313 and 314, can be accessed.  
 With the evident increase in efficiency afforded by the carbonylation 
methodology, this chemistry was applied in the production of oseltamivir analogues from 
ester 83 by Professor Machara.
164
  Furthermore, this chemistry was applied as part of the 
continued interest in developing a synthetic route towards tetrodotoxin (see sections 
3.2.2, 3.3.2).  This work was published in 2014.
152
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3.3.2 Approach towards the synthesis of tetrodotoxin 
 Because the study described in section 3.2.2 failed to identify a substrate for TDO 
with carbon substituents at the para positions, or a metabolite that was produced with 
complete enantioselectivity, an alternate route towards the synthesis of tetrodotoxin was 
envisioned.  This new synthetic plan was inspired by a report by Sato, who prepared 
tetrodotoxin (10) from D-glucose (329) in 2008 (Scheme 28).
168
  Sato’s synthesis used 
ketone 330, which was synthesized in 19 steps from D-glucose (329), as a key 
intermediate. 
 
 
Scheme 28: Synthesis of tetrodotoxin (10) from D-glucose (329) by Sato.
166
 
 
 The goal of this synthetic study was to develop an alternate route to ketone 330, 
which would constitute a formal synthesis of tetrodotoxin (10).  The synthetic strategy 
that was applied was based on the production of enone 331, which could be readily 
prepared from enzymatic metabolite 310 (Scheme 29).  Enone 331 could then be 
elaborated to ketone 330, completing the synthesis of this compound in significantly less 
than 19 steps.  If ketone 330 could be produced from metabolite 310 in less than 19 steps, 
this would constitute a major advancement in tetrodotoxin synthesis.   
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Scheme 29: Synthetic strategy for the production of ketone 330. 
 
 Having developed a methodology for the palladium-catalyzed carbonylation of 
halogenated enzymatic metabolites (Section 3.3.1), the acetonide-protected ester 317 was 
readily prepared from metabolite 78.  This methodology was employed because of the 
relatively low titres obtained in the enzymatic dihydroxylation of methyl benzoate, when 
compared to those obtained with iodobenzene (Table 8, Section 3.3.1).  Ester 317 was 
subsequently reduced with diisobutylaluminum hydride (DIBAL-H) to afford alcohol 
333.  This compound was shown to dimerize rapidly upon concentration to dryness, and 
was therefore immediately carried on to the subsequent step without further purification.  
The diene functionality of alcohol 333 was then subjected to a facially-selective [4+2] 
cycloaddition with singlet oxygen,
169
 as has been described in Lewis’ synthesis of (+)-3-
O-debenzoylzeylenone (195) (Section 2.4.3).
100
  This stable endoperoxide (334) was then 
treated with base in situ to effect the desired Kornblum-DeLaMare rearrangement.
170
  
This was accomplished either by addition of the base directly to the reaction mixture 
upon completion of the [4+2] cycloaddition, or by chromatography of endoperoxide 334 
on silica, which was deactivated with 5% triethylamine.  This tandem [4+2] 
cycloaddition/Kornblum-DeLaMare rearrangement process proceded smoothly, affording 
 96 
 
diol 335 in 90% yield.  Diol 335 was then protected as its corresponding bis-acetonide to 
provide enone 331. 
 
Scheme 30: Synthesis of enone 331 from metabolite 78. 
 
 Having developed a highly efficient route to enone 331 (6 steps from 78, 36% 
overall yield, 2 chromatography steps), we produced multi-gram quantities of this key 
intermediate.  Although the ultimate goal of this work has yet to be accomplished, studies 
are ongoing in the Hudlicky group to convert enone 331 to ketone 330, which would 
constitute a formal synthesis of tetrodotoxin (10). 
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3.4 Synthesis of pleiogenone A 
 In 2015, Kingston reported the isolation of pleiogenones A-C (14, 162, 163) from 
the bark of Pleiogynium timorense (Figure 31).
17
  In this initial report, pleiogenones A-C 
were tested for their anti-proliferative activity against the A2780 ovarian cancer cell line 
and demonstrated IC50 values of 0.8, 0.7 and 0.8 µM, respectively.
17
  Based upon the 
promising biological activity of these compounds, it was determined that they would be 
valuable synthetic targets.  Such a synthesis would serve as a proof of the structure and 
absolute stereochemistry of these compounds, and would permit their production in 
quantities large enough to facilitate further biological testing.  Furthermore, the 
development of a modular synthesis would allow for the synthesis of all pleiogenone 
congeners, as well as analogs of these compounds for future structure-activity 
relationship studies. 
 Inspired by the work of Lewis in the synthesis of 3-O-debenzoylzeylenone (195, 
Scheme 20, Section 2.4.3),
100
 it was clear that the polyhydroxylated cyclohexenone core 
of the pleiogenones could be accessed from ipso-diol 4 (Scheme 31).  The key strategy in 
the construction of the cyclohexenone core would be the [4+2] cycloaddition of singlet 
oxygen to the diene moiety, as was employed by Lewis,
100
 and in our previously 
discussed approach towards tetrodotoxin (10, Scheme 30, Section 3.3.2). 
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Scheme 31: Strategy for the synthetic approach towards pleiogenones A-C (14, 162, 
163). 
 
 The primary synthetic challenge of any synthetic approach towards pleiogenones 
A-C (14, 162, 163) is the construction of the alkenyl side-chain, in this case from the 
carboxylate moiety of ipso-diol 4.  Three potential strategies were envisioned for the 
construction of the alkenyl side-chain, each of which employed alcohol 336 as a key 
intermediate (Figure 38).  The first strategy involved the Negishi-type sp
3
-sp
3
 coupling
171
 
of an activated alcohol (337) derived from 336, with an alkyl-zinc reagent as has been 
described.
171(b)
  The second strategy involved the Grignard addition
172
 to an aldehyde 
derived from 336, and subsequent deoxygenation of the resulting alcohol (338).  The final 
strategy that was envisioned was based on a Wittig olefination
173
 of aldehyde 340, which 
would require the hydrogenation of the alkene moiety (341) at some point in the 
synthesis. 
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Figure 38: Potential strategies for the construction of the pleiogenone alkenyl side-chain. 
 
 The first strategy for the construction of the pleiogenone alkenyl side-chain to be 
investigated was the Negishi-type coupling strategy.  This strategy was considered the 
most likely to lead to an efficient synthesis, as it would not require further manipulation 
of the alkenyl side-chain after the coupling step.  In order to investigate this route, model 
studies were pursued through the key intermediate tosylate 337.  Tosylate 337 was 
synthesized from ipso-diol 4, through a series of transformations shown in Scheme 32.  
The conditions for the Negishi-type coupling used in this model study were taken from 
recent reports of the sp
3
-sp
3
 coupling of alkyl tosylates and alkyl zinc reagents.
171(b)
  To 
test the applicability of these conditions to the coupling of tosylate 337, alkyl zinc reagent 
342 was prepared and combined with tosylate 337 under the reported conditions.  
Unfortunately, none of the coupled product was observed under these conditions, with 
only tosylate 337 and a small amount (<10%) of bromide 343 being recovered after 
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prolonged reaction times.  This result could have been anticipated from previous reports, 
which have indicated that the relevant carbon of tosylate 337 is particularly sterically 
hindered.
174
  In an attempt to reduce the steric crowding of the relevant position, tosylate 
337 was converted to endoperoxide 344, which was treated under identical conditions in 
the Negishi-type coupling.  Unfortunately, heating endoperoxide 344 under conditions for 
the Negishi-type coupling resulted in a rearrangement to bis-epoxide 345.  This result 
could also have been anticipated, as the rearrangement of cyclic alkenyl endoperoxides to 
their corresponding bis-epoxides has been reported.
175
 
 
 
Scheme 32: Model studies on Negishi-type coupling route towards pleiogenones A-C. 
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 The second strategy for the construction of the pleiogenone alkenyl side-chain to 
be investigated was the Grignard addition / deoxygenation approach.  To this end, alcohol 
336 was oxidized to the corresponding aldehyde, which was subjected to a Grignard 
addition with the preformed Grignard reagent 346 (Scheme 33).  The alcohol moiety of 
the resultant compound 347 was then activated as its corresponding mesylate 348, in 
order to facilitate the hydride displacement of this moiety.  Unfortunately, the treatment 
of mesylate 348 with various hydride sources resulted in no reaction from 0 
o
C to 23 
o
C, 
even after prolonged reaction times.  Heating mesylate 348 to reflux with super hydride 
(LiEt3BH) led to no reaction, while heating to reflux with lithium aluminum hydride 
(LAH) led to decomposition.  This can be attributed to the steric congestion associated 
with the neopentyl carbon, as has been reported.
174
  In order to investigate a potential 
radical deoxygenation, compound 347 was converted to the corresponding xanthate 350,  
which was subjected to conditions for the Barton-McCombie deoxygenation,
176
 
producing a complex intractable mixture.   
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Scheme 33: Model studies on Grignard/deoxygenation route towards pleiogenones A-C. 
 
 Given the lack of success in the Negishi coupling and the Grignard/deoxygention 
model studies, the Wittig olefination/hydrogenation approach was the most likely to lead 
to an efficient synthesis of pleiogenones A-C, and pleiogenone A (14) was chosen as the 
synthetic target.  Anticipating some issues involved in the selective hydrogenation of 
Wittig olefination products, it was determined that the alkenyl side-chain should be 
constructed in a modular fasion.  This strategy would also lead to a versatile process that 
could be adapted to produce compounds with alkenyl side-chains of various lengths and 
substitution patterns.  To pursue this strategy, Wittig reagent 352 was synthesized from 
1,2-heptanediol (353), according to reported protocols (Scheme 34).
177
  Although reagent 
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352 proved difficult to purify, its identity was confirmed through high-resolution mass 
spectrometry (HRMS) of the phosphonium cation (HRMS (ESI) calcd. for C27H34O2P
+
: 
421.2296, found: 421.2295).  Wittig reagent 352 was coupled with the aldehyde derived 
from alcohol 336, affording triene 353 in 40% yield over two steps (Scheme 34).  Further 
observation identified the instability of the aldehyde intermediate as the likely cause of 
this relatively low yield.  Triene 353 was then subjected to the key [4+2] cycloaddition 
with singlet oxygen to afford endoperoxide 354, which was shown to be bench-stable for 
short periods of time and was isolated to facilitate partial characterization (NMR, optical 
rotation). 
 
 
Scheme 34: Synthesis of endoperoxide 354 from alcohol 336. 
 
 With endoperoxide 354 in hand, the Kornblum-DeLaMare rearrangement
170
 of 
this compound was performed with bases of various steric bulk (Scheme 35).  
Unfortunately, these reactions led to the exclusive production of enone 355, possessing 
the incorrect regiochemistry for the synthesis of pleiogenone A.  This occurs because of 
 104 
 
the exclusive deprotonation of the less sterically hindered site of endoperoxide 354.  
These results mirror those reported by Lewis in the synthesis of 3-O-debenzoylzeylenone 
(195).
100
 
 
 
Scheme 35: Kornblum-DeLaMare rearrangement of endoperoxide 354. 
 
 As the Kornblum-DeLaMare rearrangement was shown to proceed exclusively 
with the incorrect regiochemistry, an alternate strategy was employed wherein the 
endoperoxide moiety of 354 was reduced with thiourea to afford diol 356 (Scheme 36).  
Although endo-peroxide 354 was initially isolated for characterization, the cycloaddition 
and reduction steps in subsequent experiments were combined into a single operation 
without the need of isolation or purification. Taking advantage of the steric hindrance 
associated with diol 356, the selective protection of the less hindered alcohol was 
accomplished according to a procedure reported by Banwell.
178
  Although this protection 
step was not entirely selective, the undersired isomer (358) was recycled through 
deprotection to diol 356 and subsequent reprotection.  Alcohol 357 was then oxidized 
with 2-iodoxybenzoic acid (IBX), producing enone 359 (Scheme 36). 
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Scheme 36: Synthesis of enone 358 from endoperoxide 354. 
 
 Enone 359 was considered the desired substrate for selective hydrogenation, 
based on previous reports of the selective hydrogenation of exocyclic olefins in the 
presense of enone functionalities with Wilkinson’s catalyst (RhCl(PPh3)3).
179
  Despite 
these reports, attempts at the selective hydrogenation of enone 359 resulted in a mixture 
of hydrogenated ketones 360 and 361 (Scheme 37).  Attempts at diimide reduction in 
nucleophilic solvents resulted in Michael-type addition of solvent to the enone moiety 
(362), while experiments in non-nucleophilic solvents resulted in no reaction. 
 
 106 
 
 
Scheme 37: Attempted selective hydrogenation of enone 359. 
 
 To overcome the issues associated with the selective hydrogenation of the 
exocyclic olefin, the enone moiety was protected prior to hydrogenation.  This task was 
accomplished through the Michael-type addition of thiophenol to enone 359 (Scheme 
38), as has previously been reported for similar compounds.
180
  Thiophenol adduct 363 
was then subjected to hydrogenation with Wilkinson’s catalyst.  Experiments with 
catalytic amounts of Wilkinson’s catalyst (10-20 mol %) invariably led to incomplete 
hydrogenation, however the use of one equivalent resulted in full hydrogenation.  The 
deprotection of the thiophenol adduct with 1,8-diazabicycloundec-7-ene (DBU) allowed 
for the regeneration of the enone,
180
 affording enone 364 (Scheme 38).  The remaining 
challenge in the synthesis of pleiogenone A (14) from enone 364 was the completion of 
the alkenyl side-chain.  Reports on the deprotection of acetal/ketal functionalities 
indicated that dimethyl acetal groups could be selectively deprotected in the presence of 
an acetonide using a catalytic amount of iodine in acetone.
181
  This selective deprotection 
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of the dimethyl acetal functionality of enone 364 was successful, with complete removal 
of this functionality observed within five minutes.  The resulting aldehyde (365), without 
further purification, was immediately subjected to a Wittig reaction with reagent 366.  
This Wittig reaction smoothly afforded olefin 367, with all of the functionality of 
pleiogenone A (14) in place.  The Z-isomer (367) was the sole isomer obtained upon 
purification of the crude reaction mixture.  A final deprotetion of the acetonide and silyl 
protecting groups was performed with iodine in acetonitrile (MeCN),
182
 affording 
pleiogenone A (14) in a total of 16 steps (14 operations) and in 1.4% overall yield. 
 
 
Scheme 38: Completion of the synthesis of pleiogenone A (14). 
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A sample of the natural product was kindly provided by Professor Kingston.  The 
1
H NMR spectra of the natural sample and the synthetic sample were shown to be a  
match (see section 6 for spectral comparison).  The synthetic sample of pleiogenone A 
(14) was also matched with the natural sample by comparison of their optical rotation 
values.  The match between the natural and synthetic samples also served to confirm the 
structure and absolute stereochemistry of the natural product as proposed by Professor 
Kingston.
17
  The results of this study were published in 2016.
183
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4. Conclusions and Future Work 
 The enzymatic metabolites of substituted aromatics produced by dioxygenase 
enzymes have proven to be valuable enantioenriched building blocks for the total 
synthesis of complex targets.  It is hoped that the body of work presented here has 
provided a greater understanding of the substrate scope and selectivity of the important 
dioxygenase enzyme toluene dioxygenase (TDO), by investigating ortho- and para-
disubstituted arenes as substrates for this enzyme.  Furthermore, it is hoped that the work 
presented has demonstrated the versatility of the metabolites of dioxygenase enzymes, by 
reporting the first total synthesis of pleiogenone A, and approaches towards tetrodotoxin. 
 Further study of the substrate scope and selectivity of toluene dioxygenase will 
identify new metabolites with potential synthetic utility, and will further refine Boyd’s 
model
72
 for the selectivity of the enzymatic dihydroxylation.  Any further investigation of 
the selectivity of the toluene dioxygenase-mediated dihydroxylation should attempt to 
address the origin of the selectivity observed with alkynyl substrates.  The could 
potentially be accomplished through the crystallization of the enzyme with bound alkynyl 
substrate.  To understand the structure-activity relationship of the pleiogenones with 
respect to their anti-proliferative activity, the described synthetic sequence will be applied 
in the production of pleiogenone analogues for biological testing.  Research continues on 
the formal synthesis of tetrodotoxin through the described approach. 
 In a continued effort to develop versatile methods for the synthesis of 
polyhydroxylated cyclohexeneone natural products, research towards the synthesis of 
xylosmin (156) is ongoing.  The current synthetic route (Scheme 39) has led to the 
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production of enone 372, which can be deprotected to afford the polyhydroxylated 
cyclohexeneone fragment of xylosmin (156). 
 
 
Scheme 39: Current synthetic approach towards xylosmin (156). 
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5. Experimental Section 
 
General experimental 
All non-hydrolytic reactions were carried out under an argon atmosphere. Glassware used 
for moisture-sensitive reactions was flame-dried under vacuum and subsequently purged 
with argon. THF was distilled from sodium/benzophenone. Methylene chloride and 
acetonitrile were distilled from calcium hydride. Flash column chromatography was 
performed using Silicycle SiliaFlash P60 silica gel (40–66 μm).  Analytical thin-layer 
chromatography was performed using silica gel 60-F254 plates. Melting points were 
measured on a Thomas-Hoover melting point apparatus and are reported uncorrected. IR 
spectra were obtained on a Perkin-Elmer FT-IR 1600 Series Spectrum One instrument. 
1
H and 
13
C NMR spectra were obtained on either a 300 MHz (75 MHz) or 600 MHz (150 
MHz) Bruker spectrometer. Data are reported as (s = singlet, d = doublet, t = triplet, q =  
quartet, quin = quintet, m = multiplet, br = broad; coupling constants(s) in Hz, 
integration).  Specific rotation measurements are given in deg cm
3
 g
-1
 dm
-1
 and were 
recorded on a Perkin-Elmer 341 Polarimeter.  Large-scale fermentation was performed in 
a 15-L B. Braun Biostat C-15 fermenter. Combustion analyses were performed by 
Atlantic Microlabs, Norcross, Georgia, USA.  Chiral HPLC was carried out on an Agilent 
1100 series instrument equipped with a UV detector monitoring at 254 nm and an ODH 
chiral column. HPLC flow-rate was 0.5 mL/ min using a gradient from 95:5 
hexane/isopropanol to 5:95 hexane/isopropanol over 20 min (Condition A); or 90:10 
hexane/iso-propanol to 60:40 hexanes/iso-propanol over 20 min (Condition B). 
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General procedure for diimide reductions with potassium azodicarboxylate 
To a stirred solution of diene (2.5 mmol) and potassium azodicarboxylate (PAD) (7.5 to 
15.0 mmol) in MeOH (4 mL), glacial acetic acid was added (17.5 to 37.5 eq.) dropwise at 
-15 °C. The reaction was allowed to warm to room temperature over 14 h, then quenched 
by the addition of saturated aqueous solution Na2CO3 (7 to 15 mL of a saturated aqueous 
solution), concentrated under reduced pressure and extracted with ethyl acetate (5 x 5 
mL). The combined organic layers were washed with brine (1 x 7 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude material was recrystallized 
from ethyl acetate/pentane. 
 
General procedure for the transesterification of PAD-reduced metabolites 
To a stirred solution of an ester (0.5 mmol) in MeOH (5 mL) was added NaOMe until the 
solution was observed to be just basic by pH paper.  Reaction mixture was allowed to stir 
at room temperature until the starting material was consumed by TLC.  Product was 
purified by flash column chromatography (3:2 v/v ethyl acetate/hexanes). 
 
General procedure for carbonylation of diol 78 to corresponding esters (83, 310-312) 
 
A solution of 78
162 
(500 mg, 2.10 mmol) was dissolved in alcohol (30 mL), and carbon 
monoxide was bubbled through the reaction mixture for 15 minutes, after which 
triethylamine (0.59 mL, 4.2 mmol) was added followed by solid triphenylphosphine (110 
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mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol).  The orange suspension 
was heated to 40 ºC.  The reaction was monitored by TLC [hexanes/EtOAc (1:1)] and 
consumption of the starting material was observed after 1-2.5 hours.  Upon cooling to 
room temperature, the crude reaction mixture was concentrated to dryness under reduced 
pressure. The residue was then dissolved in diethyl ether, filtered through a plug of 
Celite, and concentrated. The crude material was purified by flash column 
chromatography [hexanes/EtOAc (1:1)] to yield the corresponding ester. 
 
General procedure for carbonylation of diol 78 to corresponding esters (313, 314, 
327, 328) 
 
A solution of 78
162 
(500 mg, 2.10 mmol) was dissolved in a solution of THF/alcohol (9:1) 
(30 mL), and carbon monoxide was bubbled through the reaction mixture for 15 minutes, 
after which triethylamine (0.59 mL, 4.2 mmol) was added followed by solid 
triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol).  
The orange suspension was heated to 40 ºC.  The reaction was monitored by TLC 
[hexanes/EtOAc (1:1)] and consumption of the starting material was observed after 4-6 
hours.  Upon cooling to room temperature, the crude reaction mixture was concentrated 
to dryness under reduced pressure. The residue was then dissolved in diethyl ether, 
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filtered through a plug of Celite, and concentrated. The crude material was purified by 
flash column chromatography [hexanes/EtOAc (1:1)] to yield the corresponding ester. 
 
General procedure for the acetonide protection of diol 78 and subsequent 
carbonylation to corresponding esters (315, 317, 321, 322) 
 
A solution of 78
162 
(500 mg, 2.10 mmol) was dissolved in 2,2-dimethoxypropane (10 
mL), to which was added a catalytic amount of p-toluenesulfonic acid. The reaction was 
monitored by thin layer chromatography (TLC), and was observed to be complete after 
0.5 hours.  The reaction mixture was concentrated under reduced pressure, diluted with 
EtOAc (15 mL) and washed with a saturated solution of sodium bicarbonate (2 x 3 mL) 
and brine (1 x 2 mL).  The reaction mixture was concentrated under reduced pressure, 
and dissolved in alcohol (30 mL).  Carbon monoxide was bubbled through the reaction 
mixture for 15 minutes, after which triethylamine (0.59 mL, 4.2 mmol) was added 
followed by solid triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 
mg, 0.21 mmol).  The orange suspension was heated to 40 ºC.  The reaction was 
monitored by TLC [hexanes/EtOAc (4:1)] and consumption of the starting material was 
observed after 1-2.5 hours.  Upon cooling to room temperature, the crude reaction 
mixture was concentrated to dryness under reduced pressure. The residue was then 
dissolved in diethyl ether, filtered through a plug of Celite, and concentrated under 
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reduced pressure. The crude material was purified by flash column chromatography 
[hexanes/EtOAc (9:1)] to yield the corresponding ester. 
 
General procedure for the acetonide protection of diol 78 and subsequent to 
corresponding esters (323-326) 
 
A solution of 6
10 
(500 mg, 2.10 mmol) was dissolved in 2,2-dimethoxypropane (10 mL), 
to which was added a catalytic amount of p-toluenesulfonic acid. The reaction was 
monitored by thin layer chromatography (TLC), and was observed to be complete after 
0.5 hours.  The reaction mixture was concentrated under reduced pressure, diluted with 
EtOAc (15 mL) and washed with a saturated solution of sodium bicarbonate (2 x 3 mL) 
and brine (1 x 2 mL).  The reaction mixture was concentrated under reduced pressure, 
and dissolved in a solution of THF/alcohol (9:1) (30 mL).  Carbon monoxide was 
bubbled through the reaction mixture for 15 minutes, after which triethylamine (0.59 mL, 
4.2 mmol) was added followed by solid triphenylphosphine (110 mg, 0.42 mmol) and 
palladium (II) acetate (47 mg, 0.21 mmol).  The orange suspension was heated to 40 ºC.  
The reaction was monitored by TLC [hexanes/EtOAc (4:1)] and consumption of the 
starting material was observed after 4-6 hours.  Upon cooling to room temperature, the 
crude reaction mixture was concentrated to dryness under reduced pressure. The residue 
was then dissolved in diethyl ether, filtered through a plug of Celite, and concentrated 
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under reduced pressure. The crude material was purified by flash column 
chromatography [hexanes/EtOAc (9:1)] to yield the corresponding ester. 
 
(+)-Ethyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (83)
66
 
 
Colourless crystals; Rf = 0.31 [hexanes/EtOAc (1:2)]; mp 49-50 
o
C (pentane) [lit.
66 
mp 48 
o
C (EtOAc/hexanes)]; [α]20
𝐷
 = +53.5 (c = 1.6, CHCl3) [lit.
66
 [α]23
𝐷
  = +54.7 (c = 3.8, 
CHCl3)]; IR (film) ν 3385, 2981, 2934, 1700, 1280, 1243, 1104, 1068, 825, 771; 
1
H NMR 
(300 MHz, CDCl3) δ 7.04 (d, J = 5.3 Hz, 1H), 6.15 (dt, J = 9.4, 1.1 Hz, 1H), 6.03 (dq, J = 
9.2, 2.3 Hz, 1H), 4.49-4.55 (m, 1H), 4.40-4.48 (m, 1H), 4.22 (q, J = 7.0 Hz, 2H), 3.65-
3.78 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 167.1, 138.7, 134.1, 
128.7, 122.5, 69.8, 64.5, 60.9, 14.2; MS (EI) m/z (%) 184 (9), 166 (20), 138 (26), 122 
(33), 121 (52), 105 (100), 77 (39), 51 (21), 45 (20); HRMS (EI) calcd. for C9H12O4: 
184.0736, found: 184.0731; Anal. calcd. for C9H12O4: C, 58.69; H 6.57. Found C, 58.77; 
H, 6.60. 
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Ethyl (3S,4S)-3,4-dihydroxy-2-iodocyclohex-1,5-dienecarboxylate (210) 
 
Off-white solid; mp 105-107 °C (pentane); [α]20
𝐷
 
= -72.4 (c = 0.2, CHCl3); 
1
H NMR (300 
MHz, CDCl3) δ 6.19 (d, J = 9.8 Hz, 1H), 6.13 (dd, J = 9.6, 3.7 Hz, 1H), 4.44 (brd, 1H), 
4.39 (brd, 1H), 4.32 (q, J = 7.2 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). 
 
Ethyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1,3-dienecarboxylate (211) 
 
Off-white solid; mp 107-110 °C (pentane); [α]20
𝐷
 
= 67.1 (c = 0.45, CHCl3); 
1
H NMR (300 
MHz, CDCl3) δ 6.47 (d, J = 9.3 Hz, 1H), 5.86 (d, J = 9.4 Hz, 1H), 4.55 (m, 1H), 4.48 (m, 
1H), 4.34 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H). 
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Allyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1,3-dienecarboxylate (215) 
 
Off-white solid; mp 63-66 °C (pentane); [α]20
𝐷
 
= 68.0 (c = 0.1, CHCl3); 
1
H NMR (300 
MHz, CDCl3) δ 6.50 (dd, J = 9.0, 2.3 Hz, 1H), 6.02 (m, 1H), 5.88 (ddd, J = 9.8, 1.9, 1.3 
Hz, 1H), 5.43 (ddd, J = 17.2, 1.5, 1.4 Hz, 1H), 5.33 (dd, J = 10.4,  1.2 Hz, 1H), 4.79 (m, 
2H), 4.58 (d, J = 5.6 Hz, 1H), 4.51 (brd, 1H). 
 
Propargyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1,3-dienecarboxylate (217) 
 
Off-white solid; mp 70-72 °C (pentane); [α]20
𝐷
 
= 77.1 (c = 0.5, CHCl3); 
1
H NMR (300 
MHz, CDCl3) δ 6.51 (dd, J = 9.8, 2.4 Hz, 1H), 5.89 (ddd, J = 9.8, 1.8, 1.0 Hz, 1H), 4.87 
(m, 1H), 4.59 (t, J = 5.9 Hz, 1H), 4.50 (m, 2H), 2.56 (t, J = 2.4 Hz, 1H). 
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Ethyl (5S,6R)-5,6-dihydroxy-2-bromocyclohex-1,3-dienecarboxylate (224) 
 
White solid; mp 78-80 °C (pentane); [α]20
𝐷
 = 46.1 (c = 1.0, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.19 (dd, J = 9.9, 2.3 Hz, 1H), 6.06 (ddd, J = 9.8, 1.9, 1.2 Hz, 1H), 4.59 (m, 
1H), 4.51 (m, 1H), 4.35 (m, 2H), 1.38 (t, J  = 7.1 Hz, 3H). 
 
Allyl (5S,6R)-5,6-dihydroxy-2-bromocyclohex-1,3-dienecarboxylate (228)    
 
White solid; mp 59-61 °C (pentane); [α]20
𝐷
  = 52.3 (c = 0.7, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.20 (dd, J = 9.9, 2.4 Hz, 1H), 6.08 (ddd, J = 8.7, 1.9, 1.4 Hz, 1H), 6.00 (m, 
1H), 5.43 (ddd, J = 17.3, 2.3, 1.5 Hz, 1H), 5.31 (dd, J = 10.4, 1.3 Hz, 1H), 4.78 (m, 2H), 
4.63 (d, J = 5.9 Hz, 1H), 4.54 (brd, 1H). 
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Propargyl (5S,6R)-5,6-dihydroxy-2-bromocyclohex-1,3-dienecarboxylate (230) 
 
White solid; mp 83-85 °C (pentane); [α]20
𝐷
  = 65.6 (c = 1.0, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.22 (dd, J = 9.8, 2.5 Hz, 1H), 6.10 (ddd, J = 9.8, 1.9, 1.1 Hz, 1H), 4.88 (d, J = 
2.6 Hz, 1H), 4.87 (d, J = 2.5 Hz, 1H), 4.64 (dd, J = 6.0, 1.2 Hz, 1H), 4.54 (m, 1H), 2.55 
(t, J = 2.4 Hz, 1H). 
 
Ethyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1,3-dienecarboxylate (240) 
 
White solid; mp 78-80 °C (pentane); [α]20
𝐷
 = 46.1 (c = 1.0, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.18 (ddd, J = 9.8, 1.9, 1.0 Hz, 1H), 6.01 (dd, J = 9.8, 2.4 Hz, 1H), 4.64 (dd, J = 
6.1, 1.4 Hz, 1H), 4.53 (m, 1H), 4.34 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H). 
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Allyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1,3-dienecarboxylate (244) 
 
White solid; mp 61-63 °C (pentane); [α]20
𝐷
 = 33.8 (c = 1.0, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.16 (dt, J = 10.7, 5.2 Hz, 1H), 5.99 (dt, J = 16.3, 5.8 Hz, 1H), 5.95 (m, 1H), 
5.39 (dd, J = 17.2, 1.4 Hz, 1H), 5.27 (dd, J = 10.5, 1.5 Hz, 1H),  4.74 (m, 2H), 4.64-4.61 
(m, 1H),  4.52-4.47 (m, 1H). 
 
Propargyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1,3-dienecarboxylate (246) 
 
White solid; mp 66-69 °C (pentane); [α]20
𝐷
 = 29.5 (c = 0.65, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.22 (dt, J = 9.8, 1.8 Hz, 1H), 6.03 (dd, J = 2.5, 9.9 Hz, 1H), 4.88 (d, J = 1.8 
Hz, 1H), 4.87 (d, J = 1.6 Hz, 1H), 4.68 (d, J = 5.9 Hz, 1H), 4.55 (brd, 1H),  2.54 (t, J = 
2.51 Hz, 1H). 
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Methyl (5S,6R)-5,6-dihydroxy-2-fluorocyclohexa-1,3-dienecarboxylate (254)
69
 
 
White solid; mp 72-73 °C (pentane), mp 73-75 °C (pentane), mp 73-76 °C (pentane), mp 
74-77 °C (pentane) [lit.
69 
value: mp 74–76 °C (ethyl acetate)]; Rf = 0.15 [1:1 
(hexanes:EtOAc)]; [α]20
𝐷
 =  +68.2 (c = 1.1, MeOH), +69.4 (c = 1.0, MeOH), +70.2 (c = 
0.9, MeOH), +72.8 (c = 1.0, MeOH) [lit.
69
 value: [α]20
𝐷
 =  +73.2 (c = 1.05, MeOH)]; IR 
(film) ν 3558, 3025, 1694, 1439, 1401, 1040; 1H NMR (600 MHz, CDCl3) δ 6.33 (m, 
1H), 5.94 (ddd, J = 10.2, 8.3, 2.6 Hz, 1H), 4.71 (t, J = 6.2 Hz, 1H), 4.55 (m, 1H), 3.83 (s, 
3H), 3.17 (brs, 1H), 3.09 (brs, 1H); 
13
C NMR (150 MHz, CDCl3) δ 166.0 (d, J = 2.2 Hz), 
163.2 (d, J = 281.0 Hz), 143.1 (d, J = 12.1 Hz), 119.6 (d, J = 36.2 Hz), 106.2 (d, J = 2.2 
Hz), 69.06 (s), 67.0 (d, J = 6.6 Hz), 52.2 (s);  MS (EI) m/z (%) 188 (15), 133 (44), 119 
(49), 102 (100), 91 (37), 90 (46), 86 (28), 74 (16), 46 (27); HRMS (EI) calcd. for 
C8H9FO4
+
 188.0485, found 188.0484; Anal. calcd. for C8H9FO4: C, 51.07; H, 4.82; 
found: C, 51.18; H, 4.76. 
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Ethyl (5S,6R)-5,6-dihydroxy-2-fluorocyclohex-1,3-dienecarboxylate (256)  
 
White solid; mp 70-72 °C (pentane); Rf = 0.24 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -11.6 (c = 
0.65, CHCl3); IR (film) ν 3418, 2986, 1693, 1601, 1407, 1260, 1138, 1096, 1045, 992, 
832; 
1
H NMR (300 MHz, CDCl3) δ 6.34 (m, 1H), 5.96 (ddd, J = 10.6, 8.3, 2.7 Hz, 1H), 
4.73 (t, J = 6.2 Hz, 1H), 4.56 (m, 1H), 4.31 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 165.6 (d, J = 2.4 Hz), 163.0 (d, J = 279.3 Hz), 142.9 (d, J = 
12.1 Hz), 119.7 (d, J = 36.0 Hz), 106.5 (d, J = 3.2 Hz), 69.0 (s), 67.1 (d, J = 6.1 Hz), 61.3 
(s), 14.2 (s); MS (EI) m/z (%) 184 (29), 156 (37), 140 (17), 139 (100), 128 (26), 127 (28), 
123 (33), 111 (13), 83 (23), 57 (14); HRMS (EI) calcd. for C9H11FO4
+
 202.0641, found 
202.0647; Anal. calcd. for C9H11FO4: C, 53.47; H, 5.48; found: C, 53.20; H, 5.51. 
 
n-Propyl (5S,6R)-5,6-dihydroxy-2-fluorocyclohex-1,3-dienecarboxylate (258) 
 
White solid; mp 52-54 °C (pentane); Rf = 0.30 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -11.3 (c = 
0.55, CHCl3); IR (film) ν 3390, 2970, 1693, 1600, 1407, 1266, 1137, 1095, 1042, 993, 
938, 829; 
1
H NMR (300 MHz, CDCl3) δ 6.34 (m, 1H), 5.96 (ddd, J = 10.6, 8.2, 2.6 Hz, 
1H), 4.73 (t, J = 6.4, 1H), 4.57 (brd, 1H), 4.21 (m, 2H), 1.74 (sextet, J = 14.2, 7.4 Hz, 
2H), 1.00 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 165.8 (d, J = 3.3 Hz), 164.8 
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(d, J = 3.4 Hz), 161.1 (s), 142.9 (d, J = 12.0 Hz), 119.7 (d, J = 36.0 Hz), 106.5 (d, J = 2.3 
Hz), 69.0 (s), 67.1 (d, J = 11.4 Hz), 66.9 (s), 22.0 (s), 10.4 (s); MS (EI) m/z (%) 216 (10), 
198 (19), 157 (18), 156 (94), 141 (33), 140 (28), 139 (100), 138 (14), 136 (10), 129 (42), 
127 (33), 123 (84), 111 (15), 95 (20), 83 (30), 78 (21), 75 (11), 57 (18), 52 (10), 51 (13), 
43 (26), 42 (10), 41 (25); HRMS (EI) calcd. for C10H13FO4
+
 216.0798, found 216.0801.  
 
Allyl (5S,6R)-5,6-dihydroxy-2-fluorocyclohex-1,3-dienecarboxylate (260) 
 
White solid; mp 56-58 °C (pentane); Rf = 0.32 [2:3 (hexanes:EtOAc)]); [α]
20
𝐷
 = -5.4 (c = 
0.35, CHCl3); IR (film) ν 3418, 1694, 1651, 1600, 1404, 1259, 1138, 1095, 1044, 994, 
930, 829; 
1
H NMR (300 MHz, CDCl3) δ 6.35 (m, 1H), 5.95 (m, 2H), 5.40 (ddd, J = 17.2, 
2.3, 1.4 Hz, 1H), 5.28 (dd, J = 10.5, 1.5 Hz, 1H), 4.75 (m, 3H), 4.57 (brd, 1H), 
13
C NMR 
(75 MHz, CDCl3) δ 165.3 (t, J = 2.9 Hz), 161.5 (s), 143.2 (d, J = 25.9 Hz), 131.7 (s), 
119.7 (d, J = 35.8 Hz), 118.4 (s), 106.3 (d, J = 2.1 Hz), 69.1 (s), 67.0 (d, J = 6.2 Hz), 65.7 
(s); MS (EI) m/z (%) 214 (15), 157 (17), 156 (100), 155 (27), 139 (56), 128 (77), 127 
(91), 123 (20), 111 (14), 107 (17), 100 (12), 99 (30), 83 (38), 71 (14), 53 (10), 51 (13), 41 
(39); HRMS (EI) calcd. for C10H11FO4
+
 214.0641, found 214.0642. 
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Propargyl (5S,6R)-5,6-dihydroxy-2-fluorocyclohex-1,3-dienecarboxylate (262) 
 
White solid; mp 82-84 °C (pentane); Rf = 0.27 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = +13.4 (c = 
1.7, CHCl3); IR (film) ν 3296, 2949, 1703, 1654, 1599, 1405, 1256, 1135, 1095, 1045, 
991, 828; 
1
H NMR (300 MHz, CDCl3) δ 6.35 (m, 1H), 5.95 (ddd, J = 10.6, 8.3, 2.8 Hz, 
1H), 4.82 (d, J = 2.5, 2H), 4.72 (t, J = 6.3 Hz, 1H), 4.56 (brd, 1H), 2.51 (t, J = 2.6 Hz, 
1H); 
13
C NMR (75 MHz, CDCl3) δ 165.8 (s), 164.6 (d, J = 2.6 Hz), 162.1 (s), 143.9 (d, J 
= 12.7 Hz), 119.6 (d, J = 35.8 Hz), 105.8 (d, J = 2.1 Hz), 77.4 (s), 75.3 (s), 69.1 (s), 66.9 
(d, J = 5.7 Hz), 52.5 (s); MS (EI) m/z (%) 194 (19), 156 (19), 140 (11), 139 (100), 128 
(11), 127 (14), 123 (54), 111 (13), 95 (13), 83 (27), 57 (19), 44 (13); HRMS (EI) calcd. 
for C9H13ClO4
+
 212.0485, found 212.0482; Anal. calcd. for C9H13BrO4: C, 56.61; H, 
4.28; found: C, 56.87; H, 4.42. 
 
Ethyl (3S,4S)-3,4-dihydroxy-2-iodocyclohex-1-enecarboxylate (263) 
 
Off-white solid; mp 108-109 °C (pentane); Rf = 0.46 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -
32.6 (c = 0.75, CHCl3); IR (film) ν 3270, 2940, 1704, 1593, 1463, 1253; 
1
H NMR (300 
MHz, CDCl3) δ 4.32 (brd, 1H), 4.30 (q, J = 7.1 Hz, 2H), 4.02 (m, 1H), 2.64 (dt, J = 18.1, 
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5.7 Hz, 1H), 2.39 (dt, J = 17.9, 6.7 Hz, 1H), 1.94 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H); 
13
C 
NMR (75 MHz, CDCl3) δ 168.0,140.7, 102.7, 74.8, 68.2, 61.7, 27.2, 25.3, 14.1; MS (EI) 
m/z (%) 312 (40), 266 (85), 231 (18), 222 (96), 194 (73), 185 (90), 167 (20), 165 (21), 
139 (100), 121 (20), 111 (61), 93 (42), 83 (53), 67 (38), 65 (38), 55 (24), 53 (21); HRMS 
(EI) calcd. for C9H13IO4
+
 311.9859, found 311.9847. 
 
Ethyl (3S,4S)- 3,4-dihydroxy-2-bromocyclohex-1-enecarboxylate (264) 
 
White solid; mp 90-92 °C (pentane); Rf = 0.26 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -52.9 (c = 
1.0, CHCl3); IR (film) ν 3255, 2950, 1708, 1461, 1252, 1094; 
1
H NMR (300 MHz, 
CDCl3) δ 4.31 (brd, 1H), 4.29 (q, J = 7.1 Hz, 2H), 4.01 (m, 1H), 2.61 (dt, J = 17.8, 6.0 
Hz, 1H), 2.34 (dt, J = 17.9, 6.6 Hz, 1H), 1.95 (m, 1H), 1.86 (m, 2H), 1.35 (t, J = 7.2 Hz, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 167.2, 134.7, 124.1, 72.2, 68.3, 61.6, 26.5, 25.2, 14.1; 
MS (EI) m/z (%) 223 (12), 222 (27), 221 (21), 220 (30), 219 (12), 185 (38), 183 (12), 177 
(18), 176 (22), 175 (21), 174 (21), 141 (100), 102 (21), 113 (12), 111 (14), 95 (61), 67 
(21), 66 (13), 65 (17), 55 (11), 53 (14), 44 (16), 43 (10); HRMS (EI) 263.9997 = 
C9H13BrO4
+
; calcd. C9H13BrO4
+
 [(M-1)
+
, H]: 262.9919; found: 262.9925; Anal. calcd. for 
C9H13BrO4: C, 40.78; H, 4.94; found: C, 40.57; H, 4.87. 
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Ethyl (3S,4S)-3,4-dihydroxy-2-chlorocyclohex-1-enecarboxylate (265) 
 
White solid; mp 68-70 °C (pentane); Rf = 0.30 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -62.3 (c = 
0.4, CHCl3); IR (film) ν 3268, 2952, 1726, 1624, 1464, 1368, 1289, 1254, 1094, 940; 
1
H 
NMR (300 MHz, CDCl3) δ 4.29 (q, J = 7.0 Hz, 2H), 4.25 (br s, 1H), 4.02 (br s, 1H), 2.65 
(dt, J = 18.0, 5.9 Hz, 1H), 2.38 (dt, J = 18.0, 6.5 Hz, 1H), 1.95 (m, 1H), 1.83 (m, 1H), 
1.35 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 166.5, 133.3, 131.1, 71.1, 68.1, 
61.4, 25.4, 25.2, 14.1; MS (EI) m/z (%) 185 (14), 178 (28), 177 (28), 176 (84), 175 (21), 
157 (17), 139 (11), 133 (13), 132 (37), 131 (41), 130 (100), 104 (19), 102 (50), 67 (27), 
65 (24), 55 (10), 53 (18), 51 (11), 43 (12); HRMS (EI) calcd. for C9H13ClO4
+
 220.0402, 
found 220.0505. 
 
Ethyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1-enecarboxylate (266) 
 
Off-white solid; mp 106-108 °C (pentane); Rf = 0.42 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -
31.6 (c = 0.45, CHCl3); IR (film) ν 3282, 2950, 1714, 1642, 1461, 1241; 
1
H NMR (300 
MHz, CDCl3) δ 4.52 (brd, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.95 (m, 1H),  3.00 (dt, J = 19.1, 
5.4 Hz, 1H), 2.75 (dt, J = 18.6, 6.9 Hz, 1H), 1.98 (m, 1H), 1.77 (m, 1H), 1.37 (t, J = 7.2 
Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 167.0, 136.7, 108.5, 68.4, 67.1, 61.7, 41.1, 28.4, 
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14.1; MS (EI) m/z (%) 312 (12), 294 (61), 278 (31), 276 (40), 269 (37), 267 (46), 249 
(43), 248 (30), 231 (62), 223 (72), 185 (99), 142 (73), 141 (100), 139 (96), 113 (61), 111 
(92), 95 (90), 83 (41), 79 (40), 66 (65), 65 (59), 53 (46); HRMS (EI) calcd. for C9H13IO4
+
 
311.9859, found 311.9859. 
 
n-Propyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1-enecarboxylate (267) 
 
Off-white solid; mp 70-72 °C (pentane); Rf = 0.43 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -42.6 
(c = 0.5, CHCl3); IR (film) ν 3271, 2962, 2879, 1715, 1606, 1462, 1231; 
1
H NMR (300 
MHz, CDCl3) δ 4.50 (brd, 1H), 4.23 (td, J = 6.5, 1.9 Hz, 2H), 3.94 (m, 1H), 3.01 (dt, J = 
19.1, 5.5 Hz, 1H), 2.77 (dt, J = 19.0, 7.1 Hz, 1H), 1.97 (m, 1H), 1.77 (m, 2H), 1.74 (m, 
2H), 1.04 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 167.0, 136.7, 108.5, 68.4, 
67.3, 67.1, 41.2, 28.4, 21.9, 10.6; MS (EI) m/z (%) 326 (10), 304 (10), 291 (20), 290 (13), 
199 (38), 155 (44), 139 (16), 132 (15), 113 (39), 111 (21), 95 (33), 69 (100), 44 (26), 43 
(11), 41 (10); HRMS (EI) calcd. for C10H15IO4
+
 326.0015, found 326.0015. 
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Ethyl (5S,6R)-5,6-dihydroxy-2-bromocyclohex-1-enecarboxylate (268) 
 
White solid; mp 87-89 °C (pentane); Rf = 0.24 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -59.8 (c = 
1.0, CHCl3); IR (film) ν 3269, 2955, 1721, 1622, 1462, 1364, 1241, 1042; 
1
H NMR (300 
MHz, CDCl3) δ 4.52 (t, J = 3.8 Hz, 1H), 4.32 (q, J = 7.2 Hz, 2H), 3.91 (m, 1H), 2.84 (dt, 
J = 19.0, 5.5 Hz, 1H), 2.63 (dt, J = 19.0, 7.3 Hz, 1H), 2.01 (m, 1H), 1.81 (m, 1H), 1.36 (t, 
J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 166.8, 131.7, 131.0, 68.5, 67.0, 61.7, 35.8, 
27.1, 14.1; MS (EI) m/z (%) 222 (13), 221 (14), 220 (41), 219 (12), 218 (30), 177 (12), 
176 (99), 175 (18), 174 (100), 148 (16), 146 (13), 139 (25), 111 (12), 83 (12), 73 (11), 68 
(10), 67 (12), 66 (11), 65 (18), 55 (20), 53 (17), 43 (12); HRMS (EI) calcd. for 
C9H13BrO4
+
 263.9997, found 263.9996;  Anal. calcd. for C9H13BrO4: C, 40.78; H, 4.94; 
found: C, 40.71; H, 4.92. 
 
n-Propyl (5S,6R)- 5,6-dihydroxy-2-bromocyclohex-1-enecarboxylate (269) 
 
White solid; mp 82-85 °C (pentane); Rf = 0.27 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -49.8 (c = 
0.6, CHCl3); IR (film) ν 3383, 2966, 1714, 1657, 1462, 1426, 1392, 1337, 1268, 1092, 
1040, 913; 
1
H NMR (300 MHz, CDCl3) δ 4.53 (t, J = 3.8 Hz, 1H), 4.23 (t, J = 6.8 Hz, 
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2H), 3.92 (m, 1H), 2.86 (dt, J = 19.0, 5.4 Hz, 1H), 2.65 (dt, J = 19.1, 7.2 Hz, 1H), 2.03 
(m, 1H), 1.82 (m, 1H), 1.77 (sextet, J = 7.2 Hz, 2H), 1.02 (t, J = 7.4 Hz, 3H); 
13
C NMR 
(75 MHz, CDCl3) δ 166.8, 132.3, 130.8, 68.6, 67.3, 67.0, 35.9, 27.1, 21.9, 10.6; MS (EI) 
m/z (%)236 (42), 234 (43), 219 (21), 199 (47), 194 (23), 192 (29), 177 (29), 176 (51), 175 
(34), 174 (50), 155 (100), 139 (31), 113 (76), 111 (31), 95 (69), 67 (30), 66 (23), 65 (30), 
53 (23), 43 (93), 41 (49); HRMS (EI) calcd. for C10H15BrO4
+
 278.0148, found 278.0169. 
 
Ethyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1-enecarboxylate (270) 
 
White solid; mp 74-76 °C (pentane); Rf = 0.33 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -72.3 (c = 
0.45, CHCl3); IR (film) ν 3271, 2958, 1717, 1624, 1461, 1424, 1365, 1241, 1097, 1043; 
1
H NMR (300 MHz, CDCl3) δ 4.54 (s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.86 (s, 1H), 2.67 
(dt, J = 19.0, 5.4 Hz, 1H), 2.49 (dt, J = 18.7, 7.3 Hz, 1H), 1.99 (m, 1H), 1.79 (m, 1H), 
1.33 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 166.3, 142.2, 127.4, 67.9, 67.1, 
61.5, 33.3, 26.0, 14.1; MS (EI) m/z (%) 185 (14), 178 (29), 177 (28), 176 (83), 175 (20), 
157 (18), 139 (14), 133 (14), 132 (38), 131 (41), 130 (100), 104 (19), 102 (49), 67 (25), 
65 (23), 55 (10), 53 (16), 51 (10), 44 (11), 43 (11); HRMS (EI) calcd. for C9H13ClO4
+
 
220.0402, found 220.0405; Anal. calcd. for C9H13ClO4: C, 48.99; H, 5.94; found: C, 
48.77; H, 5.91. 
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n-Propyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1-enecarboxylate (271) 
 
White solid; mp 60-63 °C (pentane); Rf = 0.34 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -65.6 (c = 
0.3, CHCl3); IR (film) ν 3420, 3304, 2964, 1714, 1661, 1552, 1521, 1392, 1344, 1271, 
1094, 1056, 1009, 928, 795; 
1
H NMR (300 MHz, CDCl3) δ 4.58 (m, 1H), 4.24 (t, J = 6.72 
Hz, 2H), 3.90 (m, 1H), 2.73 (dt, J = 18.8, 5.7 Hz, 1H), 2.55 (dt, J = 18.4, 7.3 Hz, 1H), 
2.03 (m, 1H), 1.85 (m, 1H), 1.77 (sextet, J = 7.1 Hz, 2H), 1.02 (t, J = 7.5 Hz, 3H); 
13
C 
NMR (75 MHz, CDCl3) δ 166.4, 143.0, 127.1, 68.0, 67.2, 67.1, 33.6, 26.1, 21.9, 10.6; 
MS (EI) m/z (%) 199 (14), 192 (20), 191 (15), 190 (57), 175 (25), 157 (12), 150 (25), 149 
(14), 148 (76), 133 (13), 132 (35), 131 (40), 130 (100), 104 (13), 102 (32), 67 (15), 65 
(16), 43 (49), 41 (19); HRMS (EI) calcd. for C10H15ClO4
+
 234.0659, found 234.0661. 
 
Methyl (3S,4S)-3,4-dihydroxy-2-iodocyclohex-1-enecarboxylate (272) 
 
White solid; mp 78-80 °C (pentane) [lit.
90 
mp 80-81 °C (hexanes)]; Rf  = 0.23 [2:3 
(hexanes:EtOAc)]; [α]20
𝐷
 = -32.5 (c = 0.1, CHCl3) [lit.
90
 [α]20
𝐷
 
= -34.5 (c = 1.1, CHCl3)]; 
IR (film) ν 3259, 2949, 1722, 1635, 1433, 1347, 1094; 1H NMR (300 MHz, CDCl3) δ 
4.33 (br s, 1H), 4.02 (m, 1H), 3.83 (s, 3H), 2.65 (dt, J = 18.0, 5.7 Hz, 1H), 2.35 (dt, J = 
18.0, 5.7 Hz, 1H), 1.97 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 167.5, 136.8, 108.5, 68.4, 
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67.1, 52.3, 41.0, 28.3; MS (EI) m/z (%) 314 (16), 299 (14), 298 (100), 296 (13), 294 (22); 
HRMS (EI) calcd. for C8H11IO4
+
 297.9702, found 297.9713. 
 
Methyl (3S,4S)-3,4-dihydroxy-2-bromocyclohex-1-enecarboxylate (273) 
 
White solid; mp 91-93 °C (pentane) [lit.
90 
mp 92-93 °C (pentane)]; Rf  = 0.42 [1:2 
(hexanes:EtOAc)]; [α]20
𝐷
  = -30.6 (c = 0.7, CHCl3), [lit.
90
 [α]20
𝐷
 = -32.4 (c = 0.7, CHCl3)]; 
IR (film) ν 3270, 2951, 1728, 1431, 1254, 1092, 756; 1H NMR (300 MHz, CDCl3) δ 4.29 
(d, J = 3.9 Hz, 1H), 4.01 (dt, J = 8.8, 3.5 Hz, 1H), 3.81 (s, 3H), 2.61 (dt, J = 17.8, 5.6 Hz, 
1H), 2.35 (dt, J = 18.0, 6.7 Hz, 1H), 1.85-1.96 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 
167.5, 134.4, 124.8, 72.2, 68.2, 52.3, 26.4, 25.2; MS (EI) m/z (%) 220 (30), 218 (33), 208 
(15), 206 (16), 177 (10), 176 (98), 175 (15), 174 (100), 148 (21), 146 (18), 139 (14), 83 
(11), 65 (16), 59 (29), 55 (17), 53 (17); HRMS (EI) calcd. for C8H11BrO4
+
 249.9841, 
found 249.9852. 
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Methyl (3S,4S)-3,4-dihydroxy-2-chlorocyclohex-1-enecarboxylate (274) 
 
White solid; mp 91-93 °C (pentane) [lit.
90 
mp 92-94 °C (pentane)]; Rf = 0.23 [2:3 
(hexanes:EtOAc)]; [α]20
𝐷
 = -59.7 (c = 0.2, CHCl3) [lit.
90
 [α]20
𝐷
 = -62.3 (c = 0.4, CHCl3)]; 
IR (film) ν 3400, 2953, 1728, 1627, 1435, 1344, 1259, 1143, 1091, 985, 931; 1H NMR 
(300 MHz, CDCl3) δ 4.24 (brd, 1H), 4.00 (m, 1H), 3.82 (s, 3H), 2.64 (dt, J = 18.1, 5.7 
Hz, 1H), 2.38 (dt, J = 18.0, 6.4 Hz, 1H), 1.94 (m, 1H), 1.83 (m, 1H); 
13
C NMR (75 MHz, 
CDCl3) δ 166.9, 134.0, 130.7, 71.1, 68.1, 52.2, 25.4, 25.2; MS (EI) m/z (%) 175 (12), 171 
(17), 164 (34), 163 (26), 162 (100), 139 (12), 133 (11), 132 (31), 131 (35), 130 (88), 104 
(14), 102 (38), 67 (17); HRMS (EI) calcd. for C8H11ClO4
+
 206.0346, found 206.0350; 
Anal. calcd. for C8H11ClO4: C, 46.50; H, 5.37; found: C, 46.69; H, 5.44. 
 
Methyl (5S,6R)-5,6-dihydroxy-2-iodocyclohex-1-enecarboxylate (275)
90
  
 
White solid; mp 83-85 °C (pentane), mp 84-86 °C (pentane) [lit.
90 
mp 85-86 °C 
(hexanes)]; Rf = 0.27 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -37.4 (c = 0.2, CHCl3), [α]
20
𝐷
 
 = -
38.0 (c = 0.2, CHCl3) [lit.
90
 [α]20
𝐷
 
= -39.5 (c = 1.1, CHCl3)]; IR (film) ν 3268, 2950, 1727, 
1634, 1432, 1236, 1093;  
1
H NMR (300 MHz, CDCl3) δ 4.50 (br s, 1H), 3.94 (m, 1H), 
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3.86 (s, 3H), 3.03 (dt, J = 19.9, 5.5 Hz, 2H), 2.77 (dt, J = 19.1, 7.1 Hz, 2H), 1.97 (m, 1H), 
1.74 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 168.2, 140.4, 103.2, 74.8, 68.2, 52.4, 27.2, 
25.3; MS (EI) m/z (%) 314 (48), 312 (51), 298 (100), 294 (24), 280 (38), 262 (36), 231 
(35), 223 (37), 171 (98), 153 (24), 139 (97), 127 (57), 125 (69), 111 (72), 95 (88), 83 
(30), 67 (36), 53 (29); HRMS (EI) calcd. for C8H11IO4
+
 297.9702, found 297.9707. 
 
Methyl (5S,6R)- 5,6-dihydroxy-2-bromocyclohex-1-enecarboxylate (276) 
 
White solid; mp 95-97 °C (pentane), mp 98-100 °C (pentane) [lit.
90 
mp 98-100 °C 
(pentane)]; Rf = 0.36 [1:2 (hexanes:EtOAc)]; [α]
20
𝐷
 = -43.5 (c = 0.7, CHCl3), [α]
20
𝐷
 = -52.8 
(c = 0.7, CHCl3) [lit.
90
 [α]20
𝐷
 = -44.9 (c = 0.7, CHCl3)]; IR (film) ν 3237, 2953, 1731, 
1430, 1217, 1099, 1037;  
1
H NMR (300 MHz, CDCl3) δ 4.53 (s, 1H), 3.90-3.93 (m, 1H), 
3.86 (s, 3H), 2.86 (dt, J = 19.0, 5.7 Hz, 1H), 2.65 (dt, J = 19.4, 7.2 Hz, 1H), 2.05-2.08 (m, 
1H), 1.85-1.86 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 167.1, 132.5, 130.7, 68.5, 67.0, 
52.3, 36.8, 27.1; MS (EI) m/z (%) 209 (13), 208 (31), 207 (14), 206 (32), 177 (17), 176 
(20), 175 (19), 174 (20), 171 (27), 139 (13), 127 (100), 95 (59), 67 (22), 66 (10), 65 (13), 
53 (11), HRMS (EI) calcd. for C8H11BrO4
+
 249.9841, found 249.9832; Anal. calcd. for 
C8H11BrO4: C, 38.27; H, 4.42; found: C, 38.33; H, 4.34. 
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Methyl (5S,6R)-5,6-dihydroxy-2-chlorocyclohex-1-enecarboxylate (277)  
 
Off-white solid; mp 74-75 °C (pentane), mp 74-76 °C (pentane) [lit.
90 
mp 75-77 °C 
(pentane)]; Rf = 0.18 [2:3 (hexanes:EtOAc)]; [α]
20
𝐷
 = -65.9 (c = 0.8, CHCl3), [α]
20
𝐷
 = -66.5 
(c = 1.0, CHCl3) [lit.
90
 [α]20
𝐷
 = -68.5 (c = 1.0, CHCl3)]; IR (film) ν 3228, 2956, 1731, 
1430, 1336, 1245, 1101, 1040, 967, 931; 
1
H NMR (300 MHz, CDCl3) δ 4.56 (brd, 1H), 
3.87 (m, 4H), 2.69 (dt, J = 19.0, 5.3 Hz, 1H), 2.51 (dt, J = 19.0, 7.3 Hz, 1H), 2.02 (m, 
1H), 1.82 (m, 1H);  
13
C NMR (75 MHz, CDCl3) δ 166.7, 142.6, 127.3, 67.9, 67.2, 52.3, 
33.4, 26.0; MS (EI) m/z (%) 176 (10), 175 (12), 174 (29), 162 (17), 132 (35), 131 (13), 
130 (100), 102 (16), 59 (14),  HRMS (EI) calcd. for C9H13ClO4
+
 206.0346, found 
206.0352; Anal. calcd. for C9H13ClO4: C, 46.50; H, 5.37; found: C, 46.63; H, 5.40. 
 
(1R,2R)-3-Bromo-6-(hydroxymethyl)cyclohexa-3,5-diene- 1,2-diol (301) 
 
White powder; mp 94-96 °C (pentane); [α]20
𝐷
 = -8.3 (c = 1.0, MeOH); IR (CHCl3) ν 3337, 
2920, 2861, 1648, 1579, 1388, 1333, 1096, 1014, 842; 
1
H NMR (300 MHz, MeOD) δ 
6.38 (d, J = 6.0 Hz, 1H), 5.80 (ddd, J = 6.1, 3.0, 1.6 Hz, 1H), 4.38 (dd, J = 6.0, 0.8 Hz, 
1H), 4.24–4.14 (m, 3H); 13C NMR (75 MHz, MeOD) δ 142.3, 127.9, 126.5, 119.2, 74.1, 
71.2, 63.0; MS (EI) m/z (%) 204 (73), 202 (83), 186 (46), 185 (30), 184 (32), 177 (26), 
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162 (31), 123 (28), 109 (49), 107 (26), 105 (34), 95 (74), 94 (86), 79 (28), 78 (27), 77 
(100), 67 (25), 65 (32), 63 (26), 61 (25), 55 (32), 53 (25), 51 (35), 44 (58), 43 (69), 41 
(29); HRMS (EI) calcd. for C7H9BrO3
+
 219.9735, found 219.9731; HPLC Condition B 
(minor enantiomer rt = 11.4 min, major enantiomer rt = 10.0 min).  
 
(1R,2R)-3-Allyl-6-bromocyclohexa-3,5-diene-1,2-diol (302) 
 
Off-white amorphous powder; Rf = 0.37 [1:1 (hexanes:EtOAc)]; mp 128-130 
o
C 
(MeOH/Et2O); [α]
20
𝐷
 = +13.6 (c = 0.86, MeOH); IR (MeOH) ν 3429, 2095, 1642, 1424, 
1286, 1097, 1079, 1049, 1018, 913, 838; 
1
H NMR (300 MHz, CDCl3) δ 6.35 (d, J = 6.1 
Hz, 1H), 5.87 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H), 5.63 (td, J = 6.0, 1.4, Hz, 1H), 5.18-5.09 
(m, 2H), 4.32 (brs, 2H), 2.97 (ddd, J = 6.5, 2.6, 1.5 Hz, 2H); 
13
C NMR (75 MHz, CDCl3) 
δ 140.0, 135.0, 127.1, 123.9, 119.7, 117.3, 72.8, 71.0, 37.3; MS (EI) m/z (%) 270 (24), 
254 (21), 252 (37), 250 (20), 212 (37), 210 (37), 185 (22), 184 (97), 183 (100), 182 (97), 
181 (76), 157 (98), 155 (91), 142 (21), 110 (73), 109 (20), 103 (27), 102 (78), 90 (21), 82 
(26), 76 (55), 75 (60), 63 (28), 51 (46), 50 (48); HRMS (EI) calcd. for C9H11BrO2
+
 
229.9942, found 229.9945; HPLC Condition A (minor enantiomer rt = 4.1 min, major 
enantiomer rt = 7.0 min). 
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(1R,2R)-3-Bromo-6-ethynylcyclohexa-3,5-diene-1,2-diol (303) 
 
Off-white solid; mp 118-120 
o
C (MeOH/Et2O); Rf = 0.31 [3:1 (hexanes:EtOAc)]; [α]
20
𝐷
 = 
+34.6 (c = 0.5, MeOH); IR (film) ν 3734, 3288, 3200, 2839, 1557, 1414, 1304, 1102, 
1085, 1014, 844;  
1
H NMR (300 MHz, CDCl3) δ 6.28 (d, J = 6.2 Hz, 1H), 6.05 (d, J = 6.1 
Hz, 1H), 4.22 (d, J = 5.9 Hz, 1H), 4.15 (d, J = 6.0 Hz, 1H), 3.24 (s, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 129.8, 127.8, 126.4, 122.1, 82.7, 81.6, 71.8, 66.8; MS (EI) m/z (%) 216 
(50), 214 (54), 198 (43), 196 (44), 145 (18), 143 (18), 135 (52), 117 (23), 118 (17), 89 
(84), 77 (100); HRMS (EI) calcd. for C8H7BrO2
+
 213.9629, found 213.9627; HPLC 
Condition A (minor enantiomer rt = 5.4 min, major enantiomer rt = 10.2 min). 
 
(1S, 2R, 3S)-3-hydroxymethyl-[1,2]-isopropylidenedioxycyclohexane (304) 
 
To a degassed solution of acetonide-protected diene diol 301 (800 mg, 3.07 mmol) in 
methanol (16.0 mL) and triethylamine (3.2 mL) was added Adams’ catalyst (PtO2) (80 
mg, 0.35 mmol) and the atmosphere was evacuated. The reaction vessel was charged with 
hydrogen, and the reaction mixture stirred for 12 h at room temperature.  The reaction 
mixture was then filtered through a pad of celite (MeOH), and the solvent was removed 
under reduced pressure.  The crude residue was purified by flash chromatography [4:1 
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(hexanes:EtOAc)] to afford cyclohexane 304 as a clear, colourless oil (320 mg, 1.75 
mmol, 57 % yield). 
Rf = 0.48 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 = -6.13 (c = 2.0, CHCl3); IR (CHCl3) ν 3691, 
3626, 3011, 2940, 2870, 1732, 1451, 1382, 1372, 1235, 1039, 863; 
1
H NMR (300 MHz, 
CDCl3) δ  4.33 (dd, J = 5.3, 3.5 Hz, 1H), 4.16 (td, J = 9.0, 5.5 Hz, 1H), 3.83 (dd, J = 
11.0, 4.3 Hz, 1H), 3.73 (dd, J = 11.0, 5.8 Hz, 1H), 1.89-1.72 (m, 3H), 1.54 (s, 3H), 1.58-
1.45 (m, 3H), 1.39 (s, 3H) 1.35-1.27 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 108.0, 74.7, 
74.5, 60.2, 39.3, 28.4, 27.9, 25.9, 21.5, 20.2; MS (EI) m/z (%) 171 (100), 111 (37), 110 
(16), 93 (47), 82 (18), 81 (35), 79 (32), 67 (39), 43 (52), 39 (38); HRMS (EI) 186.1256 = 
C10H18O3
+
; calcd. C9H15O3
+
 [(M-15)
+
, CH3]: 171.1021; found: 171.1036. 
 
(1S,2R,3R)-3-Methylcyclohexane-1,2-diol (305)
159
 
 
Viscous oil; Rf = 0.32 [95:5 (CHCl3:MeOH)]; [α]D = –3.7 (c = 1.0, CHCl3) [lit.
159
 [α]20
𝐷
 = 
–25 (c = 1.1, CHCl3)]; IR (film) ν 3375, 2929, 975; 
1
H NMR (500 MHz, CDCl3) δ 3.58 
(t, J = 2.8 Hz, 1H), 3.38 (ddd, J = 2.8, 5.8, 11.4 Hz, 1H), 1.87 (ddd, J = 2.8, 5.3, 9.1 Hz, 
1H), 1.49-1.51 (m, 2H), 1.34-1.37 (m, 2H), 1.08-1.14 (m, 2H), 0.84 (d, J = 6.8 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 73.7, 72.6, 35.3, 27.8, 26.6, 23.5, 18.0; MS (EI) m/z (%) 
130 (20), 112 (67), 97 (100), 71 (63); HRMS (EI) calcd. for C7H14O2
+
 130.0994, found 
130.1012. 
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cis-(1S,2R)-3-Allylcyclohexa-3,5-diene-1,2-diol (306)
160
 
 
White solid; mp 38 
o
C (hexane/CH2Cl2); [α]D = +10.4 (c = 0.47, MeOH); [lit.
160
 [α]20
𝐷
 = 
+21 (c = 0.73, CHCl3)]; 
1
H NMR (300 MHz) δ 5.79–5.98 (m, 3H), 5.74 (d, J = 5.0 Hz, 
1H), 5.13 (m, 2H), 4.05 (d, J = 6.0 Hz, 2H), 3.00 (d, J = 6.7 Hz, 2H); MS (EI) m/z (%) 
152 (8), 134 (100), 91 (72); HRMS (EI) calcd. for C9H12O2
+
 152.0837, found 152.0834. 
 
(1S,2R,3R)-3-Ethyl-[1,2]-isopropylidenedioxycyclohexane (307)
161
 
 
Crude (1S,2R)-3-ethyl-[1,2]-isopropylidenedioxycyclohexa-3,5-diene (98 mg, 0.54 
mmol) was dissolved in 2 mL of methanol and 500 µL of triethylamine and the solvent 
was degassed. Adams’ catalyst (10 mg, 0.044 mmol) was then added, and the flask was 
flushed with hydrogen gas. The reaction vessel was charged with hydrogen and the 
reaction mixture was stirred for 16 h under the hydrogen atmosphere. The reaction 
mixture was then filtered through a Celite pad (Et2O) and the solvent was removed under 
reduced pressure. The crude mixture was then purified through flash chromatography 
[9:1 (hexanes:EtOAc)] to provide cyclohexane 307 as a clear, colourless oil (46 mg, 0.25 
mmol, 46%). 
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bp 221–223 oC (760 mmHg); Rf = 0.44 [9:1 (hexanes:EtOAc)]; [α]
20
𝐷
 = +10.9 (c = 1.0, 
CHCl3); [lit.
160
 [α]20
𝐷
 = +9.6 (c = 0.2, CHCl3)];IR (CHCl3) ν 3752, 3155, 2938, 2254, 
1816, 1793, 1717, 1643, 1465, 1381, 1096, 905, 717; 
1
H NMR (300 MHz, CDCl3) δ 4.13 
(dd, J = 5.0, 1.9 Hz, 1H), 4.02 (td, J = 8.9, 5.5 Hz, 1H), 1.80-1.58 (m, 2H), 1.47 (s, 6H), 
1.54-1.38 (m, 1H), 1.25-1.08 (m, 3H), 0.94 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, 
CDCl3) δ 107.3, 75.1, 74.6, 39.0, 28.9, 28.0, 25.8, 25.5, 25.3, 21.0, 11.4; HRMS (EI) 
184.1463 = C11H20O2
+
; calcd. C10H17O2
+
 [(M-15)
+
, CH3]: 169.1229; found: 169.1232. 
 
(+)-Methyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (310)
66
 
 
Pale yellow oil; Rf = 0.33 [hexanes/EtOAc (1:2)]; [α]
20
𝐷
 = +68.8 (c = 0.8, CHCl3) [lit.
66
 
[α]23
𝐷
 = +71.3 (c = 1.6, CHCl3)]; IR (film) ν 3412, 2098, 1690, 1639, 1291, 820, 772; 
1
H 
NMR (300 MHz, CDCl3) δ 7.05 (d, J = 5.3 Hz, 1H), 6.17 (dd, J = 10.3, 0.6 Hz, 1H), 6.05 
(dq, J = 5.1, 2.2 Hz, 1H), 4.50-4.56 (m, 1H), 4.41-4.50 (m, 1H), 3.77 (s, 3H), 3.52-3.67 
(m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 167.5, 138.6, 134.3, 128.4, 122.6, 69.5, 64.8, 
52.1; MS (EI) m/z (%) 170 (33), 152 (61), 139 (22), 138 (96), 136 (71), 121 (100), 110 
(95), 109 (66), 105 (23), 93 (42), 92 (22) 82 (57), 81 (56), 65 (59), 5 3(49), 51 (22); 
HRMS (EI) calcd. for C8H10O4: 170.0579, found: 170.0580. 
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(+)-n-Propyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (311)
66 
 
Off-white waxy solid; Rf = 0.15 [hexanes/EtOAc (1:1)]; [α]
20
𝐷
 = +55.2 (c = 1.4, CHCl3) 
[lit.
66
 [α]22
𝐷
= +58.8 (c = 1.1, CHCl3)]; IR (film) ν 3398, 2968, 1700, 1280, 1240; 
1
H NMR 
(300 MHz, CDCl3) δ 7.08 (d, J = 5.4 Hz, 1H), 6.20 (dd, J = 9.5, 2.5 Hz, 1H), 6.09 (ddd, J 
= 9.5, 5.4, 2.2 Hz, 1H), 4.58 (d, J = 6.3 Hz, 1H), 4.48 (ddd, J = 6.3, 2.5, 2.2 Hz, 1H), 4.16 
(t, J = 6.7 Hz, 2H), 3.40 (bs, 2H), 1.72 (qt, J = 7.4, 6.7 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H); 
13
C NMR (75MHz, CDCl3) δ 167.1, 138.4, 133.9, 128.7, 122.6, 69.4, 66.6, 64.8, 22.0, 
10.4; MS (EI) m/z (%): 198 (18), 180 (22), 138 (100), 121 (81), 110 (54), 105 (77); 
HRMS (EI) calcd. for C10H14O4: 198.0892, found: 198.0892.  
 
(+)-i-Propyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (312)
66
 
 
Colourless crystals; Rf = 0.31 [hexanes/EtOAc (2:3)]; mp 80-82 
o
C (pentane) [lit.
66 
mp 
83-85 
o
C (EtOAc/hexanes)]; [α]20
𝐷
 = +66.5 (c = 1.0, CHCl3) [lit.
20
 [α]22
𝐷
 = +64.7 (c = 1.1, 
CHCl3)]; IR (film) ν 3274, 2981, 1698, 1263, 1241; 
1
H NMR (300 MHz, CDCl3) δ 7.05 
(ddd, J = 5.5, 1.0, 0.5 Hz, 1H), 6.20 (ddt, J = 9.6, 2,7, 0.9 Hz, 1H), 6.08 (ddd, J = 9.6, 5.5, 
2.2 Hz, 1H), 5.12 (hept, J = 6.3 Hz, 1H), 4.58 (dd, J = 6.4, 0.5 Hz, 1H), 4.48 (br m, 1H), 
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3.60-3.25 (br s, 2H), 1.30 (d, J = 6.3 Hz, 6H); 
13
C NMR (75 MHz, CDCl3) δ 166.5, 138.2, 
133.6, 128.9, 122.63, 69.2, 68.5, 64.9, 21.8; MS (EI) m/z (%): 198 (19), 180 (16), 156 
(14), 138 (100); HRMS (EI) calcd. for C10H14O4: 198.08921, found: 198.08896; Anal. 
calcd. for C10H14O4: C, 60.59; H, 7.12. Found C, 60.68; H, 7.19. 
 
(+)-t-Butyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (313) 
 
White crystalline solid; Rf = 0.31 [hexanes/EtOAc (1:1)]; mp 88-90
 o
C (pentane); [α]20
𝐷
 = 
+53.3 (c = 0.3, CHCl3); IR (film) ν 3382, 2977, 2932, 1699, 1639, 1575, 1477, 1456, 
1393, 1368, 1290, 1253, 1159, 1106, 1066, 1024, 993, 889, 849, 826, 783, 770; 
1
H NMR 
(300 MHz, CDCl3) δ 6.95 (d, J = 5.6 Hz, 1H), 6.22 (dd, J = 9.5, 2.8 Hz, 1H), 6.11 (ddd, J 
= 9.5, 5.7, 1.9 Hz, 1H), 4.51 (dd, J = 6.4, 4.0 Hz, 1H), 4.50-4.44 (m, 1H), 1.59 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 166.4, 137.3, 132.9, 129.8, 123.0, 81.6, 68.6, 65.7, 28.1; 
MS (EI) m/z (%): 195 (15), 194 (100), 165 (6), 162 (5), 157 (10), 156 (96), 154 (21), 152 
(6); HRMS (EI) 212.1049 = C11H16O4; calcd. for C11H14O3 [(M-18)
+
, H2O]: 194.0943, 
found: 194.0944.  
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(+)-Benzyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (314) 
 
Pale yellow oil; Rf = 0.30 [hexanes/EtOAc (1:1)]; [α]
20
𝐷
 = +48.8 (c = 0.2, CHCl3); IR 
(film) ν 3390, 2959, 1704, 1639, 1575, 1498, 1455, 1395, 1260, 1164, 1104, 1066, 1027, 
995, 915, 811, 757, 697; 
1
H NMR (600 MHz, CDCl3) δ 7.38-7.33 (m, 5H), 7.12 (d, J = 
5.6 Hz, 1H), 6.23 (dd, J = 9.7, 2.8 Hz, 1H), 6.12-6.09 (m, 1H), 5.25 (s, 2H), 4.63-4.61 (m, 
1H), 4.50-4.48 (m, 1H); 
13
C NMR (150 MHz, CDCl3) δ 166.8, 138.5, 135.7, 134.3, 
128.7, 128.4, 128.3, 128.2, 122.8, 68.9, 66.8, 65.2; MS (EI) m/z (%): 246 (13), 244 (58), 
238 (24), 228 (28), 221 (13), 220 (100), 213 (19), 212 (99), 210 (12), 207 (12), 204 (17), 
201 (10), 200 (49), 199 (16), 197 (13), 195 (15), 194 (36), 192 (12), 183 (15), 182 (14), 
181 (19), 179 (15), 172 (12), 169 (10), 168 (11), 167 (30), 166 (14), 165 (20), 159 (11), 
157 (22), 156 (31), 155 (45), 154 (13), 153 (20), 152 (18), 151 (15); HRMS (EI) 
246.0892 = C14H14O4; calcd. for C14H12O3 [(M-18)
+
, H2O]: 228.0786, found: 228.0787. 
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(+)-Ethyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(315)
66
 
 
Colourless oil; Rf = 0.56 [hexanes/EtOAc (1:1)]; [α]
20
𝐷
 = +76.2 (c = 1.3, CHCl3) [lit.
66
 
[α]23
𝐷
 = +74.6 (c = 4.0, CHCl3)]; IR (film) ν 3018, 2987, 2936, 1712, 1651, 1425, 1380, 
1259, 1155, 1031, 917, 856, 697, 667, 512; 
1
H NMR (300 MHz, CDCl3) δ 7.16-7.13 (m, 
1H), 6.12-6.10 (m, 2H), 4.95 (d, J = 8.4 Hz, 1H), 4.87 (dd, J = 8.5, 1.7 Hz, 1H), 4.35-4.23 
(m, 2H), 1.47 (s, 3H), 1.41 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) 
δ 166.2, 142.3, 130.0, 108.5, 72.6, 70.4, 60.5, 27.8, 26.2, 25.1, 20.9, 14.2; MS (EI) m/z 
(%): 211 (77), 181 (15), 169 (17), 123 (100), 105 (17), 95 (13), 83 (11), 79 (76), 67 (14), 
59 (10), 55 (11), 43 (82), 41 (14); HRMS (EI) 224.1049 = C12H16O4; calcd. C11H13O4 
[(M-15)
+
, CH3]: 211.0970, found: 211.0969; Anal. calcd. for C12H16O4: C, 64.27; H, 7.19. 
Found C, 64.52; H, 7.08. 
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(+)-Methyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(317) 
164(d),184
 
 
Colourless oil; Rf = 0.45 [hexanes/EtOAc (4:1)]; [α]
20
𝐷
  = +88.5 (c = 0.2, CHCl3); IR 
(film) ν 2988, 2952, 1715, 1651, 1589, 1437, 1371, 1260, 1160, 1108, 1081, 1030, 881, 
864, 762, 707, 631, 522; 
1
H NMR (300 MHz, CDCl3) 7.16-7.13 (m, 1H), 6.12-6.10 (m, 
2H), 4.94 (d, J = 8.4 Hz, 1H), 4.87 (dd, J = 8.5, 1.9 Hz, 1H), 3.83 (s, 3H), 1.46 (s, 3H), 
1.40 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 166.7, 134.0, 133.9, 126.1, 121.3, 105.6, 
72.5, 68.2, 52.0, 26.7, 25.1; MS (EI) m/z (%) 195 (68), 163 (11), 153 (100), 152 (39), 121 
(90), 120 (16), 109 (57), 105 (21), 94 (21), 93 (27), 92 (18), 79 (12), 77 (32), 65 (44), 63 
(10), 59 (37), 51 (11); HRMS (EI) 210.0892 = C11H14O4; calcd. C10H11O4 [(M-15)
+
, 
CH3]: 195.0657. Found: 195.0655. 
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(+)-(3aS,5aS,6S,6aS,9aS,10R,10aR,10bS)-4,6-Diiodo-2,2,8,8-tetramethyl-
3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-d:6,7-
d']bis([1,3]dioxole) (318) 
 
Acetonide 316
185
 was dissolved in o-xylene and heated to reflux for 40 hours.  The 
solution was concentrated under reduced pressure and purified by flash column 
chromatography [hexanes/EtOAc (4:1)] to obtain 0.19 g (38%) of 318 as a white solid. 
Rf = 0.39 [hexanes/EtOAc (4:1)]; mp 220-224 °C (EtOAc/pentane); [α]
20
𝐷
 = +106.5 (c = 
1.0, CHCl3); IR (film) ν 2984, 2933, 2898, 1455, 1380, 1280, 1262, 1236, 1225, 1209, 
1160, 1082, 1068, 1012; 
1
H NMR (600 MHz, CDCl3) δ 6.89 (d, J = 3.7 Hz, 1H), 6.25 (d, 
J = 8.6 Hz, 1H), 5.79 (t, J = 7.3 Hz, 1H), 4.49 (d, J = 7.2 Hz, 1H), 4.38 (dd, J = 7.2, 3.6 
Hz, 1H), 4.18 (d, J = 4.6 Hz, 1H), 4.15 (d, J = 4.1 Hz, 1H), 2.91 (m, 1H), 2.71 (dd, J = 
8.7, 3.6 Hz, 1H), 2.49 (d, J = 9.2 Hz, 1H), 1.47 (s, 3H), 1.40 (s, 3H), 1.38 (s, 3H), 1.36 (s, 
3H); 
13
C NMR (150 MHz, CDCl3) δ 140.1, 139.0, 128.7, 109.3, 108.7, 103.9, 84.7, 79.1, 
78.6, 75.2, 48.3, 45.6, 38.4, 35.2, 27.9, 26.7, 25.5, 25.1; MS (EI) m/z (%) 122 (11), 107 
(14), 105 (11), 104 (43), 93 (11), 91 (26), 79 (23), 78 (10), 77 (23), 75 (27), 70 (12), 69 
(11), 61 (14), 57 (18), 55 (15), 45 (19), 43 (100), 42 (11), 41 (18), 39 (15); HRMS (EI) 
calcd. for C18H22O4: 555.9607, found: 555.9602; Anal. calcd. for C18H22I2O4: C, 38.87; 
H, 3.99. Found: C, 39.14; H, 4.04. 
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(+)-(3aR,5aR,6S,6aR,9aS,10R,10aS,10bS)-Dimethyl 2,2,8,8-tetramethyl-
3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-d:6,7-
d']bis([1,3]dioxole)-4,6-dicarboxylate (319) 
 
Acetonide 317
162(d),171
 was dissolved in o-xylene and heated to reflux for 24 hours.  The 
solution was concentrated under reduced pressure and purified via flash column 
chromatography [hexanes/EtOAc (6:1)] to obtain 34 mg (42%) of 319 as white powdery 
solid. 
Rf = 0.33 [hexanes/EtOAc (3:1)]; mp 180-183 °C (pentane); [α]
20
𝐷
 = +50.3 (c = 0.4, 
CHCl3); IR (film) ν 2932, 1737, 1436, 1379, 1283, 1262, 1210, 1164, 1060, 882, 804, 
742; 
1
H NMR (600 MHz, CDCl3) δ 6.45 (d, J = 8.3 Hz, 1H), 6.20 (t, J = 7.2 Hz, 1H), 
5.40 (t, J = 2.6 Hz, 1H), 4.63 (dd, J = 7.2, 1.4 Hz, 1H), 4.40 (dd, J = 7.3, 3.2 Hz, 1H), 
4.29 (t, J = 7.6 Hz, 1H), 3.90 (s, 3H), 3.79 (s, 3H), 3.63 (t, J = 8.2 Hz, 1H), 3.39-3.34 (m, 
1H), 3.11 (dt, J = 7.4, 2.5 Hz, 1H), 1.94 (dd, J = 8.3, 1.9 Hz, 1H), 1.51 (s, 3H), 1.35 (s, 
6H), 1.30 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 173.0, 171.2, 138.8, 129.7, 128.5, 
117.8, 110.0, 109.9, 79.0, 78.4, 77.3, 56.3, 52.6, 52.5, 48.9, 42.6, 38.3, 27.2, 25.4, 25.0, 
24.6; MS (EI) m/z (%) 213 (8), 157 (6), 131 (6), 121 (7), 100 (13), 97 (6), 95 (6), 83 (6), 
81 (4), 77 (7), 71 (6), 70 (5), 69 (15), 61 (5), 59 (5), 58 (100), 57 (12), 55 (9); HRMS (EI) 
calcd. for C22H28O8: 420.1784, found: 420.1801; Anal. calcd. for C22H28O8: C, 62.85; H, 
6.71. Found: C, 63.10; H, 6.79. 
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(+)-(3aR,5aR,6S,6aR,9aS,10R,10aS,10bS)-Diethyl 2,2,8,8-tetramethyl-
3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-d:6,7-
d']bis([1,3]dioxole)-4,6-dicarboxylate (320) 
 
A solution of acetonide 315
66
 was dissolved in o-xylene and heated to reflux for 40 hours.  
The solution was concentrated under reduced pressure and purified via flash column 
chromatography [hexanes/EtOAc (4:1)] to obtain 0.34 g (68%) of 320 as pale yellow 
solid. 
Rf = 0.24 [hexanes/EtOAc (4:1)]; mp 91-93 °C (pentane); [α]
20
𝐷
 = +47.8 (c = 1.0, CHCl3); 
IR (film) ν 2984, 2937, 1721, 1458, 1380, 1262, 1221, 1163, 1072, 1026; 1H NMR (600 
MHz, CDCl3) δ 6.43 (d, J = 3.8 Hz, 1H), 6.38 (d, J = 8.8 Hz, 1H), 6.04 (t, J = 7.0 Hz, 
1H), 4.60 (d, J = 7.0 Hz, 1H), 4.58 (d, J = 4.8 Hz, 1H), 4.43 (dd, J = 7.0, 3.3 Hz, 1H), 
4.37 (q, J = 13.9 Hz, 2H), 4.18-4.25 (m, 2H), 4.16 (dd, J = 4.6, 1.9 Hz, 1H), 3.01 (m, 
1H), 2.95 (dd, J = 9.0, 3.3 Hz, 1H), 2.32 (d, J = 9.1 Hz, 1H), 1.35 (s, 3H), 1.33 (t, J = 7.1 
Hz, 3H), 1.29 (s, 3H), 1.28 (s, 3H), 1.27 (s, 3H), 1.26 (t, J = 7.0 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) δ 171.5, 165.9, 136.5, 131.5, 130.2, 128.8, 109.7, 108.2, 80.7, 78.3, 76.9, 
69.2, 61.5, 60.7, 53.9, 40.4, 38.6, 34.9, 28.1, 26.5, 25.4, 25.1, 14.2, 14.2; MS (EI) m/z (%) 
433 (22), 390 (27), 375 (22), 287 (22), 286 (25), 285 (65), 273 (14), 272 (27), 269 (53), 
259 (20), 258 (17), 257 (26), 245 (17), 244 (22), 241 (32), 229 (26), 228 (14), 227 (100), 
217 (14), 213 (27); HRMS (EI) 448.2097 = C24H32O8; calcd. C23H29O8 [(M-15)
+
, CH3]: 
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433.1857, found: 433.1857; Anal. calcd. for C24H32O8: C, 64.27; H, 7.19. Found C, 
63.99; H, 7.30. 
 
(+)-n-Propyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-
carboxylate (321) 
   
Clear colourless oil; Rf = 0.46 [hexanes/EtOAc (4:1)];
 [α]20
𝐷
 = +72.6 (c = 1.2, CHCl3); IR 
(film) ν 2974, 2937, 1713, 1589, 1460, 1379, 1370, 1256, 1160, 1107, 1080, 1052, 1027, 
863, 705; 
1
H NMR (300 MHz, CDCl3) δ 7.16-7.14 (m, 1H), 6.12-6.10 (m, 2H), 4.95 (d, J 
= 8.3 Hz, 1H), 4.87 (dd, J = 8.3, 1.4 Hz, 1H), 4.19 (t, J = 6.6 Hz, 2H), 1.73 (sextet, J = 
14.2, 7.7 Hz, 2H), 1.46 (s, 3H), 1.41 (s, 3H), 1.00 (t, J = 7.4 Hz, 3H); 
13
C NMR (75 MHz, 
CDCl3) δ 166.2, 133.8, 133.6, 126.4, 121.3, 105.5, 72.6, 68.2, 66.4, 26.7, 25.0, 22.0, 10.5; 
MS (EI) m/z (%) 223 (27), 181 (72), 180 (18), 179 (17), 163 (11), 139 (100), 138 (42), 
137 (18), 122 (11), 121 (69), 120 (15), 110 (18), 105 (21), 95 (65), 94 (18), 93 (15), 82 
(12), 77 (24), 66 (11), 65 (28), 58 (49); HRMS (EI) 238.1205 = C13H18O4; calcd. 
C12H15O4 [(M-15)
+
, CH3]: 223.0970, found: 223.0968. 
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(+)-i-Propyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-
carboxylate (322) 
 
Clear colourless oil; Rf = 0.51 [hexanes/EtOAc (4:1)]; [α]
20
𝐷
 = +94.8 (c = 0.1, CHCl3); IR 
(film) ν 2983, 2935, 1710, 1589, 1455, 1372, 1261, 1160, 1106, 1027, 927, 862, 803, 
706; 
1
H NMR (300 MHz, CDCl3) δ 7.13-7.11 (m, 1H), 6.11-6.09 (m, 2H), 5.16 (heptet, J 
= 18.8, 12.5, 6.2 Hz, 1H), 4.94 (d, J = 8.3 Hz, 1H), 4.87 (dd, J = 8.3, 1.4 Hz, 1H), 1.47 
(s, 3H), 1.41 (s, 3H), 1.31 (d, J = 6.3 Hz, 6H); 
13
C NMR (75 MHz, CDCl3) δ 165.6, 
133.7, 133.4, 126.7, 121.3, 105.5, 72.6, 68.2, 68.1, 26.7, 25.0, 21.9, 21.9; MS (EI) m/z 
(%) 223 (19), 181 (68), 180 (19), 179 (19), 139 (100), 138 (55), 137 (20), 122 (14), 121 
(96), 120 (22), 110 (17), 105 (18), 95 (49), 94 (21), 93 (19), 92 (12), 82 (18), 77 (24), 66 
(15), 65 (35), 59 (16); HRMS (EI) 238.1205 = C13H18O4; calcd. C12H15O4 [(M-15)
+
, 
CH3]: 223.0970, found: 223.0966. 
 
(+)-t-Butyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(323) 
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Clear colourless oil; Rf = 0.63 [hexanes/EtOAc (4:1)];
 [α]20
𝐷
 = +81.3 (c = 0.6, CHCl3); IR 
(film) ν 2981, 2933, 1707, 1589, 1456, 1368, 1275, 1255, 1160, 1109, 1050, 1025, 905, 
848, 704; 
1
H NMR (300 MHz, CDCl3) δ 7.07-7.04 (m, 1H), 6.08-6.07 (m, 2H), 4.87 (d, J 
= 8.2 Hz, 1H), 4.85 (d, J = 8.3, 1H), 1.54 (s, 9H), 1.46 (s, 3H), 1.41 (s, 3H); 
13
C NMR 
(75 MHz, CDCl3) δ 165.4, 133.5, 133.1, 127.6, 121.3, 105.5, 81.0, 72.8, 68.2, 28.2, 26.7, 
25.0; MS (EI) m/z (%) 181 (25), 179 (14), 139 (46), 138 (40), 121 (46), 95 (19), 94 (21), 
93 (13), 77 (14), 65 (24), 57 (100); HRMS (EI) 252.1361 = C14H20O4; calcd. C13H17O4 
[(M-15)
+
, CH3]: 237.1122, found: 237.1127. 
 
(+)-Allyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(324) 
 
Clear colourless oil; Rf = 0.65 [hexanes/EtOAc (4:1)]; [α]
20
𝐷
 = +79.3 (c = 0.2, CHCl3); IR 
(film) ν 2987, 2935, 1715, 1649, 1589, 1455, 1404, 1371, 1252, 1161, 1109, 1029, 993, 
923, 863, 706; 
1
H NMR (300 MHz, CDCl3) δ 7.19-7.17 (m, 1H), 6.13-6.10 (m, 2H), 
6.05-5.92 (m, 1H), 5.38 (dq, J = 17.4, 1.7 Hz, 1H), 5.26 (dq, J = 10.6, 1.6 Hz, 1H), 4.96 
(d, J = 8.5 Hz, 1H), 4.88 (dd, J = 8.5, 2.1 Hz, 1H), 4.74 (dt, J = 5.5, 1.5 Hz, 2H), 1.46 (s, 
3H), 1.41 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 165.8, 134.0, 134.0, 132.2, 126.1, 121.3, 
118.0, 105.6, 72.5, 68.1, 65.4, 26.7, 25.0; MS (EI) m/z (%) 221 (22), 220 (14), 179 (57), 
163 (13), 161 (30), 137 (15), 135 (17), 122 (14), 121 (100), 109 (11), 107 (23), 105 (32), 
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94 (15), 93 (18), 77 (25), 65 (31); HRMS (EI) 236.1049 = C13H16O4; calcd. C12H13O4 
[(M-15)
+
, CH3]: 221.0814, found: 221.0810. 
 
(+)-Propargyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-
carboxylate (325)
66
 
 
Colourless oil; Rf = 0.54 [hexanes/EtOAc (4:1)]; [α]
20
𝐷
 = +110.6 (c = 0.2, CHCl3) [lit.
66
  
[α]20
𝐷
 = +112.7 (c = 1.3, CHCl3)]; IR (film) ν 2987, 2935, 1718, 1030; 
1
H NMR (300 
MHz, CDCl3) δ 7.22 (dd, J = 5.3, 1.1 Hz, 1H), 6.19-6.09 (m, 2H), 4.95 (d, J = 8.4 Hz, 
1H), 4.89 (dd, J = 8.4, 2.4 Hz, 1H), 4.84 (dd, J = 2.5, 1.0 Hz, 2H), 2.50 (t, J = 2.5 Hz, 
1H), 1.47 (s, 3H), 1.41 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 165.3, 134.8, 134.4, 125.5, 
121.2, 105.7, 77.7, 74.9, 71.8, 68.0, 52.3, 26.7, 25.0; MS (EI) m/z (%) 219 (42), 177 (41), 
163 (17), 121 (83), 43 (100); HRMS (EI) calcd. for C12H11O4: 219.0657, found: 
219.0659; Anal. calcd. for C13H14O4: C, 66.66; H, 6.02. Found: C, 66.68; H, 6.08. 
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(+)-Benzyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(326) 
 
Clear colourless oil; Rf = 0.53 [hexanes/EtOAc (4:1)];
 
 [α]20
𝐷
 = +75.8 (c = 1.5, CHCl3); IR 
(film) ν 3034, 2987, 2935, 1712, 1588, 1455, 1371, 1253, 1161, 1108, 1028, 864, 737, 
698; 
1
H NMR (300 MHz, CDCl3) δ 7.44-1.33 (m, 5H), 7.20-7.18 (m, 1H), 6.16-6.07 (m, 
2H), 5.28 (s, 2H), 4.98 (d, J = 8.4 Hz, 1H), 4.88 (dd, J = 8.4, 2.2 Hz, 1H), 1.48 (s, 3H), 
1.42 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 166.0, 136.0, 134.2, 134.1, 128.5, 128.2, 
128.1, 126.1, 121.3, 105.6, 72.5, 68.2, 66.5, 26.7, 25.1; MS (EI) m/z (%) 105 (15), 91 
(100), 77 (14), 65 (25), 58 (11), 52 (15); HRMS (EI) 286.1205 = C17H18O4; calcd. 
C11H13O4 [(M-15)
+
, CH3]: 271.0965, found: 271.0966. 
 
(+)-Allyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (327)
66
 
 
Colourless crystals; Rf = 0.23 [hexanes/EtOAc (1:1)]; mp 44-47 
o
C (pentane) [lit.
66 
mp 
48-50 
o
C (EtOAc/hexane)]; [α]20
𝐷
 = +67.4 (c = 0.2, CHCl3) [lit.
66
 [α]22
𝐷
  = +72.5 (c = 1.6, 
CHCl3)]; IR (film) ν 3394, 1704, 1273, 1238; 
1
H NMR (300 MHz, CDCl3) δ 7.12 (d, J = 
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5.5 Hz, 1H), 6.23 (ddt, J = 9.6, 2,7, 1.0 Hz, 1H), 6.11 (ddd, J = 9.5, 5.5, 2.2 Hz, 1H), 5.98 
(ddt, J = 17.2, 10.4, 5.7Hz, 1H), 5.37 (dt, J = 17.2, 1.5Hz, 1H), 5.28 (dt, J = 10.4, 1.3 Hz, 
1H), 4.72 (ddd, J = 5.7, 1.5, 1.3 Hz, 1H), 4.61 (br s, 1H), 4.50 (br s, 1H), 3.25 (d, J = 3.8 
Hz, 1H), 3.18 (bd, J =7.3Hz, 1H); 
13
C NMR (75MHz, CDCl3) δ 166.6, 138.8, 134.4, 
131.9, 128.4, 122.4, 118.3, 69.6, 65.5, 64.5; MS (EI) m/z (%) 196 (20), 178 (18), 138 
(80), 121 (95), 41 (100). HRMS (EI) calcd. for C10H12O4: 196.07356, found: 196.07364; 
Anal. calcd. for C10H12O4 + 1/8 H2O: C, 60.52; H, 6.22. Found C, 60.52; H, 6.26. 
 
(+)-Propargyl (5S,6R)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (328)
66
 
 
Colourless crystals; Rf = 0.31 [EtOAc/hexanes (3:2)]; mp 67-69 
o
C (pentane) [lit.
66 
mp 
70-72 
o
C (EtOAc/Hexanes)]; [α]20
𝐷
 = +74.3 (c = 0.2, CHCl3) [lit.
66
  [α]22
𝐷
 = +88.20 (c = 
1.6, CHCl3)]; IR (film) ν 3385, 3291, 1707, 1270, 1234; 
1
H NMR (300 MHz, acetone-d6) 
δ 7.01 (dd, J = 5.3, 1.1 Hz, 1H), 6.16 (dq, J = 9.5, 1.4 Hz, 1H), 6.09 (ddd, J = 9.5, 5.3, 2.2 
Hz, 1H), 4.86 (dd, J = 15.8, 2.5 Hz, 1H), 4.80 (dd, J = 15.8, 2.5 Hz, 1H), 4.50–4.23 (m, 
2H), 4.10 (d, J = 7.4 Hz, 1H), 3.96 (d, J = 5.0 Hz, 1H), 3.06 (t, J = 2.5 Hz, 1H); 
13
C NMR 
(75 MHz, acetone-d6) δ 167.2, 142.5, 136.3, 131.1, 123.5, 80.0, 77.3, 72.5, 65.5, 53.4; 
MS (EI) m/z (%) 194 (7), 176 (28), 138 (47), 121 (100); HRMS (EI) calcd for C10H10O4: 
194.0579, found: 194.0581; Anal. calcd. for C10H10O4: C, 61.85; H, 5.19. Found: C, 
62.08; H, 5.18. 
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(4R,5S,6S)-4-methyl-6-hydroxy-[5,6;4,4a]-bisdiisopropylidenedioxy-cyclohex-2-en-1-
one (331) 
  
Diol 335 (600 mg, 2.80 mmol) was dissolved in 2,2-dimethoxypropane (10 mL), and to 
the stirring solution was added a catalytic amount of p-TsOH.  The reaction was allowed 
to stir at room temperature until TLC analysis [EtOAc/hexanes (1:4)] indicated the 
completion of the reaction.  The crude reaction mixture was then concentrated under 
reduced pressure, and re-dissolved in EtOAc (15 mL).  The solution was then washed 
with a saturated aqueous solution of sodium bicarbonate (1 x 3 mL) and brine (1 x 3 mL), 
dried with MgSO  and concentrated under reduced pressure.  The crude mixture was then 
purified by flash column chromatography [EtOAc/hexanes (1:8)] to afford bis-acetonide 
331 (555 mg, 2.2 mmol, 78%) as a white powdery solid. 
mp 142-144 ºC (ether/pentanes); Rf = 0.56 [EtOAc/hexanes (1:4)]; [α]
20
𝐷
 = +47.1 (c = 1.0, 
CHCl3); IR (CHCl3) ν 3691, 3607, 3025, 2992, 2938, 2897, 1689, 1602, 1454, 1384, 
1375, 1230, 1064, 852, 765; 
1
H NMR (300 MHz, CDCl3) δ 6.67 (dd, J = 10.1, 1.8 Hz, 
1H), 6.11 (d, J = 10.1 Hz, 1H), 4.45 (d, J = 4.8 Hz, 1H), 4.41 (dd, J = 4.8, 1.81 Hz, 1H), 
4.34 (d, J = 9.6 Hz, 1H), 4.03 (d, J = 9.6 Hz, 1H), 1.46 (s, 6H), 1.40 (s, 3H), 1.30 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 195.7, 146.4, 128.7, 111.4, 110.6, 79.0, 76.3, 74.5, 71.8, 
27.5, 27.3, 26.3, 26.1; MS (EI) m/z (%) 239 (40), 179 (20), 154 (58), 139 (38), 121 (37), 
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100 (65), 96 (100), 85 (68), 68 (47), 43 (70); HRMS (EI) calcd. for C13H18O5
+
: 254.1154, 
found: 254.1147; Anal. calcd. for C13H18O5: C, 61.40; H, 7.14. Found: C, 61.40; H, 7.18. 
 
(5S,6R)-6-hydroxymethyl-[5,6]-isopropylidenedioxycyclohexa-1,3-diene (333)
186
 
 
Acetonide 317 (17.4 g (crude), <83mmol) was dissolved in benzene (60 mL) and hexanes 
(60 mL) and the stirring solution was cooled to 0 ºC.  DIBAL-H (neat, 34 mL, 165 mmol) 
was added dropwise over 5 min. TLC analysis was carried out immediately and indicated 
that the reaction was complete in <5 min.  The reaction mixture was quenched with a 
saturated aqueous soln. of Rochelle’s salt (120 mL) and allowed to stir overnight (12 
hours) at room temp.  The reaction was then diluted with EtOAc (100 mL), and the 
aqueous phase extracted with EtOAc (3 x 100 mL).  The combined organic phases were 
washed with sodium bicarbonate (1 x 50 mL) and brine (1 x 50 mL), dried with MgSO4, 
filtered and concentrated under reduced pressure. The crude product was used directly for 
the next step.  
Clear colourless oil; Rf = 0.61 [EtOAc/hexanes (1:1)]; IR (film) ν 3575, 3416, 3044, 
2985, 2930, 1611, 1541, 1406, 1371, 1304, 1246, 1207, 1158, 1033, 950, 877, 820, 791, 
756, 718, 694; 
1
H NMR (300 MHz, CDCl3) δ 6.05 (dd, J = 9.4, 5.7 Hz, 1H), 5.98 (ddd, J 
= 5.6, 2.4, 1.3 Hz, 1H), 5.91 (dd, J = 8.9, 1.1 Hz, 1H), 4.73 (d, J = 1.7 Hz, 2H), 4.35-
4.29 (m, 2H), 2.07 (t, J = 5.0 Hz, 1H), 1.43 (s, 3H), 1.43 (s, 3H); 
13
C NMR (75 MHz, 
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CDCl3) δ 136.1, 124.7, 124.0, 119.5, 105.5, 71.8, 71.0, 64.6, 26.8, 24.9; MS (EI) m/z (%) 
153 (10), 139 (16), 123 (16), 121 (23), 105 (17), 95 (12), 85 (13), 83 (15), 77 (11), 73 
(20), 71 (36), 70 (13), 69 (16), 59 (32), 57 (100), 56 (40), 55 (41), 45 (23), 44 (33), 43 
(97), 42 (53), 41 (59); HRMS (ESI) calcd. for C10H14O3Na
+
: 205.0841, found: 205.0834. 
 
(4R,5S,6S)-4-hydroxymethyl- [5,6]-isopropylidenedioxy-cyclohex-2-en-1-one (335) 
 
To a solution of endoperoxide 334 (~12.6 g, 59 mmol) in DCM (200 mL) was added 
triethylamine (0.8 mL, 5.9 mmol). The reaction was allowed to stir for 16 h, when the 
reaction was observed to be complete by TLC.  The crude reaction mixture was 
concentrated under reduced pressure and purified by flash column chromatography 
[toluene -> EtOAc/hexanes (1:4)] to provide enone 335 (11.3 g, 53 mmol, 90%) as a 
white amorphous solid.  
White amorphous solid; mp 93-94 ºC (ether); Rf = 0.38 [EtOAc/hexanes (1:8)]; [α]
20
𝐷
 = -
25.6º (c = 0.25, CHCl3); IR  (CHCl3) ν 3691, 3603, 3549, 3021, 2938, 1693, 1602, 1376, 
1223, 1087, 763; 
1
H NMR (300 MHz, CDCl3) δ 6.79 (dd, J = 10.3, 1.0 Hz, 1H), 6.13 (d, 
J = 10.3 Hz, 1H), 4.54-4.46 (m, 2H), 3.80 (d, J = 11.5 Hz, 1H), 3.68 (d, J = 11.5 Hz, 
1H), 1.39 (s, 3H), 1.35 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 195.9, 147.4, 129.2, 110.9, 
79.0, 74.5, 70.3, 66.6, 27.2, 25.6; MS (EI) m/z (%) 219 (43), 214 (98), 199 (34), 139 (38), 
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126 (92), 114 (100), 109 (47), 101 (68), 97 (76), 96 (95), 85 (81), 81 (49), 78 (58), 59 
(63), 43 (55); HRMS (EI) calcd. for C10H14O5
+
: 214.0841, found: 214.0848. 
 
(3aS,7aR)-methyl 2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-
carboxylate
56,93,94(b),187
 
 
To 75 mL of 40% aqueous solution of KOH was added to 250 mL of diethyl ether, and 
the stirring solution was cooled to 0 
o
C.  To the solution was added nitrosomethylurea (25 
g, 243 mmol) in portions over 5 minutes.  The deep yellow ether layer was then decanted 
into a solution of acid 4 (7.6 g, 49 mmol) in THF (125 mL) at 0 
o
C.  The reaction mixture 
was allowed to warm to room temperature with continuous stirring, and the reaction 
progress was monitored by TLC.  After 4 h the reaction was deemed to be complete, and 
the ethereal solvents were removed under reduced pressure.  The crude mixture was then 
dissolved in 2,2-DMP (50 mL) and stirred at room temperature.  To the mixture was 
added a catalytic amount of p-TsOH, and the reaction progress was monitored by TLC.  
After 4 h the reaction was deemed to be complete, and the 2,2-DMP was evaporated 
under reduced pressure. The crude mixture was redissolved in EtOAc (50 mL) and 
washed with a saturated solution of NaHCO3 (1 x 10mL).  The organic solution was dried 
over Na2SO4 and concentrated under reduced pressure.  The crude product was purified 
by flash column chromatography [hexanes:EtOAc (4:1)] to afford the title ester as a clear 
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colourless oil which solidified to a white crystalline solid upon standing (7.4 g, 35 mmol, 
70%). 
Rf = 0.67 [2:1 (petrol:Et2O)]; mp 48-51 °C (EtOAc:pentane) [lit.
94(b),187
 mp 49-51 °C]; 
[α]20
𝐷
 =      -397.3 (c = 1.0, CHCl3) [lit.
94(b),187
 [α]20
𝐷
 = -417.2 (c = 1.0, CHCl3)]; IR (film) ν 
3041, 2977, 2956, 2924, 1750, 1735, 1453, 1432, 1384, 1368, 1251, 1214, 1166, 1081, 
1044, 885, 805, 710; 
1
H NMR (300 MHz, CDCl3) δ 6.10-6.00 (m, 2H), 6.00-5.92 (m, 
1H), 5.80-5.73 (m, 1H), 4.90 (d, J = 4.1 Hz, 1H), 3.72, (s, 3H), 1.37 (s, 3H), 1.35 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 172.1, 124.7, 124.5, 124.1, 124.0, 106.8, 79.4, 72.7, 52.9, 
26.9, 25.2. 
 
((3aR,7aR)-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxol-3a-yl)methanol 
(336)
56,94(b),187 
 
 (3aS,7aR)-methyl 2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-carboxylate (9.8 
g, 46.6 mmol) was dissolved in THF (400 mL) and the stirring solution was cooled to 0° 
C.  To the mixture was added a solution of LiBH4 (1.93 g, 88.5 mmol, 2.0 M in THF) 
dropwise over 5 min. The solution was stirred at 0 
o
C for 1 h before being allowed to 
warm to room temperature over 4 h.  The reaction mixture was then quenched with 
dropwise addition of EtOAc (200 mL) followed by H2O (300 mL).  The resulting 
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solution was extracted with EtOAc (3 x 300 mL) and the combined organic extracts were 
dried over MgSO4. The crude extract was concentrated under reduced pressure and 
purified by flash column chromatography [hexanes:EtOAc (4:1)] to afford alcohol 336 as 
a clear, colourless oil which solidified to a white crystalline solid upon standing (7.3 g, 
40.1 mmol, 86%). 
mp 42-44 °C (EtOAc:pentane) [lit.
 94(b),187
 mp 42-43 °C]; [α]20
𝐷
 = -211.4 (c = 0.8, CHCl3) 
[lit.
 94(b),187
 [α]20
𝐷
 = -215.9 (c = 1.0, CHCl3)]; IR (nujol) ν 3392, 1643, 1594; 
1
H NMR (300 
MHz, CDCl3) δ 6.08 (dd, J = 9.9, 5.0 Hz, 1H), 5.99 (d, J = 9.9 Hz, 1H), 5.98 (d, J = 9.9 
Hz, 1H), 5.67 (d, J = 9.9 Hz, 1H), 4.47 (d, J = 5.0 Hz, 1H), 3.56 (d, J = 11.5 Hz, 1H), 
3.34 (d, J = 11.5 Hz, 1H), 2.25 (s, 1H), 1.43 (s, 3H), 1.35 (s, 3H); 
13
C NMR (75 MHz, 
CDCl3) δ 128.9, 125.1, 124.4, 123.4, 106.3, 80.5, 70.9, 64.3, 27.1, 26.6. 
 
(3aS,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-3a,7a-
dihydrobenzo[d][1,3] dioxole (353) 
 
To a stirred solution of DMSO (117 µL, 1.65 mmol), in CH2Cl2 (9 mL) at -78 °C was 
added oxalyl chloride (71 µL, 0.82 mmol), and the solution was allowed to react for 15 
min. To the solution was added alcohol 336 (0.10 g, 0.55 mmol) in CH2Cl2 (5 mL) 
dropwise over 5 min, and the solution was allowed to stir for 1 h. Triethylamine (306 µL, 
2.20 mmol) was then added at -78 °C, and the solution was allowed to stir for 1 h before 
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being warmed to room temperature over 12 h.  The reaction mixture was then poured into 
water (14 mL), and the aqueous solution extracted with CH2Cl2 (3 × 14 mL). The 
combined organic layers were washed with brine (1 x 5 mL), dried over MgSO4 and the 
solvent removed under reduced pressure. The crude residue was passed through a short 
pad of silica to afford the corresponding aldehyde as a pale yellow oil, which was used 
immediately without further purification.  To a stirring solution of phosphonium bromide 
352 (0.33 g, 0.66 mmol) in THF (3 mL) at -78 
o 
C was added LiHMDS (0.69 mL, 0.9 M 
in THF) dropwise over 2 min.  The reaction mixture was stirred at -78 
o
C for 15 min 
before being allowed to warm to room temperature.  The reaction mixture was then 
cooled to -78 
o
C before the dropwise addition of aldehyde (0.10 g, 0.55 mmol) in THF (1 
mL) over 5 min.  The reaction mixture was stirred at -78 
o
C for 3 h before being allowed 
to warm to room temperature.  The reaction was then quenched with a saturated aqueous 
solution of NH4Cl (3 mL) and the product extracted with EtOAc (3 x 3 mL).  The 
combined organic extracts were dried over Na2SO4, and concentrated under reduced 
pressure.  The crude reaction mixture was purified by flash column chromatography 
[15:1, hexanes:EtOAc] to afford triene 353 (0.07 g, 0.22 mmol, 40%) as a clear, 
colourless oil. 
Rf = 0.57 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= -195.1 (c = 1.9, CHCl3); IR (film) ν 2933, 2858, 
1456, 1379, 1260, 1210, 1127, 1030, 890, 800, 710; 
1
H NMR (300 MHz, CDCl3) δ 6.11 
(dd, J = 9.9, 5.5, 1H), 6.01 (dd, J = 9.8, 4.5, 1H), 5.86 (ddd, J = 9.5, 5.4, 0.9, 1H), 5.76 
(d, J = 9.5, 1H), 5.58 (dt, J = 11.6, 1.4, 1H), 5.45-5.36 (m, 1H), 4.39 (d, J = 4.3, 1H), 4.33 
(t, J = 5.7, 1H), 3.30 (s, 6H), 2.06-1.99 (m, 2H), 1.60-1.53 (m, 2H), 1.41 (s, 3H), 1.37 (s, 
3H), 1.34-1.24 (m, 6H); 
13
C NMR (75 MHz, CDCl3) δ 133.3, 133.0, 130.3, 125.1, 124.0, 
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119.2, 104.8, 104.5, 79.5, 76.2, 52.6, 32.4, 29.5, 29.2, 28.5, 27.0, 25.8, 24.5; MS (EI) m/z 
(%) 338 (20), 322 (32), 321 (100), 264 (30), 255 (39), 232 (98), 201 (90), 200 (67), 173 
(35), 172 (29), 171 (26), 159 (26), 157 (44), 145 (47), 133 (49), 123 (28), 107 (47), 105 
(21), 75 (20); HRMS (EI) 322.2144 = C19H30O4; calcd C19H20O4 [(M-1)
+
, H]: 321.2066, 
found: 321.2079; Anal. calcd. for C19H30O4: C 70.77, H 9.38; found: C 70.89, H 9.57. 
 
(3aS,4R,7S,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-3a,4,7,7a-
tetrahydro-4,7-epidioxybenzo[d][1,3]dioxole (354) 
 
Triene 353 (0.25 g, 0.78 mmol) was dissolved in CH2Cl2 (200 mL) in a water-jacketed 
flask, and tetraphenylporphyrin (0.02 g, 0.04 mmol) was added to the stirring mixture. 
The solution was irradiated in a water cooled reaction vessel using a 500 W lamp while 
O2 was bubbled through continuously. The reaction was monitored using 
1
H NMR, and 
the reaction was deemed to be complete after 40 h. The solvent was evaporated under 
reduced pressure and the crude mixture was purified by column chromatography [toluene 
to hexanes:EtOAc (9:1)] to afford endoperoxide 354 as a clear colourless oil (0.20 g, 0.56 
mmol, 72%). 
Rf = 0.32 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= -12.4 (c = 1.4, CHCl3); 
1
H NMR (300 MHz, 
CDCl3) δ 6.65 (td, J = 6.2, 1.6 Hz, 1H), 6.50 (td, J  = 6.2, 1.5 Hz, 1H), 5.73-5.57 (m, 2H), 
4.91-4.87 (m, 1H), 4.66 (dt, J = 6.1, 1.6 Hz, 1H), 4.37-4.33 (m, 2H), 3.31 (s, 6H), 2.43-
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2.26 (m, 2H), 1.63-1.57 (m, 2H), 1.43-1.33 (m, 6H), 1.31 (s, 6H); 
13
C NMR (75 MHz, 
CDCl3) δ 135.4, 132.4, 132.0, 129.4, 110.9, 104.5, 79.7, 78.0, 77.8, 72.6, 52.6, 32.4, 29.5, 
29.2, 28.7, 26.9, 26.2, 24.5. 
(3aS,4R,7S,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxole-4,7-diol (356) 
 
 
 
A solution of thiourea (5 mg, 0.06 mmol) in methanol (0.5 mL) was added dropwise over 
20 min to a stirred solution of endoperoxide 354 (20 mg, 0.05 mmol) in CH2Cl2 (1 mL) at 
room temperature. The reaction was monitored by TLC and after 1.5 h was deemed to be 
complete.  The crude reaction mixture was then filtered and concentrated under reduced 
pressure.  The crude product was purified by flash column chromatography 
[hexanes:EtOAc (4:1)] to afford diol 356 as a clear colourless oil (15 mg, 0.04 mmol, 
74%). 
Rf = 0.41 [1:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= +8.7 (c = 0.9, CHCl3); IR (film) ν 3433, 2987, 
2933, 2856, 1455, 1380, 1259, 1212, 1127, 1056, 885, 789, 718; 
1
H NMR (300 MHz, 
MeOD) δ 5.75 (s, 2H), 5.54 (dt, J = 12.0, 7.5, 1H), 5.27 (dt, J = 12.0, 1.5 Hz, 1H), 4.37 (t, 
J = 5.7 Hz, 1H), 4.27-4.25 (m, 1H),  4.14-4.13 (m, 1H), 4.09 (d, J = 3.1 Hz, 1H), 3.33 (s, 
6H), 2.51-2.36 (m, 2H), 1.63-1.56 (m, 2H), 1.48 (s, 3H), 1.43 (s, 3H), 1.41-1.36 (m, 6H); 
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13
C NMR (75 MHz, MeOD) δ 136.3, 132.4, 131.5, 129.2, 109.4, 104.5, 85.6, 85.2, 71.2, 
68.4, 52.7, 52.6, 32.4, 29.6, 29.2, 28.6, 27.5, 25.9, 24.2; MS (EI) m/z 341 (17), 324 (16), 
294 (14), 293 (100), 270 (88), 239 (52), 238 (98), 235 (36), 181 (35), 149 (43), 148 (28), 
125 (25), 120 (39), 107 (30), 99 (20), 75 (67); HRMS (EI) 356.2199 = C19H32O6; calcd 
C19H32O6 [(M-15)
+
, CH3]: 341.1985, found: 341.1964. 
 
(3aS,4R,7S,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-7-
((triisopropylsilyl)oxy)-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (357) 
 
 
 
To a stirring solution of diol 356 (0.35 mg, 0.98 mmol) and 2,6-lutidine (0.25 mL, 2.16 
mmol) in CH2Cl2 (15 mL) at -78°C was added triisopropylsilane triflate (0.29 mL, 1.08 
mmol) dropwise over 5 min. The reaction mixture was slowly warmed up to room 
temperature over 3 h.  A saturated aqueous solution of NH4Cl (20 mL) was added and the 
aqueous layer extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were 
dried with Mg2SO4, filtered and concentrated under reduced pressure. The crude mixture 
was purified by flash column chromatography [4:1 (hexanes: EtOAc)] to afford the silyl 
ether 357 (0.33 mg, 0.64 mmol, 63%) as a clear colourless oil. 
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Rf = 0.37 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷  
= +25.4 (c = 1.0, CHCl3); IR (film) ν 3469, 2942, 
2866, 1463, 1380, 1258, 1212, 1125, 1060, 883, 683; 
1
H NMR (300 MHz, CDCl3) δ 
5.79-5.70 (m, 2H), 5.52 (dt, J = 12.0, 7.5 Hz, 1H), 5.31 (dt, J = 12.0, 1.5 Hz, 1H), 4.47-
4.45 (m, 1H), 4.37 (t, J = 5.7 Hz, 1H), 4.15 (d, J = 2.7 Hz, 1H), 4.14-4.12 (m, 1H), 3.32 
(s, 6H), 2.41 (m, 2H), 1.62-1.56 (m, 2H), 1.47 (s, 3H), 1.41 (s, 3H), 1.40-1.37 (m, 6H), 
1.16-1.10 (m, 22H); 
13
C NMR (75 MHz, CDCl3) δ 134.4, 133.9, 130.8, 129.8, 108.9, 
104.5, 85.6, 85.3, 70.7, 68.4, 52.6, 52.5, 32.4, 29.8, 29.3, 28.6, 27.5, 26.0, 24.6, 17.9, 
12.0; MS (EI) m/z (%) 462 (24), 450 (21), 449 (86), 448 (79), 438 (20), 437 (100), 405 
(15), 404 (14), 391 (28), 390 (19), 380 (16), 379 (62), 373 (15), 372 (21), 362 (14), 361 
(43), 345 (20); HRMS (EI) 512.3533 = C28H52O6Si; calcd C27H48O5Si [(M-32)
+
, 
CH3OH]: 480.3271. Found: 480.4282. 
 
(3aR,7S,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-7-
((triisopropylsilyl)oxy)-7,7a-dihydrobenzo[d][1,3]dioxol-4(3aH)-one (359) 
 
Silyl ether 357 (215 mg, 0.42 mmol) was dissolved in ethyl acetate (20 mL) and IBX 
(123 mg, 0.46 mmol) was added in portions.  The reaction mixture was heated to reflux 
and monitored by TLC and the reaction was observed to be complete after 4 h. The crude 
suspension was filtered, washed with a saturated aqueous solution of NaHCO3 (1 x 5 
mL), and the organic solution was concentrated under reduced pressure. The crude 
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reaction mixture was purified by flash column chromatography [4:1 (hexanes:EtOAc)] to 
afford enone 359 (196 mg, 0.38 mmol, 91%) as a pale yellow oil. 
Rf = 0.43 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= -69.5 (c = 1.6, CHCl3); IR (film) ν 2942, 2867, 
1698, 1463, 1383, 1229, 1127, 1077, 1053, 882, 844, 790, 684; 
1
H NMR (300 MHz, 
CDCl3) δ 6.74 (ddd, J = 10.2, 4.5, 1.8 Hz, 1H), 6.06 (d, J = 10.2 Hz, 1H), 5.59 (dt, J = 
11.6, 7.4 Hz, 1H), 5.44 (d, J = 11.7 Hz, 1H), 4.70 (d, J = 4.5 Hz, 1.0, 1H), 4.34 (t, J = 5.7 
Hz, 1H), 4.25 (t, J = 5.7 Hz, 1H), 3.30 (s, 6H), 2.55-2.39 (m, 1H), 2.39-2.22 (m, 1H), 
1.63-1.51 (m, 2H), 1.44-1.26 (m, 12H), 1.25-0.99 (m, 22H); 
13
C NMR (75 MHz, CDCl3) 
δ 196.8, 144.4, 137.3, 127.7, 122.7, 109.3, 104.6, 83.3, 83.0, 65.4, 52.6, 32.5, 29.5, 29.1, 
28.7, 27.4, 26.5, 24.6, 17.9, 12.2; MS (EI) m/z (%) 510 (20), 502 (97), 479 (68), 429 (63), 
421 (38), 414 (100), 403 (47), 223 (69), 205 (41), 174 (66), 162 (92), 146 (98), 131 (82), 
103 (74), 91 (50); HRMS (EI) C28H50O6Si calcd: 510.3377, found: 510.3362. 
 
(3aR,7R,7aR)-3a-((Z)-8,8-dimethoxyoct-1-en-1-yl)-2,2-dimethyl-6-(phenylthio)-7-
((triisopropylsilyl)oxy)tetrahydrobenzo[d][1,3]dioxol-4(3aH)-one (363) 
 
To a stirring solution of enone 359 (70 mg, 0.14 mmol) in CH2Cl2 (3 mL) was added 
thiophenol (15 µL, 0.15 mmol) and Et3N (3 µL, 0.014 mmol) at room temperature, and 
the reaction was monitored by TLC.  After 12 h the reaction was deemed to be complete, 
and the reaction mixture concentrated under reduced pressure.  The crude mixture was 
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purified by flash column chromatography [9:1 (hexanes:EtOAc)] to afford the 
corresponding thioadduct 363 (74 mg, 0.12 mmol, 87%) as a clear, colourless oil. 
Rf = 0.55 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= -81.5 (c = 1.7, CHCl3); IR (film) ν 2946, 2867, 
1738, 1463, 1382, 1245, 1226, 1126, 882, 800, 692; 
1
H NMR (300 MHz, CDCl3) δ 7.46-
7.43 (m, 2H), 7.34-7.23 (m, 3H), 5.65-5.59 (m, 2H), 4.64 (s, 1H), 4.34 (t, J = 5.7 Hz, 
1H), 4.28 (t, J = 1.8 Hz, 1H), 3.70-3.66 (m, 1H), 3.30 (s, 6H), 3.23 (dd, J = 13.9, 4.7 Hz, 
1H), 2.44 (dd, J = 13.9, 2.7 Hz, 1H), 2.44-2.37 (m, 1H), 2.26-2.15 (m, 1H), 1.60-1.54 (m, 
5H), 1.38 (s, 3H), 1.34-1.28 (m, 6H), 1.18-1.04 (m, 21H); 
13
C NMR (75 MHz, CDCl3) δ 
204.7, 138.8, 135.1, 133.4, 129.2, 127.9, 122.9, 110.4, 104.6, 86.4, 86.3, 70.9, 52.9, 52.6, 
39.4, 32.4, 29.3, 29.1, 28.5, 27.0, 26.6, 24.5, 18.0, 12.2; HRMS (EI) 620.3567 = 
C34H56O6SSi; calcd C34H56O6SSiNa [(M+23)
+
, Na]: 643.3459. Found: 643.3414. 
 
(3aR,7S,7aR)-3a-(8,8-dimethoxyoctyl)-2,2-dimethyl-7-((triisopropylsilyl)oxy)-7,7a-
dihydrobenzo[d][1,3]dioxol-4(3aH)-one (364) 
 
Thioadduct 363 (74 mg, 0.12 mmol) was dissolved in MeOH (2 mL), and Wilkinson’s 
catalyst (130 mg, 0.14 mmol), was added to the methanolic solution.  The reaction 
mixture was allowed to stir at room temperature under 1 atm of H2.  The reaction 
progress was monitored by TLC, and after 20 h the reaction was deemed to be complete.  
The crude mixture was filtered through a short pad of silica to afford the corresponding 
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thioether [
1
H NMR (300 MHz, CDCl3) δ 7.46-7.42 (m, 2H), 7.35-7.27 (m, 3H), 4.71-4.67 
(m, 1H), 4.33 (t, J = 5.7 Hz, 1H), 4.24 (t, J = 1.9 Hz, 1H), 3.68-3.65 (m, 1H), 3.30 (s, 
6H), 3.20 (dd, J = 14.0, 4.7 Hz, 1H), 2.51 (ddd, J = 14.0, 2.0, 1.0 Hz, 1H), 1.93-1.84 (m, 
1H), 1.80-1.69 (m, 1H), 1.60-1.53 (m, 2H), 1.38 (s, 3H), 1.29-1.16 (m, 13H), 1.14-1.07 
(m, 21H)], which was then dissolved in CH2Cl2 (2 mL) and stirred at room temperature.  
To the solution was added DBU (21 µL, 0.15 mmol), and the reaction progress was 
monitored by TLC.  The reaction was deemed to be complete after 8 h.  The crude 
reaction mixture was concentrated under reduced pressure and purified by flash column 
chromatography to afford enone 364 as a clear colourless oil (37 mg, 0.07 mmol, 61%). 
Rf = 0.58 [4:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= +44.6 (c = 0.8, CHCl3); IR (film) ν 2943, 2867, 
1694, 1464, 1382, 1240, 1127, 1065, 882, 844, 682; 
1
H NMR (300 MHz, CDCl3) δ 6.77 
(ddd, J = 10.2, 4.7, 1.9, 1H), 6.06 (d, J = 10.2, 1H), 4.72 (dd, J = 4.9, 1.6, 1H), 4.35 (t, J 
= 5.7, 1H), 4.26 (t, J = 1.6, 1H), 3.32 (s, 6H), 1.82-1.76 (m, 2H), 1.59-1.54 (m, 2H), 1.41 
(s, 3H), 1.34-1.24 (m, 13H), 1.15-1.08 (m, 21H); 
13
C NMR (75 MHz, CDCl3) δ 200.0, 
144.3, 127.5, 108.2, 104.6, 82.4, 80.9, 65.5, 52.6, 33.8, 32.5, 29.8, 27.3, 26.5, 24.6, 23.2, 
18.0, 17.9, 12.2. 
 
(3aR,7S,7aR)-3a-((Z)-heptadec-8-en-1-yl)-2,2-dimethyl-7-((triisopropylsilyl)oxy)-
7,7a-dihydrobenzo[d][1,3]dioxol-4(3aH)-one (367) 
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Enone 364 (35 mg, 0.07 mmol) was dissolved in prepared solution of iodine (1.7 mg, 
0.007 mmol) in acetone (0.6 mL), stirred at room temperature, and the reaction progress 
was monitored by TLC.  After 10 min the reaction was deemed to be complete, the 
reaction mixture was diluted with CH2Cl2 (1 mL) and quenched with 5% aqueous 
solution of Na2S2O3 (0.5 mL).  The aqueous layer was separated and extracted with 
CH2Cl2 (3 x 0.5 mL).  The combined organic extracts were washed with brine (1 x 0.3 
mL), dried with Na2SO4 and the solvent was removed under reduced pressure to afford 
aldehyde 365 [
1
H NMR (300 MHz, CDCl3) δ 9.75 (t, J = 1.8 Hz, 1H), 6.76 (ddd, J = 
10.2, 4.7, 1.8 Hz, 1H), 6.05 (d, J = 10.1 Hz, 1H), 4.71 (dd, J = 4.6, 1.5 Hz, 1H), 4.24 (t, J 
= 1.6 Hz, 1H), 2.40 (td, J = 7.3, 1.7 Hz, 2H), 1.80-1.75 (m, 2H), 1.62-1.51 (m, 2H), 1.39 
(s, 3H), 1.33-1.26 (m, 11H), 1.14-1.06 (m, 21H)], which was used immediately in the 
next step.  To a stirring solution of phosphonium bromide 366 (35 mg, 0.08 mmol) in 
THF (1 mL) at -78 
o
C was added n-BuLi (38 µL, 2.11 M) dropwise.  The reaction 
mixture was maintained at -78 
o
C before warming to room temperature.  The reaction 
mixture was then cooled to -78 
o
C before the dropwise addition of aldehyde 365 over 5 
min.  The reaction mixture was maintained at -78 
o
C for 3 h before being allowed to 
warm to room temperature.  The reaction was then quenched with a saturated aqueous 
solution of NH4Cl (1 mL) and the product extracted with EtOAc (3 x 1 mL).  The 
combined organic extracts were dried over Na2SO4, and concentrated under reduced 
pressure.  The crude reaction mixture was purified by flash column chromatography 
[15:1, hexanes:EtOAc] to afford olefin 367 (22 mg, 0.04 mmol, 57%) as a clear, 
colourless oil. 
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Rf = 0.53 [9:1 (hexanes:EtOAc)]; [α]
20
𝐷
 
= +36.0 (c = 0.4, CHCl3); IR (film) ν 2926, 2855, 
1695, 1463, 1372, 1240, 1177, 1065, 882, 845, 683; 
1
H NMR (300 MHz, CDCl3) δ 6.75 
(ddd, J = 10.2, 4.7, 1.9, 1H), 6.04 (d, J = 10.2, 1H), 5.38-5.28 (m, 2H), 4.71 (dd, J = 4.8, 
1.4, 1H), 4.25 (t, J = 1.6, 1H), 2.03-1.97 (m, 4H), 1.83-1.73 (m, 2H), 1.39 (s, 3H), 1.32-
1.21 (m, 24H), 1.18-1.07 (m, 22H), 0.88 (t, J = 7.0, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
200.0, 144.3, 129.9, 129.8, 127.5, 108.3, 82.5, 80.9, 65.5, 33.8, 31.9, 29.9, 29.8, 29.7, 
29.5, 29.4, 29.3, 27.3, 27.2, 27.2, 26.5, 23.2, 22.7, 17.9, 14.1, 12.2; MS (EI) m/z 576 (16), 
475 (73), 447 (18),  336 (100), 321 (12), 241 (14), 240 (83), 157 (15); HRMS (EI) 
C35H64O4Si calcd: 576.4574, found: 576.4568. 
 
Pleiogenone A (14)
100
 
 
Enone 367 (5.0 mg, 0.009 mmol) was dissolved in a prepared solution of iodine (0.75 
mg, 0.003 mmol) in acetonitrile (0.2 mL), and the solution was stirred at room 
temperature.  The reaction progress was monitored by TLC, and the reaction was deemed 
to be complete after 10 h.  The stirring mixture was diluted with CH2Cl2 (1 mL) and 
quenched with 5% aqueous solution of Na2S2O3 (0.5 mL).  The aqueous layer was 
separated and extracted with CH2Cl2 (3 x 0.5 mL), and the combined organic extracts 
were washed with brine (1 x 0.3 mL) and dried with Na2SO4.  The solvent was removed 
under reduced pressure and the crude reaction mixture was purified by flash column 
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chromatography [4:1 (hexanes:EtOAc)] to afford pleiogenone A (14, 2.1 mg, 0.006 
mmol, 64%) as a clear, colourless oil. 
[α]20
𝐷
 
= +22.1 (c = 0.2, CHCl3) [lit.
100
 [α]22
𝐷
 = +23 (c = 0.5, CHCl3)]; 
1
H NMR (500 MHz, 
CDCl3) δ 6.80 (ddd, J = 10.1, 3.9, 1.4, 1H), 6.10 (dd, J = 10.1, 0.8 Hz, 1H), 5.34 (m, 2H), 
4.62 (brs, 1H), 3.98 (brs, 1H), 2.00 (m, 4H), 1.83 (m, 2H), 1.26 (m, 20H), 1.13 (m, 2H), 
0.88 (t, J = 6.9 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 200.2, 145.8, 129.9, 129.8, 126.4, 
78.1, 75.4, 68.6, 38.9, 31.6, 29.8, 29.8, 29.7, 29.5, 29.3, 29.3, 29.3, 29.2, 27.2, 27.2, 23.0, 
22.7, 14.1; HRMS (ESI) 380.29 = C23H40O4; calcd C23H41O4 [(M+1)
+ 
H]: 381.2999. 
Found: 381.2972. 
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